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ABSTRACT 
 
 G-quadruplexes (G4s) are non-canonical secondary nucleic acid structures that exist in 
various biologically important regions within a cell, such as the promoters of DNA, 5’-untranslated 
regions (UTR) of mRNA, and telomeres. In DNA, potential G4-forming sequences tend to cluster 
within 500 bp from transcriptional start sites (TSS) across all chromosomes in an evolutionarily 
conserved manner in addition to at telomeric regions.  Extensive efforts have been dedicated to 
targeting G4s in oncogenic promoters, telomeres, and 5’-UTRs with traditional small molecules. 
However, most small molecules recognize multiple G4s, raising concerns about selectivity and 
specificity. Therefore, we developed a novel nucleic acid clamp (NA-clamp) based strategy, which 
takes advantage of both the highly specific complementary base pairing capability of nucleic acids 
and the three-dimensional variation in size of G4 structures, as compared to linear DNA, in order 
to stabilize individual structures with high specificity. In this work, we explored the possibility of 
applying this NA-clamp approach at both the transcriptional and the translational levels. 
Specifically, we used this NA-clamp approach on the MYC promoter and the NRAS 5’-UTR G4s. 
Silencing MYC and NRAS expression is an effective approach to induce apoptosis of lymphoma 
and breast cancer, and melanoma, respectively. We examined the binding specificity and G4 
stabilizing capability of the designed clamps to their corresponding targets using electromobility 
shift assay, electronic circular dichroism and DMS footprinting. Cellular studies including cell 
viability assays, luciferase assays, fluorescent microscopy, ChIP-PCR, qPCR and western blot 
were used to evaluate the pharmacological effects of the clamps. This research provided insights 
iii 
 
on the applicability of NA-clamps as specific G4 stabilizers that modulate gene expression in 
cancer cells, providing the foundation for the future development of NA-clamps into effective 
therapeutics, or as diagnostic companions, against many cancer types associated with MYC or 
NRAS.   
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CHAPTER I. INTRODUCTION 
 
 The history of nucleic acid research dates back to 1869, when the Swiss physiological 
chemist, Friedrich Miescher, first discovered “nuclein” (the name of which was later changed into 
nucleic acids and eventually DNA) inside the nuclei of white blood cells. This milestone discovery 
paved the way for genetic and molecular biology research (Dahm 2008). In 1920, Rosalind 
Franklin, a physical chemist, produced high-resolution photographs of DNA fibres, based on 
which she calculated the dimensions of the strands and proposed a possible helical structure with 
phosphates locate on the outside of the structure. In 1953, the modern double stranded helical DNA 
structure was proposed by Thomas Watson and Frances Crick (Watson and Crick 1953). This 
landmark work granted both scientists, together with Maurice Wilkins, a Nobel Prize for 
Physiology or Medicine in 1961.  
With the fast advancement of technologies and biophysical techniques, other forms of 
secondary DNA structures, including left-handed double helical Z-form DNA, right-handed A-
form DNA with more compact helical structure compared to B-form DNA, cruciform DNA, three 
stranded triplex DNA, stem and loop hairpins, and G-quadruplex (G4) DNA have been described. 
These non-B form secondary DNA structures exist in cells and play essential biological functional 
roles (Bochman et al. 2012). Our work focuses on G4 DNA (Figure 1-1), whose structure, brief 
summary the biological functions, and the therapeutic potential of this non-canonical secondary 
nucleic acid structure will be expounded below.  
Guanine-rich DNA studies started with a big “Bang” in 1910 when a Norwegian physician 
 2 
scientist named Ivar Bang elucidated the structure of Guanylic acid and discovered the phenomena 
where concentrated solutions of guanylic acids were able to form gels (Bang et al. 1910). In 1962, 
the quartet structure of the gel formed by guanylic acid was proposed by Drs. Martin Gellert, Maric 
N. Lipsett and David Davis, which marks the beginning of modern G-quartet research (Gellert et 
al. 1962). In 1988, Dr. Walter Gilbert, the Nobel prize winner of chemistry in 1980, first discovered 
that single stranded guanine rich sequences are able to self-assembly into parallel four stranded 
DNA complexes, later named G4s (Sen and Gilbert 1988). To date, both DNA and RNA G4s have 
been demonstrated to exist in human cells (Biffi et al. 2013; Biffi et al. 2014). Many research 
groups have utilized strategies to target promoter, 5’-UTR, and telomeric G4s to treat a variety of 
human diseases, especially cancer.  
G4s are formed in guanine rich DNA and RNA sequences with four runs of guanines that 
generally contain at least three continuous guanines in a row. Instead of guanine: cytosine base-
pairing in these sequences, four guanines from each continuous segment bond with each other 
through Hoogsteen base pairing to form a tetrad, and the tetrads stack on top of each other with 
nucleotides among guanine rows forming loop structures connecting the tetrads (Figure 1-1). G4 
structures exhibit high diversity topologically based on multiple factors, such as the number of 
strands involved (either intra or intermolecular structures), relative orientation of the loops 
(parallel vs antiparallel), number of tetrads comprising the structure, and the nucleotide sequences. 
In addition, the tetrads are stabilized when a monovalent cation, such as potassium, interacts with 
the tetrads, due to the electronegative nature of the negatively charged carbonyl oxygen atoms 
located in the center of the tetrads (Guschlbauer et al. 1990; Williamson 1994). Based on the 
folding pattern and loop length of G4 structures, they can be categorized into four 
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Figure 1-1. The building blocks for G4s. In guanine-rich sequences, four guanines are 
able to Hoogsteen base pair with each to form a tetrad. Three or more tetrads then stack on 
top of each through π-π interaction to form a G4 with interconnecting nucleotides forming 
loops surrounding the structure. The structure could be stabilized by a monovalent cation 
located in the center of the tetrad, interacting with a negatively charged carbonyl oxygen 
pocket. The structure shown in this figure is a parallel intramolecular G-quadruplex, with 
the loops of 1, 2, and 1 nucleotides interconnecting the tetrads, formed in the MYC promoter 
(Green=A, red=G, blue=T). Underlined guanines segments are the participating guanines 
for the physiologically relevant MYC G4 structure (Adapted from Brooks & Hurley 2009).  
 4 
classes (I, II, III, and IV) (Brooks et al. 2010).  
Human telomeres are the chromosome caps protecting the ends of the DNA.  They are 
usually 5-8 kb long with a 150-250 nucleotide 3’ single-stranded overhang. During DNA 
replication, around 50-200 bases in the end of the 3’ sequence cannot be copied due to the 
participation of Okazaki fragments. Thus, telomeric non-coding sequences get shorter with each 
cycle of proliferation (Moyzis et al. 1988; Stewart and Weinberg 2006). After the telomeres reach 
a critical short length, the apoptosis signaling pathway is activated, resulting in cellular senescence 
or death (Herbig et al. 2004). Cancer cells manage to avoid this fate by re-activating a reverse 
transcriptase called telomerase, which functions to re-synthesize the lost telomeres to elongate 
chromosomes, enabling cancer cell immortality. Even though telomerase is only active during 
embryonic development, little telomerase expression can be detected in cells after birth; however 
almost 90% of cancer cells re-express telomerase and the other 10% use alternative pathways to 
elongate telomeres (Kim et al. 1994). It is this unique trait of cancer cells, and the lack of 
telomerase activity in normal cells, that makes disrupting telomere elongation an effective 
approach to induce cancer cell apoptosis (d'Adda di Fagagna et al. 2004).  
Telomeric G4 structures were the first to be described and have been pursued as therapeutic 
targets (S. Neidle 2010; Sekaran et al. 2014; Williamson et al. 1989). The single stranded overhang 
of the telomeres is comprised of repeated sequences of d(TTAGGG), which are able to form G4s. 
Studies on G4 structures within telomeres revealed that there were multiples isoforms with varying 
loop lengths and folding patterns, including both intra- and inter-molecular structures (Bryan and 
Baumann 2011; Lin and Yang 2017). Studies have shown that the formation of G4s in telomeres 
can hamper the extension process by blocking telomerase access. Moreover, stabilization of 
telomere G4s by small molecules induce cancer cell senescence/apoptosis. 
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Cancer Hallmarks Oncogenes with DNA G4 Oncogenes with RNA G4 
Angiogenesis VEGF, VEGFR2 VEGF, FGF2 
Invade And Metastasize c-KIT, ADAM-15 
MT3-MMP, ADAM10, 
MST1R 
Tumor Promoting Inflammation FGF2 CXCL14 
Replicative Immortality Telomere, hTERT hTERT, TRF2, TERRA 
Avoid Immune Destruction TGF-β EBNA1 
Evade Growth Suppressors pRb TP53, PIM1, MLL1, MLL4 
Sustain Proliferative Signaling MYC, kRAS 
NRAS, ESR1, TGFB2, 
IGF2 
Deregulating Cellular 
Energetics MYC, HIF-1α CSBII 
Resist Cell Death Bcl-2 Bcl-2, AKTIP 
Genome Instability And 
Mutation YY1 PRX15 
Table 1-1. G4s in the Hallmarks of Cancer (Morgan & Brooks, 2016; Cammas & 
Millevoi, 2016 (Hanahan and Weinberg 2011) 
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In addition to blocking telomerase access, small molecules that are able to induce and 
stabilize G4 formation in telomeric regions can facilitate the exposure of these 3’-end of the DNA, 
making them susceptible to modulation by multiple DNA damage response pathways, which in 
turn inhibits cancer cell proliferation. (d'Adda di Fagagna et al. 2003; Stephen Neidle and 
Parkinson 2003; S. Neidle 2010) A natural product, called telomestatin, isolated from 
Streptomyces anulatus, has been identified as a potent stabilizer of telomeric G4s, which in turn 
inhibits telomerase activity and triggers DNA damage responses (Shin-ya et al. 2001).  Other major 
known telomeric G4-stabilizing compounds include BRACO-19, 12459, Quarfloxin, RHPS4, 360 
A, and Pyridostatin, each of which demonstrate a similar mechanism of action as telomestain 
(Muller and Rodriguez 2014). It is worth noting that the majority of these compounds are non-
selective, and that they also interact with non-telomeric G4s. 
Promoter G4s have also been characterized, such as MYC, KRAS, VEGF, c-Kit, hTERT, 
pRb, RET, PDGF-A and Hif-1 (Brooks et al. 2010). Structures of many promoter G4s have been 
elucidated by NMR and X-ray crystallography (Ohnmacht and Neidle 2014). During transcription, 
DNA double strands are separated transiently due to the negative superhelicity generated by the 
upstream transcriptional machineries (Brooks and Hurley 2009). As a result, single stranded 
guanine and cytosine-rich sequences are able to adopt higher order DNA structures called G-
quadruplexes and i-motifs, respectively (Verma et al. 2008). Recently, DNA G4s have been 
visualized in human cancer cells with an engineered antibody (BG4) specific to G4 structures, 
demonstrating their bona fide intracellular formation (Biffi et al. 2013; Biffi et al. 2014). Research 
using a novel ChIP-seq protocol with the same BG4 antibody revealed that G4 structures mark 
human regulatory chromatin with around 10,000 G4 formation sites, primarily in regulatory and 
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nucleosome depleted regions, where transcription is highly active. Within these nucleosome-
depleted regions, the chromatin structures are open, which allows for better access of 
transcriptional machineries, including RNA Pol II and other transcriptional factors (Hansel-
Hertsch et al. 2016; S. K. Wang et al. 2015a). Notably, more than 40% of human gene promoters, 
especially many oncogenes of the hallmarks of cancer (Table 1-1), contain potential G4-forming 
regions that regulate gene expression (Huppert and Balasubramanian 2007; Jayaraj et al. 2012). 
Biologically, the majority of promoter G4s are silencers of transcription by hindering the binding 
of regulatory protein complexes. However in some cases, G4s, such as one formed in Bcl-2 
promoter, can function as transcription activators (Brooks et al. 2010).  
G4s also play an important role in RNA. These naturally single stranded structures more 
readily adopt more complexed secondary structures and are more stable thermodynamically than 
DNA G4s (Agarwala et al. 2015a; Halder and Hartig 2011). The first described RNA G4 was in 
the 3’-end of 5s rRNA in escherichia coli (Jin et al. 1992). RNA G4s have also been described in 
5’ and 3’-UTRs and coding regions of mRNA, highlighting its biologically functional importance 
(Agarwala et al. 2015a; Jayaraj et al. 2012; Kumari et al. 2007; Millevoi et al. 2012). RNA G4s 
have also been visualized in human cells using BG4 antibody, demonstrating their intracellular 
existence as well (Biffi et al. 2014). Recent research employing a novel methodology combining 
whole cell DMS treatment with a reverse transcription stop assay and next generation sequencing, 
revealed that RNA G4s are globally unfolded by RNA binding proteins in mouse embryonic stem 
cells and evolutionally depleted in bacteria. However, this study did not probe the folding state of 
RNA G4s in human cells (Guo and Bartel 2016). Other studies have shown that RNA G4s are 
involved in various cellular activities relating to both DNA and RNA. At the DNA level, RNA 
G4s participate the transcription, recombination, and telomere homeostasis. At the RNA level, 
 8 
they are involved in the processing of pre- and micro-RNAs, the splicing of introns, the 
transportation and translation of mRNAs (Rhodes and Lipps 2015). RNA G4s regulate the 
expression of many oncogenes that belong to the hallmarks of cancer (Table 1-1), including 
NRAS, Bcl-2, VEGF, TRF2 (Cammas and Millevoi 2017).  
In addition to targeting telomeric quadruplexes as anti-cancer therapies, work has been 
conducted to target promoter and RNA G4s to downregulate oncogene expression at the 
transcriptional and translation level, respectively (Balasubramanian et al. 2011; Cammas and 
Millevoi 2017; Cimino-Reale et al. 2016). Stabilizing G4s in promoters or 5’-UTRs generally 
sequesters binding sites for activating factors and polymerases. (Balasubramanian et al. 2011; 
Cimino-Reale et al. 2016). Small molecules have been the primary focus of G4 targeting and many 
G4-interacting compounds have been discovered and studied (Ohnmacht and Neidle 2014). The 
major mode of interaction between small molecules and G4s are either tetrad binding (stacked on 
the tetrads) or loop/groove binding (vertical to the tetrads)  (Muller and Rodriguez 2014). Studies 
on many small molecules targeting promoter and RNA G4s; a summary of select G4 stabilizing 
small molecules and their proposed mechanisms of action is shown in (Table 1-2).  
To date, two G4 stabilizing compounds have made it to clinical trials – quarfloxin and CX-
5461. Quarfloxin indirectly stabilized the G4 in MYC promoter by the displacement of nucleolin 
from rRNA G4s, decreased transcription and mediated cell death in pancreatic cancer cells (Denis 
Drygin et al. 2008). Unfortunately, quarfloxin failed in Phase II trials due to high albumin binding 
(Balasubramanian et al. 2011). The other compound, CX-5461 is still under investigation in 
clinical trials for triple negative breast cancer, has been found to be a DNA G4 stabilizer (H. Xu 
et al. 2017).  
The small molecule approach has been the primary strategy for stabilizing G4s, however, 
 9 
high specificity across structurally homologous G4s is hard to achieve, mediating possible off-
target toxicity and affecting the utility of small molecules as G4 modulating anti-cancer agents 
(Chen et al. 2014). Other than a small molecule strategy, a nucleic acid approach has also been 
taken to target G4s. Guanine rich peptide nucleic acids (PNAs) was used to form a DNA: PNA 
hybrid G4 in the MYC promoter, and has been demonstrated to downregulate MYC promoter 
activity. Another PNA sequence was found to cause scissions in the genome by forming DNA: 
PNA hybrid G4s (Gupta et al. 2013; Ishizuka et al. 2012). Pu27, the G4-forming region of MYC 
promoter has been directly applied to leukemia cells, resulting in profound DNA damages in both 
telomeric and non-telomeric regions triggering cellular apoptosis (Islam et al. 2014; Sedoris et al. 
2012). An unmodified DNA oligonucleotide, PNT 2258, was used to target the distal region of the 
Bcl-2 promoter, resulting in decreased mRNA expression and cellular apoptosis (Ebrahim et al. 
2016; Tolcher et al. 2014). While PNT 2258 is a non-G4-targeted therapy, it is the first-in-class 
DNA interference therapy that has progressed into clinical trials, highlighting the potential of 
targeting DNA with DNA as A therapeutic strategy. Exploring novel G4-targeting strategies, 
differing from the conventional small molecule approach, has the potential to enhance the 
pharmacological specificity of G4 modulation, thus benefitting the development of novel 
therapeutics.  
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G4-interacting 
small molecule Proposed biological activities References 
TMPYP4 
Inhibiting MYC and hTERT by stabilizing 
promoter G4s, telomerase inhibition, disturbing 
protein binding to RNA G4s (c9 or f72) 
(Grand et al. 2002; 
Zamiri et al. 2014)  
Telomestatin  
Telomerase inhibition, triggering DNA damage 
response, c-Myb inhibition  
(Miyazaki et al. 
2012; Shin-ya et al. 
2001) 
BRACO19 
Telomere uncapping, telomerase inhibition, 
chromosomal end fusion 
(Burger et al. 2005; 
Taetz et al. 2006) 
RHPS4 
Telomere uncapping, telomerase inhibition, 
hTERT displacement  
(Phatak et al. 2007; 
Salvati et al. 2007) 
Quarfloxin 
Inhibiting MYC by the displacement of 
nucleolin from nucleoli into nucleus 
(D. Drygin et al. 
2009; Duan et al. 
2001) 
Pyridostatin 
Altering shelterin binding, DNA damage 
response, downregulating SRC 
(Muller et al. 2010; 
Muller et al. 2012) 
307A and 360A  
Telomere damage, Inducing DNA damage 
response, downregulating MYC 
(Lemarteleur et al. 
2004; Pennarun et 
al. 2008) 
Phen-DC(3) 
and Phen-
DC(6) 
Causing genome instability, telomere 
uncapping, inhibiting the translation of TRF2 by 
stabilizing its mRNA G4 
(Chung et al. 2014; 
Piazza et al. 2010) 
NSC 338258 Inhibiting MYC by stabilizing its promoter G4 (Brown et al. 2011) 
CX-5461 
MYC, c-KIT Promoter G4 stabilization, 
inducing DNA damage response and genome 
instability  
(H. C. Lee et al. 
2017; H. Xu et al. 
2017) 
12459  
Telomerase inhibition, DNA damage response 
induction, hTERT RNA G4 stabilization  
(Gomez et al. 
2003; Gomez et al. 
2004) 
CarboxyPDS 
(RNA G4 
selective) TERRA inhibition, RNA G4 stabilization  (Biffi et al. 2014) 
RGB1 (RNA 
G4 selective) 
TERRA inhibition, inhibiting NRAS translation 
by stabilizing its 5’-UTR G4 
(Katsuda et al. 
2016) 
 
Table 1-2. Summary of selected G4-interacting small molecules and their proposed biological 
activities. 
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In the departure from the small molecule based stabilizing strategy and from PNAs, we 
developed a novel nucleic acid (NA) clamp approach that can specifically bind to, and stabilize, 
individual G4s. It is our central hypothesis that NA-clamps possess highly specific binding and 
stabilization of the G4s to which they are designed. We explored NA-clamps as specific G4 
stabilizing agents at both the transcriptional and translational level. Crucial oncogenes possessing 
regulatory G4 in the promoter or 5’-UTR, MYC and NRAS, were selected as proof of principle 
targets to demonstrate our central hypothesis.   
 12 
 
 
 
 
CHAPTER II. MATERIALS AND METHODS 
 
2.1. Reagents  
Most oligonucleotides and NA-Clamps (Tables 2-1 and 2-2) were synthesized by Eurofins 
MWG Operon, LLC (Louisville, KY); NRAS WText and NRAS 6~FAM-WText sequences (Table 
2-2) were purchased from Midland Certified Reagent Co., Inc. (Midland, TX, USA). Most of the 
chemical reagents and cell culture materials were purchased from either Thermo Fisher Scientific 
(Waltham, MA), or Sigma-Aldrich (St. Louis, MO) with the exception of 
Acrylamide/bisacrylamide (29:1) being purchased from Bio-Rad Laboratories (Hercules, CA).  
2.2. DNA Dissolution, Concentration Determination and Purification 
Upon arrival, all DNA was suspended in nuclease free water and vigorously vortexed until 
no precipitates were observed. G4-forming sequences were heated at 95 C for 5 min before 
concentrations were determined (while the DNA was still hot) utilizing a NanoDrop 2000 
spectrometer to measure the absorbance at 260 nm (A260) (BioRad Laboratories, CA). The final 
concentration of the DNA was calculated by the nearest neighbor technique, dividing the A260 by 
the extinction coefficient ɛ260 (obtained from IDT oligo analyzer) x 106. All fluorescently labeled 
oligonucleotides were purified by formamide treatment (100% for 15 min at 95 C); snap cooled 
on ice and isolated on a 10% polyacrylamide gel as described above and extracted before 
concentration and determination. 
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2.3 Electrophoretic mobility shift assay (EMSA) 
All DNA samples were prepared by mixing 6-FAM labeled oligonucleotides (1 M) with 
Tris-HCl buffer (50 mM, PH7.4), and KCl (25 mM for MYC and 100 mM for NRAS), and 
acetonitrile (ACN, 40% for NRAS only) before annealing as described above; nucleic acid clamps 
(varying concentration as denoted in text) were added either pre- or post- annealing. Samples were 
heated immediately if the NA-clamps were added pre-annealing. If the NA-clamps were added 
post-annealing, the mixture solution was incubated at room temperature for 30 min in order to 
allow sufficient binding between oligonucleotides and clamps. For the NA-clamp competition 
assay, non-fluorescent oligonucleotides were added to the mixture solution simultaneously with 
the clamps, before the 30 min incubation. dsDNA of the MYC G4-forming Pu46 sequence was 
constructed by annealing (heating to 95 C and slow cool to room temperature) the G-rich strand 
with the C-rich complementary sequences. For all EMSAs, the polyacrylamide gels for DNA 
isolation were freshly prepared. Solutions were mixed to reach final concentration of 10% 
acrylamide/bisacrylamide (29:1), 1X Tris/Borate/EDTA (TBE), 0.5% ammonium persulfate 
(APS), and 0.1% tetramethylethylenediamine (TEMED). Then the mixture was evenly cast into a 
glass sandwich to allow gel formation. All gels were pre-electrophoresed at 150V for 30 min before 
DNA samples were loaded; all DNA samples were supplemented with 10% glycerol and 1X DNA 
loading dye before loading onto the gels. DNA samples were then electrophoresed at 150V until 
the dye front reached the lower 1/5 of the gel. DNA separation was visualized in a FotoDyne 
Analyst Investigator FX documentation system equipped with Blue LED epifluorescence. 
Densitometry analysis was performed by using Image J software (Bethesda, MD, USA) to 
determine the optical density of each isolated DNA band.  
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2.4. Electronic Circular Dichroism (ECD) 
Non-FAM labeled oligonucleotides (5 M) were dissolved in 50 mM Tris-HCl buffer (pH 
7.4) with KCl (25 mM for MYC and 100 mM for NRAS) and 40% ACN (NRAS samples only) 
either with or without clamps (5 M). Before annealing, the concentration of all samples were 
determined as describe. Samples were transferred into a quartz cell of 1 mm optical path length, 
and before spectra were recorded in millidegrees, with response time as a function of high volts 
from 225-350 nm. ECD spectra with an Olis DSM-20 spectropolarimeter equipped with a Peltier 
cell holder (Huntsville, AL). ECD units were converted from millidegrees to molar ellipticity using 
this olis DSM-20 software to empirically determined concentration.  
2.5. Dimethyl sulfate (DMS) footprinting  
FAM labeled oligonucleotides (10 M) were dissolved in 50 mM Tris-HCl buffer together 
with 25 or 100 mM KCl and 40% ACN as described above, in a final volume of 25 l, and annealed 
as described above; clamps (10 M) were added either pre- or post- annealing. The solutions were 
then treated with DMS by adding 1.3 L of 10% DMS (DMS : EtOH = 1: 9) to reach a final 
concentration of 0.5%; 1.3 l of 90% EtOH was added to a no DMS sample as a control. Samples 
were then incubated at room temperature for 15 min before the DMS reaction was quenched with 
7 l of DMS stop solution (1 M β-mercaptoethanol, 1 M Tris-HCl, 1.5 M sodium acetate) together 
with 1 l of 10 mg/ml calf thymus DNA. Samples were supplemented with 10% glycerol and 1X 
DNA loading dye before loading onto the pre-run 10% acrylamide gel. DNA species were 
separated by electrophoresis at 150 V for 1 hr. DNA banding was visualized with a FotoDyne 
imager. Bands of interest were excised with a scapula, transferred into 1.5 mL amber Eppendorf 
tubes and crushed with a sterile pipette tip before 250 l of gel elution buffer (0.4 M ammonium 
acetate, 1mM MgCl2, 0.2% sodium dodecyl sulfate) was added. All samples were vortexed for 10 
 15 
seconds before transferring into a 37 C shaking incubator overnight. Crushed gel particles were 
removed by 0.22 m centrifuge filter tubes and the liquid was transferred into new 1.5 ml amber 
tubes. 100% EtOH and sodium acetate solution was added to a final concentration of 80% EtOH 
and 0.3 M sodium acetate. Samples were then vortexed for 10 seconds and stored at -20 C 
overnight. Tubes were centrifuged at 4 C for 15 min at 13,000 rpm to collect the DNA pellets, 
which were air-dried and resuspended in 50 l of 1 M (10%) freshly diluted piperidine solution. 
Samples were heated at 90 C for 30 min and snap cooled on ice. All samples were ethanol 
precipitated with sodium acetate as described above, to purify the cleaved DNA. Finally, a 16% 
denaturing polyacrylamide gel with 8 M urea in 1X TBE was cast in 20x40 cm glass plates and 
pre-run for at least 30 min at 1600 V. DNA pellets were resuspended in 20 l of water plus 2 l of 
6X DNA loading dye, heated to 85 C for 3 min and snap cooled on ice before loading on the gel. 
Ten l of each sample was loaded onto the gel and electrophoresed at 2 W, overnight at 4 C. The 
gel was then visualized with a FotoDyne FX imager using blue LED epifluorescence. 
Densitometry analysis was performed with Imgae J software, and the resulting histograms were 
overlaid using Photoshop software (Adobe systems, CA). 
2.6. Pull down assay 
Non-FAM labeled oligonucleotides (5 M) were dissolved in 50 mM Tris-HCl buffer (pH 
7.4) with KCl (25 mM) with 5 M of biotinylated clamp A 5T, and annealed as described. The 
solutions were subjected to EMSA, as described above, bands of interests were excised and DNA 
was isolated and purified by centrifugation. Magnetic streptavidin beads (50 l) was added to each 
sample and incubated at room temperature for 1 hr. The beads were concentrated by the application 
of a magnetic field with a magnetic bar; DNA complexes were released from the beads by boiling 
with SDS-PAGE reducing buffer at 100°C for 5 min and snap cooling on ice. The recaptured DNA 
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was subjected to EMSA again for visualization under FotoDyne FX imager. Densitometry analysis 
was performed using Image J software. 
2.7. Cell Culture  
All cell lines described in this work were obtained from ATCC (Frederick, MD). Human 
embryonic kidney (HEK-293) cells and breast cancer (MCF-7) cells were maintained in 
Dulbecco’s modified eagle’s medium (DMEM) in tissue culture treated flasks. Burkitt’s 
lymphoma cells, RAJI and CA46, were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium in non-tissue culture treated flasks. All media solutions were supplemented with 10% 
fetal bovine serum and 1x penicillin/streptomycin. Culture flasks were incubated at 37 C in an 
incubator supplied with 5% CO2; cells were maintained in exponential growth until use.  
2.8. Transfection and Luciferase Assay 
HEK-293 cells were transfected with the Del4 plasmid (Addgene, Cambridge, MA), which 
contains the MYC promoter +/- 400 base pairs from the TSS driving luciferase expression. Cells 
were seeded at 8 x 104 cells/well in 1 ml of medium in 24-well plates and allowed to attach 
overnight. Cells were co-transfected with either the Del4 plasmid (250 ng) or the promoterless 
empty vector plasmid pGL4.17 (250 ng) (Promega, WI) and 125 ng of renilla plasmid (pRL-SV40) 
(Promega, WI) either with or without the indicated NA-Clamps in micelles formed with FuGene 
HD (Promega, WI) at a 3:1 ratio. Cells and the DNA were incubated for 24 or 48 hr and lysed in 
1X passive lysis buffer (Promega, WI) and taken through two freeze/thaw cycles to promote cell 
lysis. Luciferase was measured with the Dual Luciferase Assay kit (Promega, Madison, WI) on a 
Lumat LB9507 luminometer; firefly: renilla ratios were recorded.  All luciferase experiments were 
repeated three times, with internal biological duplicates. Luciferase expression changes were 
normalized to those with the empty vector plasmid; statistical significance was determined by one-
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way ANOVA with post-hoc Tukey’s test.  
2.9. Cellular Viability Assay (MTS Assay) 
For all cytotoxicity assays, cells were plated in 96 well plates with 90 l of media in each 
well 24 hr before treatment. MCF-7, HEK-293, and human melanoma WM3682 cells were plated 
at 2,000, 5,000, 20,000, and 40,000 cells per well for 144, 72, 48, and 24 hr time points respectively. 
RAJI and CA46 cells were plated at density of 7,000, 50,000, 100,000, 200,000 cells per well for 
144, 72, 48, 24 hr time points, respectively. For viability assays, with transfected clamps, Fugene 
HD or block co-polymers were added and incubated with the DNA for 30 min before cellular 
transfection. Transfected or just clamps (10 l) were added to each well. At the end of the 
incubation times, cellular viability changes were measured using the MTS assay (Mosmann 1983). 
Methane thiosulfonate (MTS) (2 mg/ml) in Phosphate-buffered saline (PBS) was mixed with 5% 
phenazine methosulfate (PMS), and 20 l of the solution was added to each well; plates were 
incubated at 37 °C for 2-4 hr. Absorbance at 490 nm was recorded using a BioTek Synergy 2 
spectrophotometer (BioTek Instruments, VT, USA), which was normalized to untreated control 
cells. Non-linear regression for a sigmoidal inhibition dose response was used to determine the 
IC50 using GraphPad Prism software.  
2.10. Cellular Uptake Assay  
MCF-7 breast cancer cells or Burkitt’s lymphoma (RAJI and CA46) cells were plated in 
96 well plates one day before transfection. MCF-7 cells were plated at a density of 5x104 cells/well 
in 100 µl of medium and lymphoma cells were plated at a density of 2x105 cells/well in 100 µl of 
medium 24 hr prior to transfection. FAM labeled clamp A 5T (500 ng) were either transfected with 
FuGene HD or block co-polymers, or were directly introduced into wells. Five hour post-
transfection, Hoechst 33342 (Invitrogen, SF, CA) was added to the wells at a final concentration 
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of 5 µg/ml and incubated for 1 hr at 37 °C, before media containing clamps was captured and 
stored in a clean 96-well plate. Cells were washed with PBS for 3 times before being supplied with 
fresh media. Images were collected in a Cytation 5 live cell imaging station equipped with an 
imaging chamber maintaining 37 °C supplemented with 5% CO2 (Bio-Rad, CA, USA). The first 
removed media with clamps was reintroduced into the original wells post imaging. After 24 and 
48 hr, media was captured again and cells stained with Hoechst 33342 again as previously before 
being supplemented with fresh warm media before repeating the imaging process. Scale bars were 
added to all collected images using the original Bio-Rad cytation 5 processing software. 
2.11. ChIP-PCR Assay 
MCF- 7 cells were plated into a 6 well plate at the density of 5x105 cells/well with 2 ml of 
media one day before transfection. Biotinylated clamp A 5T (10 µg or 20 µg) was transfected, as 
indicated, using Fugene HD at 3:1 ratio. Cell cultures were then maintained in a 37°C incubator 
supplemented with 5% CO2 for 24 hrs. One hour before cell lysis, test cells were treated with 2 
nM estradiol (E2) to stimulate MYC transcription and cells were placed back into the incubator. 
Media in the wells was removed 1 hr later and cells were rinsed with sterile PBS three times before 
adding 300 l of passive lysis buffer (Promega, WI). Genomic DNA was then purified with a 
purification kit (Promega), rehydrated and centrifuged at 13,000 rpm for 30 min. The supernatant 
was discarded and the DNA pellets were air dried for 30 min at room temperature. An enzymatic 
ChIP kit (Active motif, San Diego, CA) was used to shear the genomic DNA. Digestion buffer (50 
l, supplemented with 1.75 μl protease inhibitor cocktail and 1.75 μl phenylmethane sulfonyl 
fluoride) (Active motif, San Diego, CA) was added to each sample and incubated for 5 minutes at 
37 °C. Each sample was treated with 5 μl of enzymatic shearing cocktail (200 U/mL) and incubated 
at 37°C for 20 min; tubes were vortexed every 5 min during the incubation process. Ice cold 0.5 
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M EDTA (1.5 μl) was added to each tube, and all samples were chilled on ice for 10 min to stop 
the shearing reaction. Magnetic streptavidin beads (50 μl) were added to each tube and the samples 
were incubated at room temperature for 1 hr to allow sufficient biotin-streptavidin interaction. No 
beads were added to the positive controls (input); and 50 μl of beads were added to the no clamp 
control group. A magnetic field was applied to all tubes to pull down the DNA complex associated 
with biotinylated clamps. The precipitates were washed with nucleus free water three times and 
then suspended in 10 mM EDTA (pH 8.2) with 95% formamide. All samples were heated at 90 °C 
for 10 min and snap cooled on ice. DNA was then precipitated with 80% EtOH supplemented with 
0.3 M sodium acetate at -20 °C, overnight. DNA pellets were collected by centrifugation at 13,000 
rpm for 30 min and resuspended in 30 μl of nuclease free water. The DNA concentration was 
determined by using a Nanodrop 2000 as described; 500 ng of template DNA and MYC primers 
(RB 26F and RB 26R) were used for PCR amplification with hot start Taq DNA polymerase kit 
(Phenix, Candler, NC). Cycling conditions were 94 °C for 3 min followed by 30 cycles of 94 °C 
for 30 s, 55°C for 30 s, and 72°C for 60 s. Post PCR amplification, DNA samples were subjected 
to agarose gel (supplemented with GelGreen (Phenix)) electrophoresis at 100 V for 40 min. Bands 
were visualized under a FotoDyne FX imager. Densitometry analysis was performed using Image 
J software.  
2.12. Quantitative Real-Time PCR (qRT-PCR) 
MCF-7 were plated in 12 well plates at the density of 2.5x105 cells/well in 1 ml of DMEM; 
RAJI and CA46 cells were plated in 12 well plates at the density of 1x106 cells/ml in 1ml of RPMI 
1640 media. All cells were cultured in a 37 °C incubator supplemented with 5% CO2 for 24 hr 
before transfection. Clamp A 5T (2.5 g) was transfected into each well with Fugene HD at 3:1 
ratio. Estradiol (2 nm) was added to MCF-7 cells 1 hr before cell lysis. After 24 hr transfection, 
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cell pellets collected from each plate were lysed with lysis buffer (Thermo Scientific, SF, CA) 
supplemented with 2% -mercaptoethanol. RNA samples were extracted with a GeneJET RNA 
purification kit (Thermo Scientific). RNA concentrations were determined using a Nanodrop 2000; 
the purity of RNA was monitored with the A260/A230 ratio and only samples with values >2 were 
used in the study. cDNA synthesis was conducted using an Applied Biosystem cDNA synthesis 
kit (ABI, SF, CA). 500 ng (MCF-7) and 2 g (RAJI and CA46) of mRNA were reverse transcribed. 
qRT-PCR was performed on a BioRad CFX Connect™ Real-Time PCR Detection System 
(BioRad, CA) using Taqman primers from ABI (MYC Exon 1: Hs01562521_m1, MYC Exon 2: 
Hs00153408, GAPDH: Hs02758991_g1). mRNA expression level was normalized to GAPDH 
and again vehicle controls, using the Cq method. All experiments were run in biological 
triplicates with qPCR run with technical duplicates. One-way ANOVA with post hoc-Tukey’s test 
was used to determine the statistical significance using GraphPad Prism software. 
2.13. G4 Induction assay 
MCF-7, RAJI, and CA46 cells were plated into 96-well plates one day before treatment 
with the MYC selective G4-stabilizing compound NSC 338258 (Brown, et al, JBC, 2011) at 0.5X, 
1X and 1.5X IC50 of 24 hr for each cell line. Six hr post treatment, cells were fixed with 4% 
formaldehyde for 15 min and permeabilized with 0.2% Triton-X 100 for 10 min at room 
temperature. Cells were then incubated with 0.1 μM of FAM labeled clamp A 5T or control ODN 
(negative control) and 5 μg/ml Hoechest 33342 at room temperature for 1 hr. Cells were washed 
with PBS for three times before imaging on a Cytation 5 imaging station. The fluorescence was 
normalized to the control cell (no treatment group) by deducting the auto fluorescence of control 
cells. 
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2.14. Western Blotting 
Melanoma WM3682 cells were plated in 12 well plates at a density of 3x105 cells/well in 
1 ml of Leibovitz's L-15 medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin 24 hr before transfection. Varying concentrations of NRAS clamp 1 and 
clamp 2 (500, 1000, 2500, 5000 ng) were transfected into cells using Fugene HD at a 3:1 ratio. 
Cells were lysed 24 hr post-transfection using radio immunoprecipitation RIPA buffer 
(Thermofisher Scientific). Plates were shaken for 30 min before transferring the lysates into 
microcentrifuge tubes. The lysates were centrifuged for 20 min at 12,000 rpm at 4 °C before the 
supernatants were collected. The bicinchoninic acid (BCA) assay was used to determine the 
protein concentrations of all lysates. Briefly, BCA working reagents were prepared first by mixing 
BCA reagents A and reagent B at a 50:1 ratio. Bovine serum albumin (BSA, 30 µl of 2 mg/ml) 
were transferred into the first well for the BSA standard followed by series dilution (10 times) in 
RIPA buffer; the mixture working reagents (200 µl) were then added into each well of a 96-well 
plate. For sample measurements, samples collected from lysis buffer were diluted 10 fold then 30 
µl of each diluted cell lysate was added to wells containing 200 µl of working reagents. Plates 
were incubated at 37 °C for 30 minutes prior to absorbance reading at 562 nm on a Bio-Tek 
Synergy II spectrophotometer. Protein concentrations were calculated based on the standard BSA 
curve by linear regression. After obtaining the total protein concentration, 30 µg of total protein 
from each sample denatured by heating to 95 °C for 5 minutes, and loaded onto an 8% pre-cast 
bis-polyacrylamide gel (BioRad) along with a molecular weight ladder. The gel was 
electrophoresed at 100 V for 1 hr. For protein transfer, a polyvinylidene difluorid (PVDF) 
membrane pre-activated with methanol for 1 minute and rinsed with transfer buffer (25 mM Tris, 
190 mM glycine, 20% methanol) was used. Proteins were transferred from the gel to the membrane 
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at 25 V overnight. For immunostaining, the membranes were blocked by soaking at with 5% BSA 
in TBST overnight at 4 °C. Primary purified mouse monoclonal NRAS antibody (Abgent, SD, CA) 
diluted in blocking buffer at a 1:5000 ratio was incubated with the membranes overnight at room 
temperature on a shaker. Membranes were then washed with TBST (Tris-buffered saline, 0.1% 
Tween 20) three times for 5 minutes each, then incubated with fluorescent-labeled (LiCOR IRDye 
800CW) secondary anti-mouse antibody (LICOR Biosciences, NE, USA) in blocking buffer for 1 
hour. The membranes were washed again with TBST three times. Finally, images were acquired 
on a Li-COR Odyssey CFX imaging system. Densitometry analysis was performed on the Li-COR 
Odyssey software.  
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Table 2-1. MYC oligonucleotide sequences (5’-3’).   
Pu46 GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAGGAGAC
mt5 GCGCTTATGGGGAGGGTGGGGAGGGTGTGGAAGGTGGGGAGGAGAC
mt3 GCGCTTATGGGGAGGGTTTTTAGGGTGGGGAAGGTGGGGAGGAGAC
mt1,6 GCGCTTATGGTGAGGGTGGGGAGGGTGGGGAAGGTGTGGAGGAGAC
mt2,3 GCGCTTATGGGGAGTGTGGTGAGGGTGGGGAAGGTGGGGAGGAGAC
mt1,2,3,4 GCGCTTATGGTGAGTGTGGTGAGTGTGGGGAAGGTGGGGAGGAGAC
[6-FAM]	Pu46 [6-FAM]	GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAGGAGAC
[6-FAM]	mt5 [6-FAM]	GCGCTTATGGGGAGGGTGGGGAGGGTGTGGAAGGTGGGGAGGAGAC
[6-FAM]	mt3 [6-FAM]	GCGCTTATGGGGAGGGTTTTTAGGGTGGGGAAGGTGGGGAGGAGAC
[6-FAM]	mt1,6 [6-FAM]	GCGCTTATGGTGAGGGTGGGGAGGGTGGGGAAGGTGTGGAGGAGAC
[6-FAM]	mt2,3 [6-FAM]	GCGCTTATGGGGAGTGTGGTGAGGGTGGGGAAGGTGGGGAGGAGAC
[6-FAM]	mt1,2,3,4 [6-FAM]	GCGCTTATGGTGAGTGTGGTGAGTGTGGGGAAGGTGGGGAGGAGAC
Clamp	A	 CTCCTCCCCACCTTCCCC[C-18]ATAAG
Clamp	A	5’ CTCCTCCCCACCTTCCCC
Clamp	A	5’	link CTCCTCCCCACCTTCCCC[C-18]
Clamp	A	3’ ATAAG
Clamp	A	3’	link [C-18]ATAAG
Clamp	B CTGAGTCTCCTCCCCACCTT	[C-18]TCCCC
Clamp	C CTGAGTCTCCTCCCCACCTT	[C-18]ATAAG
Clamp	A	5T CTCCTCCCCACCTTCCCCTTTTTATAAG
[6-FAM]	Clamp	A	5T [6-FAM]	CTCCTCCCCACCTTCCCCTTTTTATAAG
[Biotin]	Clamp	A	5T [Biotin]	CTCCTCCCCACCTTCCCCTTTTTATAAG
5T	 TTTTT
Clamp	A	5’	5T	 CTCCTCCCCACCTTCCCCTTTTT
Clamp	A	3’	5T TTTTTATAAG
Clamp	A	4T CTCCTCCCCACCTTCCCCATTTTATAAG
Clamp	A	3T CTCCTCCCCACCTTCCCCATTTATAAG
RB	26F	 CGATGATTTATACTCACAGGACAAG
RB	26R GCGAGAGAGGATCTTTTTTCTTTTCC
[6-FAM] Control ODN [6-FAM]	AGTCCCTCCTCCCGCCAA
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Table 2-2. NRAS oligonucleotide sequences (5’-3’).   
NRAS	WT TGTGGGAGGGGCGGGTCTGGGTGC
NRAS	MT TGTGGGATTTTCGGGTCTGGGTGC
NRAS	WText GAAACGTCCCGTGTGGGAGGGGCGGGTCTGGGTGCGGCCTGCCGCA
NRAS	MText GAAACGTCCCGTGTGGGATTTTCGGGTCTGGGTGCGGCCTGCCGCA
NRAS	clamp	1 TGCGGCAGGCCGCA[C-18]ACACGGGACGTTTC
NRAS	clamp	2 GCAGGCCGCA[C-18]ACACGGGACG
[6-FAM]	NRAS	WText [6-FAM]	GAAACGTCCCGTGTGGGAGGGGCGGGTCTGGGTGCGGCCTGCCGCA
[6-FAM]	NRAS	MText [6-FAM]	GAAACGTCCCGTGTGGGATTTTCGGGTCTGGGTGCGGCCTGCCGCA
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CHAPTER III. TARGETING MYC PROMOTER G4 USING NA-CLAMPS 
 
 
3.1. Introduction 
G-quadruplexes (G4s) are non-canonical secondary DNA structures that are formed by 
guanine-guanine, instead of guanine-cytosine, base pairing. A G4 structure can occur if there are 
more than four consecutive guanine runs with at least three guanines in a row in any nucleic acid 
sequence. Genome wide sequencing analysis, together with visualization studies in human cancer 
cells have demonstrated that G4 structures form in human cells, generally clustering around the 
regulatory, nucleosome-depleted, regions of DNA and RNA, indicating that they play important 
functional roles in the regulation of oncogene expression at both transcriptional and translational 
levels (Biffi et al. 2013; Biffi et al. 2014; Verma et al. 2008). As discussed previously, potential 
G4-forming sequences were discovered to exist in over 50% of human gene promoters, especially 
these associated with the cancer hallmarks (Huppert and Balasubramanian 2007; Jayaraj et al. 
2012). As shown in Table 1-1, many DNA and RNA G4s form in critical cancer associated genes 
across the ten hallmarks of cancer. These G4s formed in various locations within the genome can 
modulate transcription, translation, direct splicing of introns, and control telomere associated 
signaling pathways that are closely correlated with tumorigenesis (Balasubramanian et al. 2011; 
Brooks and Hurley 2010; Brown et al. 2011; Cammas and Millevoi 2017; Ivancich et al. 2017; 
Kumari et al. 2007; Marcel et al. 2011; Phatak et al. 2007; Siddiqui-Jain et al. 2002)  
 Among the oncogenic genes that contain biologically active G4s, the promoter of proto-
oncogene MYC was the first identified, and has been the most, studied. The discovery of the 
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relationship between MYC overexpression and chromosomal translocation in Burkitt’s lymphoma 
cells marked MYC as a major oncogene (Dalla-Favera et al. 1982). MYC is a basic helix-loop-
helix/leucine zipper transcription factor that regulates up to 15% of gene expression genome-wide 
with over 30,000 potential binding sites (Patel et al. 2004). MYC has been described as a 
symphony conductor that regulates a wide range of cellular functions from cellular proliferation, 
differentiation, metabolism, apoptosis, and metastasis to angiogenesis. However, the best-known 
function of MYC is driving cancer cell proliferation, and alterations of MYC are commonly found 
to relate to tumorigenesis (Dang 2010).  
Initially, the ability of MYC to drive cellular proliferation was thought to be associated 
with its ability to directly regulate DNA replication, which was supported by the early evidence in  
several studies including: (1) In the Xenopus laevis oogenesis process, maternal cytoplasmic MYC 
was translocated to the nucleus during a developing period with no transcriptional activity and 
activates rapid replication of these non-dividing cells (Gusse et al. 1989); and (2) polyclonal and 
monoclonal MYC antibodies can inhibit DNA synthesis and polymerase activity in human 
leukemia cell lines that contain a high concentration of MYC (Studzinski et al. 1986). Their studies 
pointed out that MYC is regulating and activating DNA synthesis and driving cellular replication; 
however, research using MYC antibodies produced in other laboratories did not recapture a similar 
phenomenon. Gutierrez’s research pointed out the replication inhibition of MYC antibody from 
watt lab’s study might result from the contamination of their antibody preparation process by an 
unknown DNA polymerase inhibitor (Dominguez-Sola et al. 2007; Gutierrez et al. 1988).  
In the late 1980s, interest in further studying the relationship between MYC and DNA 
replication was overshadowed by studies on MYC’s role as a transcriptional regulator (Luscher 
and Eisenman 1990; Marcu et al. 1992; Meyer and Penn 2008). The MYC protein contains an N-
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terminal transcriptional regulatory domain followed by a nuclear localization sequence and a C-
terminal domain comprised of a basic helix-loop-helix-leucine zipper (HLH-/Leu-zipper) 
dimerization motif. As a transcription factor, MYC dimerizes with another protein, MAX, through 
the HLH/Leu-zipper domain to facilitate DNA binding. The MYC-MAX complex can bind E-
boxes with a consensus sequence (5’-CACGTG-3’) (Amati et al. 1993; Kerkhoff et al. 1991). It 
can either activate or repress its target gene expression by different mechanisms. For activation, 
MYC binds to E-boxes in the promoter of the target gene and recruits multiple proteins, including 
RNA Pol II, transcription cofactors, and chromatin remodeling complexes to activate transcription 
(Eberhardy and Farnham 2002; Gomez-Roman et al. 2006; Kanazawa et al. 2003; Park et al. 2001). 
On the other side, MYC represses gene expression either epigenetically, by recruiting proteins like 
histone methyltransferases to reduce chromatin accessibility, or by binding to other transcriptional 
factors, such as Miz1 and Sp1, to repress their transactivating capability on the expression of genes 
that are normally cell cycle inhibitors or differentiation signaling (Amati et al. 2001; Herkert and 
Eilers 2010).  
In addition to being a transcription initiator, MYC affects transcriptional elongation 
globally throughout the nucleus by affecting the phosphorylation of the C-teminal domain (CTD) 
of RNA Pol II (Cowling and Cole 2007). MYC binds to and recruits CTD kinases and other 
transcriptional factors to the promoters of target genes to induce further phosphorylation of RNA 
Pol II and thus transcriptional elongation (Bouchard et al. 2004; Cowling and Cole 2007; 
Eberhardy and Farnham 2002).  
As a key regulator of cellular proliferation, differentiation, apoptosis and cellular growth, 
MYC also participates in significant transcription-independent biological functions (Cole and 
Cowling 2008). Previous research has shown that a MYC mutant protein, devoid of DNA binding 
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capacity, promotes global phosphorylation of RNA Pol II, thus activating transcription. Also, the 
transcription activation of MYC is associated with MYC’s function as a facilitator for the 5’ 
capping and methylation of mRNA, and protein translation by the recruitment of transcription 
factor IIH (TFIIH) and other co-factors (Cowling et al. 2006; Cowling and Cole 2007). In addition, 
MYC directly interacts with many components of the pre-replicative complex, such as mini 
chromosome maintenance complex (MCM) proteins and Carbohydrate deficient transferrin 1 
(CDT1), and initiates replication by binding to DNA replication origins (Dominguez-Sola et al. 
2007).  
 As a master commander of cellular activities, especially proliferation and metabolism, the 
overexpression of MYC can play an essential role in oncogenesis. MYC expression is strictly 
controlled and usually expressed at low levels, both transcriptionally and translationally, under 
normal cellular proliferation circumstances. In these non-transformed cells, MYC expression is 
balanced by positive or negative signal transduction pathways such as WNT, MAPK, and Notch, 
or TGF-, respectively (Oster et al. 2002). MYC is overexpressed in over 80% of cancers via 
various mechanisms, including (1) insertional mutagenesis, (2) chromosomal translocation, and 
(3) gene amplification, all of which enable MYC signaling independent from the extracellular 
context (Meyer and Penn 2008). As MYC participates in many key cellular functions of a cell, 
such as DNA replication, RNA processing, differentiation, cell cycle regulation, transcriptional 
factor and tumor suppressor interaction, and cellular apoptosis, dysregulation and aberrant 
expression of the oncogene is keenly involved in tumorigenesis (Dang 2010). 
The first mechanism that enables MYC deregulation is retroviral insertional mutagenesis. 
The discovery of the MC29 v-gag-myc chimeric protein in leukemia in 1979 was the first 
demonstration that retroviral promoter insertion into a non-mutated cellular gene can account for 
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tumorigenesis and MYC became the first oncogene known to be activated through this mechanism 
(Payne et al. 1982; Varmus 1984). Since the discovery of v-myc, it has been shown that the 
overexpression MCY can readily transform various types of cells, including chicken embryonic 
fibroblasts, murine bone marrow, and hematopoietic cells with high efficiency (Chisholm et al. 
1992; Pirami et al. 1991; Ramsay et al. 1990).   
Similar to the well-known BCR-ABL1 fusion protein that resulted from a chromosomal 
translocation (Gabert et al. 1989), the second mechanism that deregulates MYC is also based on 
chromosomal translocation that was first discovered in Burkitt’s lymphoma cells. In these cells, 
the immunoglobulin (Ig) light or heavy chain on chromosome 2, 14, or 22 are translocated to 
chromosome 8, proximal to the MYC locus. As a result, Ig chains are situated by the MYC gene 
and function as transcriptional enhancers for MYC in these immune cells (Dalla-Favera et al. 
1982). This juxtaposition enables MYC with unrestrained expression and transform these cells (L. 
M. Boxer and Dang 2001).  
The third mechanism that deregulates MYC is gene amplification where greater copy 
numbers of the MYC gene increase expression, thus transforming the cells. This amplification 
phenomenon was reported in the early 1980s from different groups on several human cancer cell 
types. The first copy number alteration of MYC was discovered in human promyelocytic cell line 
HL-60 and primary leukemia cells from the same patient (Dalla Favera et al. 1982). Later, 
amplified gene copies of MYC was noted in colon carcinoma, neuroblastoma, breast cancer, small 
cell lung cancer and diffuse large B-cell lymphoma, which further demonstrated the importance of 
amplification of MYC on tumorigenesis (Alitalo et al. 1983; Escot et al. 1986; Nau et al. 1985; 
Slavc et al. 1990; Stasik et al. 2010).  
In addition to viral promoter insertion, chromosomal translocation, and gene amplification, 
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other mechanisms that also activate MYC expression include the activation of hormones, growth 
factors and their receptors, activated upstream signaling pathways, and mechanisms that either 
directly or indirectly stabilize MYC mRNA or protein, such as disrupted ubiquitination of mRNA 
in cells  (Dani et al. 1984; Dubik and Shiu 1988; Lacy et al. 1989; Meyer and Penn 2008; Spencer 
and Groudine 1991).   
In contrast to normal cells, MYC overexpressing cancer cells can become obligated to the 
fast-paced and non-restricted cellular growth and proliferation (Dang 2012). MYC-induced 
cancers are addicted to the downstream benefits of MYC overexpression, such as nutrients and 
growth signals; however, they are addicted to the MYC protein itself in many human tumor types, 
including breast cancer, lymphomas, nasopharyngeal carcinoma, and colon cancer (Brown et al. 
2011; Niu et al. 2015; Y. H. Wang et al. 2005; X. Zhang et al. 2009). Turning off ectopic MYC 
expression in these cancer cells triggers an imbalance between biogenesis and nutrient supply and 
subsequent cell death. Notably, not all MYC overexpressing cancer cells are susceptible to MYC 
deactivation, possibly due to multiple oncogenic dysregulation, such as kRAS and VEGF, to 
sustain cancer cell survival (R. B. Boxer et al. 2004; Jain et al. 2002; Soucek et al. 2008).  
On the path to cancer, MYC not only contributes to the sustained proliferation and 
heightened biogenesis, but also to genomic instability and cell metastasis (Dang 2012). Previous 
researchers has established a solid correlation between MYC overexpression and increased 
genomic instability that in turn leads to tumor initiation (Kuzyk and Mai 2014). As discussed 
previously, MYC regulates a large network of cellular activities including transcription activation, 
DNA replication, translation, RNA processing, microRNA expression profile regulation and 
heightened ribosomal and mitochondrial biogenesis. All of these hyperactive states, which are 
linked to increased mutational rates, boosted reactive oxygen species (ROS) generation, telomere 
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damage and DNA repair, set the stage for the genomic alterations in MYC overexpressing cancer 
cells (Egler et al. 2005; Louis et al. 2005; Prochownik 2008; Vafa et al. 2002; Wade and Wahl 
2006). In addition to inducing genomic instability, MYC facilitates epithelial-mesenchymal 
transition (EMT) and subsequent invasion, migration, and metastasis, by inhibiting genes 
regulating cell to cell contact and attachment, such as E-cadherin (Rapp et al. 2009; Wolfer and 
Ramaswamy 2011). With all of these capabilities of MYC transforming cell, targeting MYC and 
deactivating MYC expression is a viable therapeutic pursuit.  
It is clear that MYC is a key oncogene that plays an essential role in the genesis and 
progression of many cancer types. Many studies have demonstrated that inhibiting MYC can 
trigger cellular apoptosis in a tissue- and cell-type-dependent manner, as discussed above. 
Inhibiting MYC expression is well tolerated in a mouse model, where whole body knockout 
decimated cancer development but only reduced proliferation rates in the skin, testes, 
gastrointestinal tract, and hematopoietic cells with no overt phenotypic effects (Soucek et al. 2008). 
Moreover, a threshold of MYC expression was required to maintain the tumor phenotype; 
decreasing MYC expression below this threshold was sufficient to induce the apoptosis of T-cell 
lymphocytes (Shachaf et al. 2008). This research indicates that MYC inhibition can be a practical 
strategy for treating sensitive human cancers.  
A variety of strategies have been utilized to target this well-established driver of cancer. 
However, there are hurdles that need to be overcome to successfully inhibit the MYC protein or 
its expression. As a transcription factor, MYC is localized in the nucleus, which erased the 
possibility of using antibody based strategies to block its activity due to the size of antibodies. As 
a protein lacking enzymatic function and small molecule binding pockets on the surface, it has 
been described as “undruggable” (Posternak and Cole 2016). So far, several methods have been 
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employed to regulate MYC expression and function, mainly by the following five strategies: (1) 
blocking the interaction between MYC and MAX; (2) inhibition of bromodomain-containing 
protein BRD4; (3) targeting cyclin-dependent kinase 7 (CDK7); (4) synthetic lethality of MYC 
overexpressing cells; and (5) targeting MYC expression by stabilizing its promoter G4. Among 
these strategies, only number one and five inhibits MYC function or expression directly (Brooks 
and Hurley 2010; Posternak and Cole 2016). 
 MYC functions primarily through dimerization with MAX using the HLH/Leu-zipper 
motif to achieve DNA binding at a consensus sequence (5’-CACGTG-3’) of its targets genes’ E-
boxes, oncogenic activity of MYC is dependent on this interaction with MAX (Amati et al. 1993; 
Blackwood and Eisenman 1991; Kerkhoff et al. 1991). Significant effort has been devoted to 
disrupting the dimerization between MYC and MAX in order to inhibit MYC’s function as a 
transcription factor. Several small molecule inhibitors have been developed to achieve this goal 
(Prochownik and Vogt 2010). The most potent small molecular developed so far that inhibits 
MYC-MAX dimerization is KJ-Pyr-9, which has shown efficacy on inhibiting the expression of 
MYC target genes and retarding cell cycle progression, as well as inhibiting cell proliferation in 
vitro and in vivo (Hart et al. 2014).  However, this class of compounds functions through targeting 
the HLH-LZ domain, they can non-specifically bind to any other proteins also containing a HLH-
LZ domain in the cell, such as HIF. Other researchers have tried to inhibit the binding of MYC-
MAX complex to DNA by utilizing a mutant MYC HLH-LZ domain (Omomyc), which forms a 
homodimer itself, as a competing binder to MYC/MAX complex, thus inhibiting its function 
(Savino et al. 2011; Soucek et al. 1998). This mutant domain triggers apoptosis of MYC 
overexpressing tumor cells in vitro and in vivo (Jung et al. 2017; Soucek et al. 2002; Soucek et al. 
2008).  
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 Indirectly, MYC has been targeted by bromodomain (BRD) and extra terminal (BET) 
inhibitors, specifically inhibitors for BRD4 that belongs to the mammalian BET protein family 
together with BRD2, BRD3, and BRDT. BET proteins comprise two tandem bromodomains and 
an extra-terminal domain. Functionally, BRD4 binds to acetylated lysines (Ac-K) on histones, 
together with the binding to P-TEFb. BRD4 can bind to and activate P-TEFb, which in turn 
phosphorylates the CTD of RNA Pol II, thus sustaining transcriptional elongation (Itzen et al. 
2014). As discussed previously, MYC not only initiates transcription, but also promotes 
transcription elongation globally when overexpressed by phosphorylating the lysine on the CTD 
of RNA Pol II (Cowling and Cole 2007). Even though the mechanism of MYC downregulation by 
BET inhibitors is still unknown, it is plausible that by inhibiting BRD4 and P-TEFb function, more 
MYC is recruited as a general kinase for CTD, thus leaving less for transcription initiation of its 
target genes. Small molecules have been developed to inhibit the binding between BRD4, and Ac-
K. The most well studied compound is JQ1, which binds to the Ac-K binding site of BRD4 thus 
preventing transcriptional elongation (Filippakopoulos et al. 2010). Intriguingly, studies have 
found that treatment with JQ1 results in over 80% MYC downregulation within 1 hour in multiple 
myeloma cells (Aird et al. 2017; Delmore et al. 2011). Multiple studies have evaluated the efficacy 
of this compound against a variety of leukemias, lymphomas, ovarian, gastric, and triple negative 
breast cancers in vitro and in vivo, which revealed that JQ1 leads to tumor regression by 
downregulating MYC and its downstream targets (Bid et al. 2016; Delmore et al. 2011; Mertz et 
al. 2011; Montenegro et al. 2016; Z. Zhang et al. 2016). In terms of toxicity, JQ1 produces a dose-
dependent decrease of MYC expression in immune and lymphoid cell compartments and lead to a 
decrease in B- and T- cell counts in the peripheral system at an efficacious dose-range (D. U. Lee 
et al. 2016). Currently, seven bromodomain inhibitors, including GSK525762 (NCT01587703), 
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BAY 1238097 (NCT02369029), MK-8628 (NCT02698176), RO6870810/TEN-010 
(NCT02308761), CPI-0610 (NCT01949883), BMS-986158 (NCT02419417), and INCB057643 
(NCT02711137) are in clinical trials at varying stages for multiple hematopoietic and solid tumors 
(clinical trials.gov). With current limited trial results that suggest promise for BET inhibitors on 
several cancer types, further investigations and trial data are needed to determine the clinical 
impact for these small molecules and BET inhibition approach for cancer treatment (Aird et al. 
2017).  
CDK7 is the catalytic subunit of transcription factor II H (TFIIH), which phosphorylates 
the CTD of RNA Pol II for transcription initiation (Egly and Coin 2011). Small molecules, 
including benzamide THZ1 and THZ2, have been developed for inhibiting CDK7 activity. Initial 
research has shown that THZ analogues are able to reduce tumor size, halt proliferation, and induce 
apoptosis in a variety of MYC and MYC-N driven tumors, including neuroblastoma, small cell 
lung cancer, and triple negative breast cancer. These effects have been attributed to the significant 
downregulation of MYC due to the inhibition of super enhancers upstream of the gene that are 
responsible for transcription (Chipumuro et al. 2014; Christensen et al. 2014; Y. Wang et al. 
2015b).   
Other efforts have been made to target the synthetic lethality of cancer cells that are 
overexpressing MYC. Previous research has revealed that MYC-driven cancer cells are susceptible 
to the manipulation of certain pathways, including aurora B kinase, AMPK related kinase 5, 
spliceosome core factors, RAS phosphorylation pathways and glucose uptake pathways that are 
critical for cancer cell growth or survival (Hsu et al. 2015; L. Liu et al. 2012; Sabnis et al. 2017; 
Sears et al. 2000; Yang et al. 2010). Further investigations towards the therapeutic opportunity of 
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these pathways or a combination of multiple pathways that are lethal to cancer cells should be 
explored in future to facilitate MYC targeted cancer therapy.  
Lastly, but most importantly for the current work, targeting MYC expression directly 
through the stabilization of the promoter G4 has been well characterized (Brooks and Hurley 2010). 
The MYC G4 in the NHE III1 region upstream of the P1 promoter is a well-characterized 
biologically active promoter structure that represses transcription (Simonsson et al. 1998). The 
MYC gene possesses four promoters – P0, P1, P2, and P3 (Levens 2008; Wierstra and Alves 2008).  
Among these four promoters, P1 and P2 are the major promoters that initiate most of the 
transcription of MYC. Previous studies have shown that these two start sites, and most notably P2 
(75-90%), initiate 90% of MYC transcription, while P0 and P3 each initiate less than 5% of 
transcription (Albert et al. 2001; Levens 2008). Just upstream of the P1/P2 sites, there is a nucleus 
hypersensitivity element (NHE III1) region (Figure 3-1) that is guanine- and cytosine-rich, with 
the ability to form higher order structures, including G4s and i-motifs, during transcription. Early 
studies demonstrated that this NHE III1 region is required for the transcription initiation of MYC 
regardless of which promoter (P1 or P2) is being used (Berberich and Postel 1995; Simonsson et 
al. 1998). During transcription, the negative superhelicity generated by transcriptional machineries 
enables the dynamic equilibrium between single stranded, double stranded, and secondary DNA 
structures within the NHE III1 region (Brooks and Hurley 2009). Instead of being relieved from 
the negative superhelicity generated by transcription immediately through the action of 
topoisomerase I and II, the supercoiling in the MYC promoter is maintained by the melting of the 
Far Up Stream Element (FUSE) 1.7 kb upstream of the P2 promoter site (J. Liu et al. 2006). This 
FUSE element can bind to FUSE binding protein (FBP) and FBP interacting repressor (FIR) 
protein to positively and negatively, respectively, control the rate of promoter firing as a cruise 
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control system (Kouzine et al. 2008; Lavelle 2008). Due to this maintained torsional stress, the 
NHE III1 region is able to adopt G4s and i-Motifs. When the DNA is in duplex form, Sp1 can bind 
and activate transcription. During transcription; in single stranded form, CNBP and hnRNP K bind 
to the G- and C-rich strands, respectively, and activate the transcription. However, when there is 
G4 or i-motif formation, transcription is deactivated (Gonzalez and Hurley 2010). Proteins 
nucleolin and NM23-H2 have been identified as proteins that assist the folding and unraveling of 
the G4s formed in this region, respectively (Dexheimer et al. 2009; Gonzalez et al. 2009).  
 Within the NHE III1, there are six guanine runs that facilitate the formation of multiple 
isoforms of G4s. Studies on the linear DNA oligonucleotide Pu27, which contains the first five 
guanine runs of the NHE III1 region, highlighted the participation of guanine runs II, III, IV, and 
IV with the loops of 1:2:1 (5’-3’), that adopts a parallel G4 conformation (Siddiqui-Jain et al. 2002). 
However, DMS footprinting studies using plasmid DNA that contained the MYC G4-forming 
region revealed that the predominant physiologically relevant G4 isoform formed under 
supercoiled conditions is G41-4, a parallel structure with loops of 1:2:1 in the 5’ to 3’ direction, 
which involves the participation of guanine runs I, II, III, and IV, despite its lower thermal stability 
compared to G42-5 in a later study (Mathad et al. 2011; Sun and Hurley 2009).  
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Figure 3-1. MYC promoter structure and the NHE III1 region capable of forming G4s. 
Within the MYC promoter, there are four transcription start sites from P0 through P3, with 
P1 and P2 initiate majority of the transcription. –142 to –115 base pairs upstream of the P1 
promoter, there is a NHE III1 region that regulates 90% of the transcription. This region is 
guanine and cytosine rich and contains six consecutive guanine runs capable of forming 
multiple G4s. As shown in the figure, the major isoform of G4 isoform in single stranded 
(ssDNA) is G42-5 while the physiologically relevant G4 isoform is G41-4 formed in 
supercoiled DNA (scDNA), both structure share loops of 1:2:1 configuration from 5’ to 3’ 
(Adapted from Brook & Hurley, 2009; González, Verónica & Hurley, 2010).  
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MYC G4s have been demonstrated to be transcriptional silencers by the sequestration of 
transcriptional binding sites (Brooks and Hurley 2009, 2010; Gonzalez and Hurley 2010). By far, 
the most marked efforts have been exerted to discover small molecules that stabilize the MYC G4 
to downregulate MYC transcription. The most successful G4 stabilizing compound (Quarfloxin, 
NCT00780663), as discussed above, went to Phase II clinical trials in patients with low to 
intermediate grade neuroendocrine carcinoma. However, this compound stopped at phase II trials 
due to high albumin binding (clinicaltrials.gov). Interestingly, a recent study revealed that one 
analogue of Quarfloxin, CX-5461, which is already on active phase I/II clinical trials 
(NCT02719977) for multiple solid tumor types, is a G-quadruplex stabilizer that induces structure 
formation and chromosomal instability in vivo (H. Xu et al. 2017). CX-5461 is an inhibitor of 
rRNA synthesis that selectively inhibits Pol I-driven transcription of rRNA with nano molar range 
of IC50 on a variety of cancer cell lines, it showed no effect on Pol II, and selectivity inhibits rRNA 
transcription over DNA replication and protein translation. Also, this compound is demonstrated 
to be orally bioavailable and present in vivo antitumor activity against murine xenograft human 
tumor models, especially MIA PaCa-2.  Currently, it has been tested on several patients showing 
promising tumor regression, further investigation is needed to determine if it possess better 
efficacy than current standard care (clinicaltrials.gov).  
These data strongly suggest that G4-interacting small molecules can be effective as cancer 
therapeutics. Specifically, for MYC, many G4-interacting compounds ranging from perylene 
derivatives, cationic porphyrins, quindolines, DNA dyes, alkaloids, metal complexes, carbamide 
and its analogues, and many other ligands, stabilize the MYC promoter G4. Notably, an ellipticine 
compound called NSC 338258 has been identified as an active and moderately selective MYC G4 
stabilizer, with nanomolar affinity. In vitro studies on Burkitt’s lymphoma cell lines RAJI and 
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CA46 demonstrated that the antiproliferation effect of this compound is mediated by the 
stabilization of MYC promoter G4. This compound showed G4 class-related effects on other 
promoter quadruplexes, such as VEGF and HIF-1α, which dampens its development as an anti-
cancer therapeutic (Brown et al. 2011). To date, however, it is the only compound to have 
demonstrated a mechanism of action in cells of stabilizing the higher order structure.  
All these studies demonstrate that targeting the MYC promoter G4 is a practical and 
effective strategy for the treatment of MYC-related or driven cancer types. However, the limitation 
of selectivity of small molecules for an individual G4, like MYC, can be a challenging obstacle to 
overcome due to the high homology of G4s in the cell. Therefore, a novel G4-targeting approach 
possessing higher specificity for an individual gene promoter, or even a specific isoform of G4 
within the promoter of a gene should be developed. 
To address the issue of specificity, some nucleic acid-based approaches have also been 
explored. An oligonucleotide, Pu27, from the G4-forming region of MYC promoter was directly 
applied to leukemia cells, wherein it induced profound cellular apoptosis by damaging both 
telomeric and non-telomeric regions (Islam et al. 2014). Other works using complementary locked 
nucleic acids targeting the G4-forming region of MYC have downregulated MYC promoter 
activity by targeting this G4-forming region (Gupta et al. 2013; Kumar et al. 2008).  
 In this work, we took advantage of the nucleic acid approach and developed a novel NA-
clamp-based strategy to target specific G4s. NA-clamps are composed of two pieces of DNA 
complementing the G4-flanking 5’ and 3’ regions linked by a polyethylene glycol phosphate 
spacer or sequential thymines to span the three-dimensional space occupied by a particular 
structure. Our working hypothesis is that an NA-clamp will recognize and stabilize the biological 
relevant G4 in the promoter region of MYC, thus down-regulating its transcription. Although we 
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are testing the transcription regulation ability of NA-clamps only on MYC in our proposed 
research, the success of this aim will indicate the potential of NA-clamps as applied to more 
promoter G4s. 
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3.2. The development of Clamp A as a stabilizer for the physiologically relevant MYC G4 
3.2.1. The design, optimization and concept demonstration of MYC clamps 
 Our novel approach began with the design of the MYC G4-targeting NA-clamp. Briefly, 
two factors were taken into consideration for the design of NA-clamps: (1) when the G4 is formed 
in the MYC sequence, the distance between the proximal nucleotides on the 5’ and 3’-side of the 
G4 was shortened from 58 Å to 16.7 Å, (2) when the G4 is formed within the MYC promoter, the 
flanking nucleotides became single-stranded, which offers the opportunity for complementary 
binding. We took advantage of both factors, and designed NA-clamps that complementarily bind 
to the flanking region of the G4, and restrict these regions to the shortened distance of <20 Å, thus 
stabilizing or facilitating the formation of the G4 (Figure 3-2).   
Previous research has identified the predominant physiologically relevant G4 isoform 
under supercoiled DNA condition to be G41-4 (Sun and Hurley 2009). With computational 
modeling, we were able to determine the three-dimensional space occupied by G4 to be 16.7 – 
30.7 Å. In particular, the distance between the nucleotides (nt) on the 5’ and 3’- side of the G4 is 
16.7 Å, to the second most proximal nt on either side is 20.1 Å, and to the third most proximal nt 
measured 30.7 Å, as compared to 58 Å for the linear sequence of the 16 nt (Figure 3-3A). Three 
distinct clamps were engineered to match these distances and the remaining flanking regions, as 
detailed in Table 3-1; the region connecting the two complementary regions consisted of varying 
lengths of polyethylene linkers. Clamp A1 contained 5 matching nt on the 3’ side of the G-
quadruplex and 19 nt on the 5’ side connected by a 17.7 Å linker, clamp A2 used a 21.3 Å linker 
to connect 4 and 18 nt on the 3’ and 5’ sides, respectively, and clamp A3 used a 31 Å linker to 
connect 3 and 17 nt, respectively (Figure 3-3B and C). The binding affinity was examined by using 
EMSA as shown in Figure 3-3D. The MYC G4 was induced from the Pu46 sequence with 25 mM 
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KCl, all clamps retarded that migration of Pu46 sequence on the polyacrylamide gel in a dose-
dependent manner (from 0.01 to 10 µM). Clamps A1 and A2 were able to isolate distinct higher 
bands, with clamp A1 demonstrating the greatest affinity and most distinct binding to the wild type 
MYC sequence. Based on this data, all future linkers were maintained at 17.7 Å corresponding to 
clamp A1 (simplified as clamp A hereafter).  
 In addition to the physiologically relevant MYC G41-4, two other major isoforms have been 
reported. The most well-known G4 isoform is the parallel G42-5 with loop lengths of 1:2:1 from 5’ 
to 3’, formed from short linear DNA sequences, which was the first discovered and most 
extensively used G4 isoform for the screening of MYC G4 stabilizing compounds based on early 
studies. (Siddiqui-Jain et al. 2002). The other, less studied, isoform (G41-5) is also a parallel 
structure with loop lengths of 1:6:1 in the 5’ to 3’ direction, formed by guanine runs I, II, IV, and 
V (Dettler et al. 2011). To enable studies on all G4 isoforms in this region, G to T mutations were 
made to the Pu46 sequence in different runs of guanines (as shown in table 2-1) to either isolate 
individual G4s formed in this region or knock out all G4 formation. In addition to clamp A, two 
other clamps, clamp B and clamp C were designed to recognize the reported G4 isoforms, G42-5 
and G41-5, respectively, with linker lengths maintained at 17.7 Å and overall flanking regions 
lengths maintaied. The correspondence of the G4 isoforms to their recognizing NA-clamps is 
described in Figure 3-4B. 
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Figure 3-2. NA-clamp binding to the MYC wild type Pu46 sequence. During MYC 
transcription, the negative superhelicity enables the separation of the dsDNA and 
allows for G41-4 (red) formation within the NHE III1 region. The unpaired single 
stranded overhang on both 5’ and 3’ ends were complemented by the designed MYC 
clamp A (as shown in green) to form a G4-Clamp complex as shown on the bottom 
of the figure. The 17.7 Å polyethylene glycol linker connecting the 5’ and 3’ ends of 
the clamp restricts the G4 within its computationally modeled space thus stabilizing 
the structure.  
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Figure 3-3. Computational modeling of the physiologically relevant MYC promoter 
G4 and clamp-mediated recognition. (A) 3D modeling of the G4-forming region in the 
NHE III1 of MYC promoter, distance between the first (16.69 Å, yellow), second (20.05 
Å, white) and the third (30.7 Å, blue) proximal bases were calculated. (B) The offset of 
G4 and iM in supercoiled DNA allows for the binding of (C) designed NA-clamps to the 
unpaired flanking 5’ and 3’-end of the G4 structure. (D) EMSA analysis shows the binding 
and recognition pattern of each designed clamp (0.01 to 10 µM) to the MYC sequence. 
Clamp A1 showed the greatest affinity for WT MYC.  (Hao, Gaerig & Brooks, 2016) 
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Figure 3-4. Designed NA-clamps for multiple G4 isoforms formed in the MYC 
promoter. (A) Within the NHE III1 region of the MYC promoter, there are six consecutive 
guanine runs that are capable of forming multiple G4 isoforms. Previous research have 
identified the isoform under supercoiled condition (bolded), G41-4; and two other isoforms 
formed in linear DNA (Dettler et al. 2011; Siddiqui-Jain et al. 2002; Sun and Hurley 2009). 
(B) Mutations were made to isolate individual G4 isoforms and clamps recognizing each 
isolated G4 were designed with constant linker length of 17.7 Å. (Hao, Gaerig & Brooks, 
2016) 
 46 
3.2.2. NA-clamp binding and its specific G4 recognition 
The designed clamps A, B, and C were subjected to EMSA and ECD studies to evaluate 
their ability to recognize and bind to their corresponding target G4s either in the wild type or the 
mutant sequences. All three clamps, at a concentration gradient of 0.1, 1 and 10 µM, were 
incubated with either 1 µM of MYC WT or the complete G4 knockout mt 1,2,3,4 sequences at 
room temperature for 1 hour after the sequences were annealed as described. The DNA species 
were isolated by Polyacrylamide gel electrophoresis (PAGE) and visualized fluorescently. As 
shown in Figure 3-5A, as compared to no clamp controls, all clamps produced an upward shift of 
DNA, indicating some binding between the clamp and the target sequence. A supra shift was 
produced in a dose-dependent manner only with clamp A, indicating higher order G4 structure 
complex formation due to the larger size of the G4 DNA complex. No supra-shifted banding was 
evident with the mt knockout sequence with any clamp; only the moderately retarded bands 
occurred. This pattern is consistent with the lower of the two shifted bands being that of the clamps 
binding to their complementary flanking regions and the higher supra-shift band representing 
binding the flanking regions with a G4 formed between them.   
To demonstrate the G4 structure or DNA-clamp complex formation within each sequence, 
ECD spectrums were recorded to analyze the incubated DNA alone or DNA clamp mixtures as 
shown in figure 3-5B. With both the MYC WT sequence and the mt 5 sequence isolating the 
physiological G41-4 isoform, to which only clamp A should bind, signature parallel G4 formation 
cotton effects with minima at 240 nm and maxima at 265 nm were observed. Upon the incubation 
with clamp A post-annealing at one equivalence, WT and mt 5 sequences produced, more intense 
cotton effects at 265 nm indicating G4 formation, as well as a broadening of the cotton effect 
around 275, which is in accordance with dsDNA produced by the complementary binding of the 
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flanking region. The addition of clamp A to mt 1,2,3,4 shifted the spectrum from a nondescript 
signature to a typical dsDNA cotton effect at 275 nm. These ECD spectra indicated that the 
moderately slower migration bands presented on all mt 1,2,3,4 EMSA and with clamp B and C 
represent the complementary clamp binding to the flanking region of DNA, but no G4 structure 
formation. In contrast, the spectrum of WT and mt 5 incubated with clamp A demonstrated that 
there are G4-dsDNA complex formation besides the dsDNA. As presented in Figure 3-5C, supra-
shifted bands were only observed in between clamp A and MYC WT or mt 5, but not mt 1, 6 and 
mt 3 groups, which demonstrates a specific recognition pattern for clamp A to its designed G4 
target G41-4. In contrast, with mt 1,6 and mt 3, only moderately shifted bands, which also occurred 
during the incubation of clamps with the complete knockout sequence mt 1,2,3,4, were observed, 
denoting that only the complementary binding on the flanking region occurred between clamp A 
and mutant sequences isolating G42-5 and G41-6. The post-annealing incubation experiments, in 
which clamps were added after the G4 annealing process, examines whether clamps can 
specifically bind to and recognize their corresponding G4 isoforms. We also sought to explore the 
possibility of clamps being able to participate in the ssDNA G4 equilibrium and to shift the 
equilibrium towards G4s.Interestingly, the incubation of clamp A with MYC WT sequence pre-
annealing fostered more supra-shifted banding as compared to post-annealing samples as shown 
in Figure 3-5D. Image J was employed to quantify the band density; band i represents the G4-
clamp complex, band ii represents the dsDNA complex, and band iii represents the linear DNA 
sequences. The incubation with clamp A produced a dose-dependent induction of the supra-shifted 
band i regardless of pre- or post- annealing. Noticeably at the presence of 1 µM clamp A, the pre-
annealing group (lane 3) produced more G4-clamp complex (black bar) as compared to the post-
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annealing group (lane 6); annealing MYC WT DNA in the presence of clamp A increased the 
formation of a G4 approximately 2.5-fold. 
Further studies were carried out to elucidate that the DNA complex formed between clamp 
A and mt 5 DNA isolates G41-4. Both mt 5 and mt 1,2,3,4 sequences were incubated with 
biotinylated clamp A, post-annealing, and the samples were subjected to EMSA (Figure 3-6A). 
The migration pattern of the DNAs post incubation with biotinylated clamp A matched with the 
previously observed pattern using clamp A, demonstrating the equal efficacy of a biotinylated 
clamp. For lanes 3,4, 7, and 8, samples post-incubation were subjected to streptavidin pulldown, 
the recaptured DNA complexes were released from the streptavidin beads and were then subjected 
to EMSA, together with samples without the pulldown process. The bandings post-pulldown in 
lanes 4 and 8 were enhanced by adjusting contrast (Figure 3-6B). In lane 4, the only evident 
banding was the supra shift, compared to lane 3, indicating that the majority of the biotinylated 
clamp A was involved in the apparent clamp:G4 complex. This is compared to lane 8 where only 
the moderately shifted band was observed, versus lane 7, which is consistent with complementary 
DNA formation only on the flanking regions of mt 1,2,3,4 with clamp A. The structural 
characterization of the mt 5-clamp A complex was evaluated by ECD (Figure 3-6C). Without 
clamp A, the mt 5 sequence (blue) showed a signature parallel G4 cotton effect at 265 nm 
indicating the formation of a G4. Upon incubation with biotinylated clamp A, the complete DNA 
mixture (initial) was separated by pulldown process into the final pulldown products (final) and 
supernatant (left over DNA post pulldown). Upon the addition of biotinylated clamp A, mt 5 
(initial) maintained the signature G4 cotton effect and presented a broadening maxim around 275 
nm, indicating the formation of dsDNA. Post-pulldown with streptavidin beads, both the 
broadening and signature parallel G4 cotton effects were decreased in mt 5 supernatant (green) 
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compared to mt 5 initial (red), which was expected based on the biotin-streptavidin and clamp-mt 
5 interaction. Excitingly, in the final pulldown DNA released from streptavidin beads, the 
spectrum of mt 5 final (purple) presented both the signature parallel G4 and the dsDNA cotton 
effects demonstrating that the DNA complex possesses not only the complementary binding on 
the flanking regions, but also the G41-4 structure locked in between. This observation further 
supports that the supra shift shown in MYC WT and mt 5 sequences post-annealing with clamp A 
detected a G4-clamp A complex.  
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Figure 3-5. Specific binding and recognition of clamps to MYC G4s. (A) The binding 
specificity of clamps A, B, and C to MYC WT and the complete knockout mt 1,2,3,4 were 
examined by EMSA in a dose-dependent manner. (B) ECD further demonstrated the 
formation of G4 structure (black line) by both WT and mt 5 but not mt 1,2,3,4 sequence. 
After incubation with clamp A (blue line), the signature parallel G4 cotton effect was 
maintained in WT and mt 5 group, while all three groups produced a dsDNA broadening 
cotton effects around 275 nm denoting complementary binding on the flanking region. (C) 
Clamp A (designed against the G41-4 isoform isolated by mt 5) mediated a supra-shifted band 
with WT and mt 5, and a moderately shifted band indicating dsDNA of the flanking region 
with mt 1,6 (isolating G42-5) and mt 3 (isolating G41-6). (D) Incubation of clamp A with 
MYC WT, pre-annealing, promotes more of the supra-shifted band (band i) formation 
compared to post-annealing incubation, most noticeable at 1 equivalence of clamp to DNA 
(lane 3 vs 6). Densitometry analysis by Image J revealed that there is an ~2.5-fold increase 
of G4 formation with pre-annealing at 1 µM. (Hao, Gaerig & Brooks, 2016) 
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Figure 3-6. Clamp-DNA complexes separated by streptavidin-mediated pull down. (A) 
The incubation of biotinylated clamp A with mt 5 (isolating G41-4) (lanes 1&2) and the 
complete knockout mt 1,2,3,4 (lanes 5&6) induced the same pattern of DNA migration as in 
figure 3-5A. Post pull down using streptavidin beads, the recaptured DNA species were 
redistributed in lanes 3,4,7,8. (B) The clarity of lanes 4 and 8 were enhanced by adjusting 
contrast using image J software. In lane 4, only the supra shift was evident indicating 
majority of the clamp A was bound in this DNA complex. In contrast, lane 8 showed only 
the moderately slower migrating band which is consistent with the flanking region dsDNA 
band. (C) ECD analysis of the pull-down DNA species with mt 5. Notably, compared to the 
mt 5 supernatant (green) which is the residue DNA after pulling down, the final pull-down 
product mt 5 final (purple) showed not only a signature parallel G4 cotton effect at 265 nm, 
but also a maximum around 275-280 nm indicating dsDNA formation on the flanking region 
of the G4.  
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3.2.3. Clamp A G4 affinity and MYC G41-4 stabilization 
A series of competing EMSAs were conducted to examine the recognition and binding 
preference of clamp A to its designed target, G41-4. The MYC WT sequence and clamp A ratio 
was maintained at 1:1, while a panel of non-FAM labeled competing oligonucleotides were added 
and incubated with the annealed WT G4 post-annealing (Figure 3-7). dsDNA of the G-rich region 
of the MYC promoter, at up to a 5-fold excess, could not compete for the binding of clamp A. 
With the MYC mutant sequences mt 1,2,3,4 and mt 1,6, which knockout or isolate other G4 
isoforms, respectively, the recognition of clamp A to MYC WT sequence was disrupted only at 5-
fold excess of competing oligonucleotides, indicated by the disappearance of supra-shifted band. 
Only with mt 5, which isolates the target structure G41-4, the binding between WT and clamp was 
significantly disrupted at one equivalence of competing oligonucleotide (Figure 3-7A). A narrower 
range of competing concentrations was then performed with mt 5 to probe the general affinity of 
clamp A for G41-4 from a mixture of all the G4 structures in equilibrium within the MYC WT 
sequence. As shown in Figure 3-7B, the mt 5 formed G4 is able to compete off the binding of 
clamp A to MYC WT at ratio as low as 0.5, and completely displace the binding at ratio of 1.2. 
This observation denotes the high binding specificity of clamp A for its target structure G41-4. 
There are three fragments that compose clamp A: a 5-nucleotide portion complementing 
the 5’-end flanking region, an 18-nucleotide portion that complements the 3’-end flanking region, 
and a 17.7 Å polyethylene glycol linker. We next probed which fragments are necessary or 
responsible for G4 recognition and induction. Clamp A was dissected into fragments (Table 3-2) 
and EMSAs were done to demonstrate the interaction of each partial clamp to the MYC WT 
sequence (Figure 3-7C). The longer fragment (5’), complementing the 3’-end flank of the G4, 
either with or without the polyethylene glycol linker, showed more binding as compared to the 
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shorter fragment (3’), complementing the 5’-end flank of the G4, regardless of linker attachment; 
this is expected due to strength of complementary bases where the longer fragment shows 
enhanced binding. When both 5’ and 3’ fragments are added independently, the band migration is 
slower than either fragment presented alone, but does not facilitate G4 recognition or formation 
that would be evidenced by a supra-shifted band. Importantly, when we compare clamp A (lane 2) 
to the presence of all disconnected fragments either as 5’link + 3’ or 3’link + 5’, only clamp A is 
able to facilitate the supra-shifted band but not the disconnected fragments. This observation made 
it clear that the complementary binding of the flanking regions, and the spatial restriction are both 
necessary for the recognition and induction of a G4 structure. 
In order to confirm that the recognized and induced G4 formation by clamp A is indeed 
G41-4, DMS footprinting study was conducted on species separated by EMSA from MYC WT pre-
annealed with clamp A (Figure 3-8A); each band separated by EMSA was excised and extracted 
to recapture the DNA species before all the DNA was subjected to DMS footprinting (Figure 3-
8B). MYC WT without clamp A incubation (lane i) is a mixture of G4 isoforms, denoted by clear 
protection from guanine runs 2-4, and less distinctive protection from runs 1 and 5. After 
incubation with clamp A, there is a proportion of the species with no change in migration pattern 
(lane ii), a band of moderate migration retardation (lane iii), and a supra-shifted band (land iv). 
Band ii contains linear DNA, as evidenced by clear cleavage after each guanine. Band iii is a 
mixture of linear DNA and multiple G4 isoforms as evidenced by a broad pattern of partial guanine 
protection in multiple runs. Most notably, lane iv showed a clear protection pattern from guanine 
runs 1-4 which is consistent with the target G4 structure (G41-4).     
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Figure 3-7. Preferential G4 affinity of clamp A for G41-4. (A) Clamp A binding was 
competed for by various unlabeled oligonucleotides from MYC WT. dsDNA was not 
able to compete for any clamp A binding even at 5-fold ratio while mt 1,6 and 1,2,3,4 
reduced the binding of clamp A to WT at 5-equivalence. In contrast, competition starts 
by one equivalence with mt 5 that isolates the target structure of clamp A. (B) A 
narrower range of competing mt 5 showed as low as 0.5 equivalence of mt 5 disrupts 
the binding of clamp A to WT sequence, indicating clamp A’s preference for G41-4. (C) 
A comparison of the dissected fragments of clamp A to the intact species demonstrated 
that all fragments and physical connection among the three fragments are essential for 
the G4 recognition and induction. (Hao, Gaerig & Brooks, 2016) 
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Figure 3-8. DMS footprinting of the DNA species of MYC WT DNA post incubation 
with clamp A.  (A) MYC WT was annealed at the presence of clamp A and 25 mM KCl, 
the samples were then subjected to EMSA. (B) DNA species were extracted from (A) and 
subjected to DMS footprinting.  (C) Histograms were generated by Image J based on the 
banding density of (B). Band i represents a mixture of linear and G4s as evidenced by the 
protection throughout guanine runs. Band ii represents linear DNA reflected by the 
disappearance of protection patterns. Band iii represents a mixture of linear and non-G41-4 
isoforms supported by the partial protection in various runs of guanines. In lane iv, guanine 
runs 1-4 presented clear protection pattern, in accordance with G41-4, which is the target 
structure of clamp A.  
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3.2.4. Clamp A-mediated inhibition of MYC promoter activity and differential cytotoxicity 
  As clamp A is able to recognize and stabilize the physiologically relevant MYC G4 with 
high specificity, we investigated if clamp A was able to downregulate MYC promoter activity 
within the cell, whether clamp A possesses cytotoxicity and towards what cells, and whether clamp 
A was able to downregulate MYC expression in cancer cells.  
 To examine if any of the clamps were able to shift the equilibrium of the DNA structures 
within the NHE III1 region, thus altering promoter activity, we used the MYC promoter-containing 
Del4 plasmid (He et al. 1998; Siddiqui-Jain et al. 2002), and the promoterless empty vector (EV) 
plasmid as a control, to probe if MYC promoter activity could be altered by clamps. None of the 
clamps significantly downregulated promoter activity 24 hr post-transfection. Forty-eight hr post-
transfection, only clamp A significantly reduced the expression of firefly luciferase indicating 
decreased MYC promoter activity from the Del4 plasmid. In contrast, clamp B significantly 
increased MYC promoter activity, while clamp C showed no effect (Figure 3-9A). A dose-
response of clamp A 48 hr post-transfection was performed (Figure 3-9B). MYC promoter activity 
decreased significantly from 0.5 to 5 equivalences of clamp A. These observations further support 
the finding that the MYC G41-4 isoform is the predominant physiologically relevant G4 isoform 
that functions as a silencer in the MYC NHE III1 region; disruption of the formation of this G4 
might result in increased MYC promoter activity as evidenced by the increased promoter activity 
induced by clamp B.  
 The inherent cytotoxicity of clamp A on both cancerous (MCF-7) and non-cancerous cells 
(HEK-293) was examined. Previous research has shown that knocking down MYC protein 
expression through RNAi in MCF-7 cells inhibits tumor cell growth both in vitro and in vivo (Y. 
H. Wang et al. 2005). It has also been demonstrated that naked DNA oligonucleotides can enter 
 57 
cells and regulate gene expression through various mechanisms (Bates et al. 2009; Ebrahim et al. 
2016; Islam et al. 2014).  
In this work, varying concentrations of clamp A were directly applied to HEK-293 and 
MCF-7 cells, and the MTS assay was used to determine the cellular viability 48 hr later. As shown 
in Figure 3-10A, the viability of cancerous MCF-7 cells was significantly decreased at doses, as 
low as 30 µM of clamp A, and through 120 µM, which showed an over 80% viability reduction. 
The calculated IC50 of clamp A on MCF-7 breast cancer cells is 44.26 ± 1.77 µM. In contrast, the 
cellular viability of non-cancerous HEK-293 cells were not affected at all by the treatment of clamp 
A up to 120 µM. This observation indicated that clamp A may possess a selective cytotoxic profile 
and has the potential to be developed as a cancer therapeutic.  
 MYC mRNA expression level was examined in MCF-7 breast cancer cells by qPCR (figure 
3-10B). MCF-7 cells were transfected with 0, 250, or 500 ng of clamp A one day after plating; 
cells were lysed 48 hr post-transfection and total mRNA was extracted and qPCR was performed. 
GAPDH was used as internal control and MYC exon 2 expression level was measured. With 250 
and 500 ng of clamp A transfection, we can observe a slight, but not statistically significant, 
downregulation of MYC expression. Further investigations are required to examine clamp A’s 
effect on MYC expression.  
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Figure 3-9. Clamp A significantly decreases MYC promoter activity. (A) One 
equivalence of clamps A, B or C were transfected together with either MYC promoter-
containing Del4 plasmid or promoterless EV plasmid plus the control renilla plasmid 
into HEK-293 cells. Twenty-four or 48 hr post-transfection, luciferase was measured to 
determine the promoter activity. At 24 hr, MYC promoter activity was not altered by 
any of the three clamps. After 48 hr incubation, clamp A significantly downregulated 
MYC promoter activity. In contrast, clamp B significantly upregulated MYC promoter 
activity while clamp C showed no effect. (B) A dose response of clamp A was examined 
48 hr post-transfection. Starting from as low as 0.5 equivalence of clamp A, an over 
50% decrease of MYC promoter activity was observed, which was maintained through 
5 equivalences. *p<0.05 as compared to control (0 eq clamp), as determined by one way 
ANOVA with post-hoc Tukey’s test. (Hao, Gaerig & Brooks, 2016) 
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Figure 3-10. Clamp A’s cytotoxic profile on cancerous and non-cancerous cells and 
its ability on MYC expression. (A) Varying doses of clamp A were directly applied to 
HEK-293 and MCF-7 cell one day post plating, cell viability was measured by MTS assay 
48 hr post incubation. Clamp A significantly decreased the cell viability of MCF-7 breast 
cancer cells starting from 30 µM but not non-cancerous HEK-293 cells. The IC50 was 
reported to be 44.6 µM in MCF-7 cells as calculated by GraphPad Prism software 
(*p<0.05, as compared to untreated control, determined by one-way ANOVA). (B) MCF-
7 cells were transfected with either 250 or 500 ng of clamp A, and MYC mRNA 
expression level was measured through real time qPCR 48 hr post-transfection. MYC 
mRNA level was not significantly changed (*p<0.05, as compared to untreated control, 
determined by one-way ANOVA).  
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3.3. Development of Clamp A 5T as an alternative for clamp A  
So far, we have demonstrated that clamp A is able to recognize and stabilize the 
physiologically relevant MYC G41-4 isoform and downregulate MYC promoter activity in a 
luciferase reporter gene assay. Further investigations to determine the intracellular localization, 
and the binding target of clamp A to chromosomal DNA, require modifications to the clamp. 
However, the current clamp A with the polyethylene glycol linker is costly and the modification 
potential of this clamp A is restricted. In order to reduce the cost of the clamp and to reach more 
flexible oligonucleotides modification potential, we replaced the polyethylene glycol phosphate 
linker (clamp A) with five thymines (clamp A 5T), which maintain the linker length of ~18 Å. 
Clamp A 5T can be fluorescently tagged with FAM, or internally modified with biotin, which 
enable the possibility for microscopy and immunohistochemistry studies, respectively. All the 
oligonucleotides and clamps used in this section of the study are listed in table 3-3-1. To further 
this research with clamp A 5T, its G4 recognizing ability had to be compared to clamp A.  
 MYC WT, or the knockout mt 1,2,3,4, were annealed in the presence of clamp A, 5’ link, 
clamp A 5T, 5T, or 5’ 5T. With the mt 1,2,3,4 sequence, all full or partial clamps induced one 
slower migration band, indicating complementary binding of the flanking region. All inclusions of 
5 thymines, as compared to the polyethylene glycol linker, resulted in slower band migration due 
to the increased size and weight of the thymines. With the MYC WT sequence, only the intact 
clamp A or clamp A 5T fostered a supra-shifted band, indicating the formation of G4-clamp 
complex (Figure 3-3-1A).  
  As with the original clamp A, clamp A 5T was dissected into its fragments and the 
migration patterns of FAM labeled MYC WT were examined by EMSA, including the linker 5 
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thymines alone. Clamp A 5T fragmented parts included the 5’ complementing sequence plus 5 
thymines (5’ 5T), the 3’ complementing sequence plus 5 thymines (3’ 5T) and five thymines (5T) 
alone; each fragment was incubated with MYC WT (Figure 3-3-1B). The longer 5’ 5T 
complemented better than the shorter 3’ 5T at equal molarity, as expected. Any fragments 
containing the 5’-end produced moderately slower migrating bands compared to the control. The 
5T alone did not induced any band migration at all. In contrast, only the complete clamp constructs, 
either clamp A and clamp A 5T introduced supra-shifted bands indicative of G4-Clamp complex 
formation. This data is consistent with previous findings with clamp A, which further demonstrates 
that the spatial restriction of G4 structure is essential for the recognition and stabilization of MYC 
G41-4. 
 The binding specificity of clamp A 5T was examined by incubating FAM-labeled clamp 
A 5T with non-fluorescently labeled MYC sequences, including the WT and all mutants, and other 
random non-MYC G4-forming sequences (Figure 3-3-2A). All MYC sequences incubated with 
clamp A 5T, including WT; mt 5; mt 2,3; mt 1,6; and even the complete knockout sequence mt 
1,2,3,4, fostered moderately slower migrating bands as compared to either labeled clamp A 5T 
alone or any of the other G4-forming sequences (VEGF, KRAS, Bcl-2 and NRAS). Moreover, 
none of the other G4-forming sequences induced any changes to the migration of clamp A, 
confirming the binding specificity of clamp A 5T to the flanking region of the MYC promoter G4. 
Only with MYC WT and mt 5, both of which are able to form the MYC G41-4 isoform, were supra-
shifted bands induced by clamp A 5T. This demonstrates the specific recognition of clamp A 5T 
to the target gene and to the physiologically relevant MYC G41-4 isoform.  
 The structure of the binding complex formed by clamp A 5T and MYC WT was examined 
by ECD (Figure 3-3-2B). MYC WT alone (orange) showed a signature 240 nm minimum, and a 
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265 nm maximum, cotton effect, indicating the formation of a parallel G4 structure. Upon the 
addition of 25 mM KCl, MYC WT (cyan) formed more parallel G4 structure, reflected by a more 
intense 265 nm cotton effect. After incubation with clamp A 5T, more G4 formation was noted, as 
compared to either WT alone or WT plus 25 mM KCl, as well as a broadening of the cotton effect 
from 270-280 nm, indicating the formation of dsDNA between clamp A 5T and MYC WT on the 
flanking regions of the G41-4. 
 To confirm the structure of the fostered DNA complexes, all DNA species introduced by 
the binding of clamp A 5T on MYC WT separated by EMSA were DMS footprinted (Figure 3-3-
3). 6-FAM labeled MYC WT sequence was annealed at the presence of clamp A 5T at equal 
molarity, samples were subjected to chemical (DMS) footprinting and loaded on a polyacrylamide 
gel for species separation. Four DNA bands (lanes i – iv) (Figure 3-3-3A) were excised and 
extracted; DNA complexes were then recaptured and cleaved by piperidine and the cleaved 
samples were separated on a DNA sequencing gel (Figure 3-3-3B). Histograms of all banding 
patterns from lanes i-iv were generated using Image J software and aligned by Photoshop software 
(Figure 3-3-3C). MYC WT without clamp A 5T incubation in lane i (black) is a mixture of G4 
isoforms, denoted by partial protection throughout the guanine runs. In band ii (blue), linear DNA 
is evident by the loss of protection pattern throughout the guanines runs. Band iii (green) is mixed 
by linear DNA and other non-G41-4 isoforms evidenced by partial guanine protection in multiple 
runs. Lane iv (red), in a manner consistent with the original clamp A, showed a clear protection 
pattern specifically from guanine runs 1-4, which is consistent with the target G4 structure (G41-4) 
of clamp A 5T.  
 Based on the results above, clamp A 5T with five thymines as the interconnecting linker 
showed the same G41-4 recognizing and stabilizing ability as clamp A and is suitable for further 
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study. These findings highlighted again that the spatial restriction is the key for the recognition 
and stabilization of the physiologically relevant MYC G41-4.  
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Figure 3-3-1. DNA and G4 recognition comparison between clamp A, clamp A 
5T and clamp fragments. (A) MYC WT and mt 1,2,3,4 sequences were incubated 
with clamp A, clamp A 5T and their 5’ fragments at equal concentrations (1 µM); 
Banding pattern was examined by EMSA. Only the intact clamp constructs (clamp A 
and clamp A 5T) fostered the supra-shifted bands, indicating G4-clamp complex. (B) 
fragments of clamp A 5T were compared to the intact clamp constructs for post-
annealing binding to the MYC WT sequence by EMSA. The supra-shifted band was 
only evident in the presence of the intact clamps, including both clamp A and clamp 
A 5T.  
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Figure 3-3-2. Specific recognition of clamp A 5T to the physiological MYC G41-
4. (A) FAM-clamp A 5T was incubated with MYC sequences or other DNA 
sequences, pre-annealing and was then examined by EMSA. Only WT MYC and mt 
5 that are able to form G41-4 isoform but not any MYC mutant or other sequences 
produced supra-shifted bands indicating G4-clamp complex formation indicated by 
(B) The signature cotton effect at 260 nm plus the broadening dsDNA maximum 
around 270-280 nm post incubation with clamp A 5T as examined by ECD spectrum, 
as compared to WT alone or WT+25 mM KCl, which only showed the cotton effects 
indicative of G4 formation. 
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Figure 3-3-3. Structure elucidation of the DNA-clamp complexes by DMS 
footprinting. (A) MYC WT was annealed at the presence of clamp A 5T, and the samples 
were DMS footprinted before subjected to EMSA. (B) Each band on the EMSA was 
extracted and cleaved at methylated guanine sites, samples were then visualized on a DNA 
sequencing gel, and band indicators (i to iv) and colors are consistently used throughout the 
figure. (C) Histograms were generated by Image J based on the density of the bandings. 
Band i showed partial protection in all the guanine runs indicating its nature of multiple 
G4s in equilibrium. Band ii showed loss of protection pattern throughout the guanine runs, 
especially runs 1-4, which indicated its nature as linear DNA. Band iii showed weak partial 
protection on some runs indicating its nature as a mixture of linear and non-G41-4 isoforms. 
Notably, band iv, which corresponds to the supra-shifted band on the EMSA, showed 
significant protection in guanine runs 1-4, suggesting its nature as G41-4, which is consistent 
with the target G4 of clamp A 5T.  
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3.4. Cellular uptake and delivery of clamp A 5T 
 To study the cellular uptake and the intracellular localization of clamp A 5T, 6-FAM 
labeling was employed. FAM-clamp A 5T was introduced into MCF-7 breast cancer, RAJI, and 
CA46 lymphoma cells either directly or via transfection with Fugene HD, for up to 48 hr. After 
the nuclei of cells were stained with Hoescht 33342, images were collected in a Cytation 5 imaging 
multi-mode reader to monitor the migration of the clamp (Figures 3-4-1 to 3-4-3). For all cells at 
all times points, intracellular oligonucleotide was only evident post-transfection. Six hr post 
treatment, no FAM-clamp A 5T uptake was evident in any of the MCF-7 cells; minor uptake was 
noted in both the RAJI and CA46 cells. Twenty-four hr post treatment, marked FAM fluorescence 
signal was observed in the cytoplasm and nuclei of MCF-7, RAJI, and CA46 cells. Forty-eight hr 
post treatment, no FAM-clamp A 5T was evident in any cell line.   
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Figure 3-4-1. Time course cellular uptake of clamp A 5T in live MCF-7 cells. 
FAM labeled clamp A 5T was introduced into MCF-7 cells either directly or 
transfected with Fugene HD. Before all images were obtained, cells were 
incubated with Hoeschst 33342 nuclear dye (blue). Six hr post treatment, neither 
naked nor Fugene transfected clamp were notably accumulated in the cells. 
Twenty-four hr post-transfection, marked FAM fluorescence was observed in 
the transfected group, both in the cytoplasm and in the nucleus. Forty-eight hr 
post-treatment, FAM fluorescence was no longer evident.  
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Figure 3-4-2. Time course cellular uptake of clamp A 5T in live RAJI 
lymphoma cells. FAM labeled clamp A 5T was added to RAJI cells either directly 
or transfected with Fugene HD. Before all images were obtained, cells were 
incubated with Hoeschst 33342 nuclear dye (blue). Six hr post treatment, no 
fluorescent signal was observed in the non-transfected group. In contrast, green 
FAM fluorescence was detected on cellular membranes with Fugene transfected 
group. Twenty-four hr post-transfection, marked FAM fluorescence was observed 
in the transfected group, both in the cytoplasm and in the nucleus. Forty-eight hr 
post treatment, FAM fluorescence was no longer evident. 
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CA46	lymphoma	cells
100	µm
Figure 3-4-3. Time course cellular uptake of clamp A 5T in live CA46 lymphoma 
cells. FAM labeled clamp A 5T was added to CA46 cells either directly or transfected 
with Fugene HD. Before all images were obtained, cells were incubated with Hoeschst 
33342 nuclear dye (blue). Six hr post treatment, no fluorescent signal was observed in 
the non-transfected group. In contrast, green FAM fluorescence was detected on cellular 
membranes with Fugene transfected group. Twenty-four post-transfection, marked 
FAM fluorescence was observed in the transfected group, both in the cytoplasm and in 
the nucleus. Forty-eight hr post treatment, FAM fluorescence was no longer evident. 
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Based on the observations above, it is clear that a delivery system that can transport clamps 
into cells is essential. However, current viral and non-viral mediated transduction or transfection 
systems have their limitations and sides effects for in vivo application. Therefore, developing and 
testing a system that is able to effectively introduce clamps into cancer cells, and particularly into 
difficult to transfect lymphoma cells, is a key step for developing NA-clamps into therapeutics. To 
fulfill this need, we collaborated with Dr. Adam Smith, an Assistant Professor in the Department 
of Chemical Engineering at the University of Mississippi, to test polymer delivery systems.  
Polymers have attracted significant interest in the field of NA delivery. The efficacy of the 
polymers depends on their ability of transport NA across the cellular membrane and to escape from 
the endosomes and releasing the NA into the cytoplasm. Cationic polyamine-containing polymers 
have exhibited a great buffering capability around endosomal pH (5.5-6), which causes osmotic 
swelling and the final rupture of the endosomal compartment (Du, Wang et al. 2010; Aied, Greiser 
et al. 2013; Jones, Chen et al. 2013). However, the polyplexes formed from unmodified cationic 
polymers tend to be unstable when anionic serum proteins are present thus leading to premature 
NA unpackaging, degradation, aggregation, and clearance in vitro and in vivo. The incorporation 
of a neutral, hydrophilic segment, such as polyethylene glycol (PEG), into cationic polymers has 
been utilized to address the colloidal stability issue. In addition, the inclusion of a hydrophilic 
stabilizing segment increases the stability and blood circulation time of the polyplexes (Zhang, 
Satterlee et al. 2012). PEG-based polymers have been widely used to deliver NA into cells, but 
there are still obstacles to overcome. Previous research found that PEG can nonspecifically interact 
with blood components and induce antibody production, thus promoting the clearance of 
nanomedicine and limiting the utility of PEG-based polymeric delivery systems clinically (Knop, 
Hoogenboom et al. 2010). Other non-ionic, hydrophilic polymers, including poly(amino acid)s, 
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poly(glycerol), poly(2-oxazoline)s, and vinyl polymers have been proposed to substitute PEG to 
overcome this issue (Knop, Hoogenboom et al. 2010).  It is still important to discover new polymer 
vehicles that possess efficacy without these drawbacks.  
Synthetic glycopolymers have gained interest for their improved colloidal stability and 
possible cellular surface binding interactions (Alexandra, Orietta et al. 2013; Wang, Hong et al. 
2013). Previous work by Dr. Smith has demonstrated that glycopolyplexes can efficiently deliver 
DNA to HeLa cells and siRNA to U- 87 glioblastoma cells with low cytotoxicity (Smith, Sizovs 
et al. 2011). More recent work on copolymers comprised of different sugar moieties demonstrated 
selective cellular uptake of NAs in cells overexpressing the GLUT-5 transporter, suggested the 
potential utilization of glycopolymers as targeted NA delivery system for cancer cells (von der 
Ehe, Rinkenauer et al. 2016).  
Dr. Smith’s laboratory synthesized nine block copolymers (Figure 3-4-4), each comprised 
of a hydrophilic block of oligo (ethylene glycol) methyl ether methacrylate (OEGMA) and a 
varying number of tertiary amine blocks, for the delivery of NAs. These block copolymers were 
able to effectively deliver anti-MYC siRNA into MCF-7 cells and to decrease MYC expression 
(data not shown; submitted to Macromolecular Biosciences). All nine block copolymers were 
evaluated for their ability to delivery clamp A 5T into RAJI and CA46 lymphoma cells. FAM 
labeled clamp A 5T was incubated with each block copolymers at a ratio of 3:1 for 30 minutes 
before being applied to plated RAJI and CA46 lymphoma cells. Six - 48 hr post-transfection, cells 
were stained with Hoechst 33342 and imaged with a BioRad Cytation 5 multi-mode imaging 
reader (Figures 3-4-5 and 3-4-6).  With both RAJI and CA46 cells, no FAM fluorescence was 
detected 6 hr post-transfection with any of the nine polyplexes; 24 hr post-incubation, the 
DNA:polyplex complexes formed with the ethyl copolymer series were able to qualitatively 
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transfect clamp A 5T into cells, as evidenced by the green FAM fluorescence in the cytoplasm and 
the cyan colored co-localization with blue Hoechst 33342 nuclear stain. As with the FuGene HD 
transfections, 48 hr post-complex application, no FAM fluorescence signals were detected, under 
any condition, in either cell line.  
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Figure 3-4-4. Block copolymers evaluated for the delivery of NA-clamps into 
lymphoma cells. (A) Hydrophilic OEGMA and cationic methacracrylate moieties 
with terminal methyl, ethyl, or isopropyl substituents linked in blocks of 25, 50, or 
75 were synthesized into block copolymers and (B) characterized by gel permeation 
chromatography (Mcclellan et al., 2016). 
B
A
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Figure 3-4-5. Delivery of clamp A 5T into RAJI lymphoma cells by block 
copolymers. 6-FAM labeled clamp A 5T was transfected by nine copolymers into RAJI 
lymphoma cells. Twenty-four post-transfection, the nuclei were stained with Hoechst 
33342 and cells were imaged. No FAM fluorescence was detected at any time point in 
cells transfected by methyl and propyl polymer series. With ethyl polymers, no FAM 
fluorescence was detected at 6 or 48 hr time points (data not shown). Only at 24 hr, and 
with the ethyl series, was FAM fluorescence clear.  
 76 
 
  
Figure 3-4-6. Delivery of clamp A 5T into CA46 lymphoma cells by block copolymers. 
6-FAM labeled clamp A 5T was transfected by nine copolymers into CA46 lymphoma cells. 
Twenty-four hr post-transfection, the nuclei were stained with Hoechst 33342 and cells 
were imaged. No FAM fluorescence was detected at any time point in cells transfected by 
methyl and propyl polymer series. With ethyl polymers, no FAM fluorescence was detected 
at 6 or 48 hr time points (data not shown). Only at 24 hr, and with the ethyl series, was FAM 
fluorescence clear.  
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 The MTS assay was used to evaluate the inherent cytotoxicity of clamp A 5T on HEK-293 
and MCF-7 cell lines (Figure 3-4-7) at 24-144 hr. No cellular viability changes were observed after 
24 and 48 hr incubation with clamp A 5T in either cell line. Seventy-two hr after treatment with 
clamp A 5T, differential cytotoxicity was evident at 70 M, with 33% vs 15% decrease in cellular 
viability in the MCF-7 and HEK-293 cells, respectively.  144 hr post-clamp A 5T incubation, 
similar patterns of decreased cell viability were evident in both cell lines, with IC50s of 52.13 ± 1.8 
and 68.1 ± 3.0 µM in the MCF-7 and HEK-293 cells, respectively. 
 As seen above, the ethyl series copolymers were able to effectively transfect clamp A 5T 
into both RAJI and CA46 lymphoma cells after a 24 hr incubation. Here, we evaluated the 
cytotoxic profile of the ethyl series block copolymers and the polyplexes formed by clamp A 5T 
or scramble clamp with the copolymers in both cell lines (Figure 3-4-8). All three copolymers 
alone, E25 (ocean blue), E50 (orange), and E75 (gray), demonstrated a dose-dependent cytotoxic 
profile in both RAJI and CA46 lymphoma cell lines with up to 38% decreased cellular viability at 
72 hr. Among the three copolymers, E75 (grey) showed the highest inhibition of cell growth (35% 
with RAJI, 38% with CA46) in both cell lines, followed by E50 (orange, 24% with RAJI, 36% 
with CA46) and E25 (ocean blue, 0% with RAJI, 22% with CA46). Compared to copolymers 
alone, the polyplexes formed by scramble clamp reduced the cytotoxic profile in RAJI and CA46 
cells at 72 hr. Compared to the polyplexes formed by scramble clamps, polyplexes formed by 
clamp A 5T demonstrated more cytotoxicity on both RAJI (5% with E50, 23% with E75) and 
CA46 (20% with E50, 32% with E75) cell lines, as evidenced by the lower cellular viability of 
E50/75 plus clamp A 5T (blue/green) vs E50/75 plus scramble clamp (brown/dark gray) at 72 hr 
time point, indicating that clamp A 5T likely contributes to the inhibition of cellular growth of 
both RAJI and CA46 lymphoma cells.   
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Figure 3-4-7. Cytotoxicity of clamp A 5T on HEK-293 and MCF-7 cells. MTS assay was 
used to measure the cytotoxicity of clamp A 5T on HEK-293 and MCF-7 cells. Twenty-four 
or 48 hr post treatment, no significant dose-dependent cytotoxicity was clear in either cell 
line. By 72 hr, up to a 20 or 40% decrease was noted in HEK-293 and MCF-7 cells, 
respectively. By 144 hours of treatment with clamp A 5T, cells demonstrated a dose-
dependent decrease in viability; no difference were notable between the two cell lines.   
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Figure 3-4-8. Lymphoma cells cytotoxicity of clamp A 5T transfected by ethyl 
series copolymers. Clamp A 5T or scramble clamp were transfected with the ethyl 
series block copolymers into RAJI and CA46 lymphoma cells and the cellular viability 
was determined by MTS assay at various time points. E75 (green) and E50 (orange) 
copolymers alone demonstrated dose and time dependent cytotoxicity on both cell lines. 
When complexed with NAs, either clamp A 5T or scramble clamp, the cytotoxicity of 
all three copolymers were decreased as compared to polymers alone. Polyplexes formed 
by clamp A 5T, showed a more cytotoxic profile compared to polyplexes formed by 
scramble clamp, which is most evident at 48 or 72 hr with E75 copolymers (green vs 
dark gray).   
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3.5. Intracellular activity of clamp A 5T  
The binding of clamp A 5T to its target region of the MYC promoter and the impact of 
clamp A binding on MYC transcription was evaluated in MCF-7 breast cancer cells. Estrogen-
receptor positive MCF-7 cells transcriptionally upregulate MYC within 1 hr of stimulation by 17β-
estradiol (E2, 2 nM) (C. Wang et al. 2011). We confirmed this effect in our cells, where MYC 
mRNA was elevated over 6-fold at one hour post-E2 stimulation in MCF-7 cells (Figure 3-5-1A). 
In order to probe the binding of clamp A 5T to the promoter of MYC, MCF-7 cells were transfected 
with biotinylated clamp A 5T one day post plating. Twenty-three hr later, as indicated, cells were 
treated with 2 nM of E2 for 1 hr. Cells were then washed and harvested for genomic DNA 
extraction. The extracted DNA was then sheared enzymatically and streptavidin beads were used 
to pull down the DNA bound to biotinylated clamp A 5T. The pulled-down DNA was then released 
from the beads and amplified by PCR reaction with MYC specific PCR primers. The final DNA 
products were visualized on an agarose gel (Figure 3-5-1B). As expected, the MYC promoter could 
be PCR amplified from extracted genomic DNA (positive control). In the absence of biotinylated 
clamp A 5T, and after isolation by streptavidin, no MYC promoter was able to be amplified 
(negative control). After treatment with biotinylated clamp A 5T (10 µg and 20 µg), the final 
pulldown products were enriched for MYC promoter DNA, as evidenced by the clear banding at 
287 bp. After E2 stimulation, which activates the transcription activity of the MYC gene, thus 
allowing for more G4 formation in the NHE III1 region, more binding of clamp A 5T to MYC 
promoter was observed as evidenced by the darker bands at both 10 µg and 20 µg. These 
observations demonstrate that clamp A 5T is able to enter the nucleus and bind to the MYC 
promoter region in live cells, and that as more active transcription of MYC generates more negative 
 81 
superhelicity, the double stranded DNA is separated and more G4 is formed, clamp A 5T binding 
to the promoter region was markedly promoted.  
 Next, we examined the impact of clamp A 5T on the transcription of MYC in MCF-7 breast 
cancer cells without and with E2 stimulation (Figure 3-5-2A). Clamp A 5T or scramble clamp 
were transfected with FuGene into MCF-7 cells, that were subsequently stimulated by E2. Twenty-
four hr post-transfection, cells were harvested and mRNA was extracted. MYC expression in 
MCF-7 cells was not significantly changed either with or without E2 treatment. The effect of clamp 
A 5T on MYC regulation in RAJI lymphoma cells was also determined by qPCR (Figure 3-5-2B). 
Compared to control, clamp A 5T either alone or transfected by E25 and E50 decreased the 
expression of MYC by up to 40%, though no significance was found (n=2). When complexed with 
E75, the expression of MYC was not significantly changed, as compared to control; further 
experiments with more replicates and more time points are required to determine the effect of 
clamp A 5T on MYC expression in RAJI cells.  
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Figure 3-5-1. Clamp A 5T binding to the promoter region of MYC. (A) MYC mRNA 
expression post-E2 stimulation in MCF-7 cells was measured using qPCR. MYC 
transcription was activated by 2 nM E2 treatment as evidenced by the 6-fold increase of 
MYC mRNA expression compared to the control with no E2 treatment (p<0.05, as 
determined by student T-test). (B) Clamp A 5T binding to the MYC promoter was confirmed 
by a ChIP-PCR assay. Biotinylated clamp A 5T was transfected into MCF-7 cells one day 
post plating. Twenty-three hr post incubation, 2 nM E2 was added as indicated, and the 
extracted and sheared DNA was amplified using MYC primers; amplified DNAs were 
visualized on an agarose gel. Input DNA was diluted 20 times before loading. The input 
positive control but not the negative streptavidin beads control, regardless of E2 treatment, 
showed clear bands of amplified MYC promoter as evidenced by the 287 bp bands. After 
pulldown, from cells treated with either 10 µg or 20 µg of biotinylated clamp A 5T, amplified 
MYC promoter was detected. Notably, after E2 stimulation, more binding of clamp A 5T to 
the MYC promoter was observed, as evidenced by more promoter amplified, indicating 
active transcription facilitates the binding of clamp A 5T to the MYC promoter.  
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Figure 3-5-2. The effect of clamp A 5T on MYC expression in MCF-7 and RAJI 
cells. (A) Clamp A 5T and scramble clamp were transfected into MCF-7 cells and their 
impact on MYC transcription was determined by qPCR. For both E2 treated and non-
treated groups, clamp A 5T did not significantly affect the expression of MYC. (B) The 
transcriptional impact of clamp A 5T, polyplexes formed by clamp A 5T and Fugene or 
the E series polymers on MYC transcription in RAJI lymphoma cells were evaluated by 
qPCR. Clamp A 5T alone, with Fugene, or with E50 decreased the expression of MYC 
while clamp with E75 affected no change. However, no significant difference was 
identified.   
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3.6. Clamp A 5T as a diagnostic companion 
 As demonstrated above, clamp A 5T is able to recognize and stabilize the physiologically 
relevant MYC G41-4 isoform in vitro. In addition, ChIP-PCR assay demonstrated that clamp A 5T 
can bind to the MYC promoter in live cells. These data suggest that clamp A 5T could possibly be 
employed as a diagnostic tool to detect MYC G4 formation in cells in order to inform the use of 
small molecules that recognize and stabilize this structure. In this section, we will explore the 
potential of using clamp A 5T to detect induced MYC G4 formation in fixed and permeabilized 
MCF-7 breast cancer, RAJI and CA46 lymphoma cells.  
 Previous research, through fluorescence-based screening identified an ellipticine 
derivative, NSC 338258, as a MYC G4 stabilizer with nanomolar affinity. This compound has 
been demonstrated to be moderately MYC G4 selective and most notably, its mechanism of action 
has been validated to be MYC promoter G4-mediated (Brown et al. 2011). Here, we utilized this 
compound to induce MYC G4 formation, and then detected the G4 formation using fluorescent 
labeled clamp A 5T in fixed and permeabilized MCF-7, RAJI, and CA46 cells. The IC50 of NSC 
338258 on MCF-7 cells was determined to be 25 µM at 24 hr (Figure 3-6-1A). For the G4 induction 
assay, MCF-7 cells were treated with varying concentrations of NSC 338258 (12.5, 25, and 37.5 
µM) for 6 hr. Cells were then fixed and permeabilized before incubation with either FAM clamp 
A 5T or FAM control ODN, together with Hoechst 33342 (nuclear stain), for 1 hr and imaged on 
a Cytation 5 multi-mode imaging reader (Figure 3-6-1B). With no G4 induction by NSC 338258, 
no visible binding of clamp A 5T was observed, as compared to control. Starting from 12.5 µM 
(0.5X IC50) of NSC 338258 treatment, a dose-dependent colocalization of FAM and Hoechst 
33342 nuclear dye was observed, which was maximally noted at 25 µM (1X IC50). With 37.5 µM 
(1.5X IC50) of NSC 338258, a loss of detectable FAM fluorescence, indicating the loss of clamp 
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binding to the DNA was observed, this was likely due to chromatin condensation induced by the 
apoptosis of MCF-7 cells. As compared to clamp A 5T probed cells, FAM labeled control ODN 
probed cells showed only sporadic fluorescence in the 12.5 µM (1X IC50) NSC 338258 treated 
group, but no dose-dependency.   
  The same G4 induction and detection assay was also conducted on RAJI and CA46 
lymphoma cells (Figure 3-6-2). As it relates to the MYC promoter, RAJI and CA46 Burkitt’s 
lymphoma cells differ from each other by the location of the translocation between the MYC gene 
and the immunoglobin heavy chain gene. Translocated RAJI cells retained the entire MYC gene 
including the promoter G4, and exons 1, 2, and 3. In contrast, translocated chromosomes in CA46 
cells have lost the endogenous G4-forming region and exon 1, only retaining exons 2 and 3 (which 
are the minimal requirements for a functional MYC protein), with expression driven by the Ig gene. 
Therefore, the heightened MYC transcriptional activity reflected by increased MYC promoter G4 
formation should be most evident with RAJI, versus CA46 lymphoma cells. The 24 hr IC50s of 
NSC 338258 were determined for both cell lines previously to be 2.6 and 13 µM, respectively 
(Brown, et al, 2011). For both cell lines, incubation with FAM labeled clamp A 5T, but not the 
control ODN, coincided with NSC 338258 dose-dependent G4 induction, as evidenced by the cyan 
colored colocalization of FAM fluorescence and Hoechst 33342 nuclear dye. When we compare 
(Figure 3-6-2A) RAJI to (Figure 3-6-2B) CA46 cells incubated with FAM-clamp A 5T, we can 
observe binding of clamp A 5T in the nucleus of RAJI, but not CA46, cells at low dose (0.5X IC50) 
of NSC 338258 treatment. With RAJI cells incubated with high dose (1.5X IC50) of NSC 338258, 
we could see marked colocalization of FAM fluorescence with Hoechst dye indicating the binding 
of clamp A 5T to the promoter G4 of MYC. In contrast, with CA46 cells, even incubation with 
high dose (1.5X IC50) of NSC 338258 only produced small amount of G4 detection by clamp A 
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5T. These data further support the hypothesis that the binding of clamp A 5T to the nuclear DNA 
in these fixed and permeabilized cells is through a promoter G4-mediated mechanism. These data 
also suggest that clamp A 5T has potential to be used as a diagnostic companion to detect the 
hyper-transcriptional activity, and G4 formation in certain cancer cells. 
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Figure 3-6-1. Detecting the physiologically relevant G4 formation induced by selective 
MYC G4 stabilizing compound NSC338258. (A) The IC50 of NSC 338258 on MCF-7 cells 
was determined to be 25 µM by MTS assay. (B) MCF-7 cells were treated with varying 
concentrations of NSC 338258 6 hr before fixation and permeabilization. Fixed cells were 
incubated with either FAM clamp A 5T or control ODN with Hoechst 33342 nuclear dye for 
1 hr before being subjected to imaging. Compared to control, cells incubated with clamp A 
5T presented a dose-dependent binding to the DNA, as evidenced by the cyan color 
colocalization maximized at 25 µM NSC 338258, compared to control. With 37.5 µM NSC 
338258, a loss of fluorescence signal was observed, possibly due to chromatin condensation 
induced by apoptosis. No dose-dependent binding was observed with FAM control ODN 
(negative control), further demonstrating that the dose-dependent binding is MYC G4-
mediated. 
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Figure 3-6-2. G4 induction assay on RAJI and CA46 cells. (A) RAJI and (B) CA46 
lymphoma cells were treated with NSC 338258 for 6 hr before fixation and 
permeabilization. Cells were then incubated with either FAM-clamp A 5T or control 
ODN, together with Hoechst 33342 nucleus blue dye for 1 hr before images were 
collected. With both cell lines, only incubation with clamp A 5T demonstrated dose-
dependent effect of colocalization with NSC 338258 treatment.  
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3.7. Discussion 
In this work, we described the development, optimization, delivery, in cell activity and 
potential diagnostic value of a novel nucleic acid clamp-based approach that targets the 
physiologically relevant G41-4 isoform in the NHE III1 region of the MYC promoter. The central 
tenant of the clamp approach utilizes the spatial restriction generated by the complementing DNA 
flanking the G4 structure to constrain it within the locked distance in between the 5’- and 3’- 
flanking regions. Through computational modeling and a series of affinity assays, the optimal 
linker length was determined to be ~18 Å, and the lead clamp A designed to detect the G41-4 
isoform showed its specific recognition. Interestingly, we observed that this clamp A can 
specifically recognize G41-4 and also can shift the equilibrium of the possible DNA structures 
within this region to a G41-4 favorable state, as evidenced by DMS-footprinting.  
Within the NHE III1 region of the MYC promoter, three major G4 isoforms have been 
described by previous research. The most well studied G4 isoform is from the linear DNA 
oligonucleotide Pu27, which contains the first five guanine runs of the NHE III1 region. With this 
linear DNA sequence, research has shown that the G4 formed in linear DNA within this region 
was G42-5, with loops 1, 2, and 1 nucleotides in the 5’-3’ direction, involving the participation of 
guanine runs II, III, IV, and IV in a parallel conformation (Siddiqui-Jain et al., 2002). This G4 
isoform has been widely used for the screening of G4-interacting compounds, but so far, no 
compound screened specifically against this isoform selectively interacts with MYC promoter. 
Most notably, a DMS footprinting study using Del4 plasmid that contains the MYC G4-forming 
region under supercoiled conditions revealed that the predominant G4 isoform formed under 
physiologically relevant torsional stress is G41-4, another parallel G4 conformation with the same 
loops of 1, 2, and 1 nucleotides in the 5’ to 3’ direction, but involving the participation of guanine 
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runs I, II, III, and IV (Sun & Hurley, 2009). Supercoiling has been identified to be the major driving 
force, at least in the MYC promoter, that opens double stranded DNA and allows for non-canonical 
secondary DNA structures including G4s and iMs to form (Brooks and Hurley 2009). In our study, 
a reporter gene assay using the same Del4 plasmid containing the MYC promoter, we 
demonstrated that only clamp A 5T, which specifically recognizes and stabilizes the G41-4 isoform, 
is able to downregulate MYC promoter activity. In contrast, clamp B, which is designed against 
the predominant G42-5 isoform found in linear DNA, induced a significance increase in MYC 
promoter activity. This could be due to clamp B disrupting the dynamics of NHEIII1 region, 
decreasing the formation of the physiologically relevant MYC G41-4 isoform, thus impeding the 
G4 regulation on MYC transcription. These observations extended further support that G41-4 is the 
physiologically relevant G4 isoform that regulates MYC transcription. Further research efforts on 
screening MYC G4 targeting compounds should be focusing on against this physiologically 
relevant G41-4 isoform or the entire NHE III1 region, rather than G42-5 that forms in the linear DNA 
with Pu27.  
Within MYC promoter, the G4 and iM structures form offset from one another, which 
leaves a 14 bp long ssDNA overhang on the 5’ side of the G4. Also, computational modeling 
studies suggested that there are at least 5 bases serving as buffer regions for the transition from 
secondary DNA structures to dsDNA. This offset plus the buffering regions provided us with the 
basis for the designed NA-clamps. This clamp approach takes advantage of this over 20 bp long 
complementing region, which offers great selectivity for the MYC promoter. In contrast, with 
current small molecule G4 targeting strategies, high selectivity for one single G4 is hard to achieve 
due to the general homologous topology of these G4 structures. For example, G41-4 and G42-5 
isoforms are both parallel G4 structures with 1:2:1 loops from 5’ to 3’ direction, the only variance 
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that differ these two structures is the loop components which are T: GA: T for G41-4 and A: TG: 
A for G42-5. Other promoter G4 structures, such as the ones from HIF-1α and VEGF, also share 
high structural topology with the MYC promoter G4. This topological homology introduces 
obstacles to drug screening processes that lead to non-selective G4-interacting small molecules. 
In our qPCR studies, we did not observe significant downregulation of MYC transcription 
by clamp A in MCF-7 breast cancer cells 48 hr post-treatment. It is possible that clamp A is 
degraded or expelled from the cell, as supported by our study of cellular localization. It is well 
known that non-modified DNA suffers from stability issues in cells. It can be readily digested by 
nucleases and other intracellular enzymes when transported into cells (Watts and Corey 2012). 
MYC mRNA has a rapid turnover rate in the cytoplasm at approximately half an hour in both 
human and murine cells (Jones and Cole 1987). The rapid MYC mRNA turnover rate of MYC in 
MCF-7 breast cancer cells might also contribute to the rapid replenishment of the MYC mRNA 
pool in clamp A-treated cells. Other possible reasons for this negative data include the choice of a 
single concentration of the clamp A and the possible accessibility issues of clamp A into the 
nucleus. Further investigation is required to confirm and explain the lack of a significant change 
in MYC gene expression.  
With the selectivity drawbacks of small molecules, other nucleic acid based approaches 
have been used to target the MYC G4-forming region. A 27-base pair oligonucleotide, Pu27, from 
the G4-forming region of MYC promoter was directly applied to leukemia cells, wherein it induced 
profound cellular apoptosis by damaging both telomeric and non-telomeric regions (Islam et al. 
2014). Other works using complementary peptide nucleic acid (PNA) probes invading the G4-
forming region of MYC to form heterologous PNA:DNA hybrid G4s have also downregulated 
MYC promoter activity (Gupta et al. 2013; Kumar et al. 2008; Roy et al. 2007). In addition, 
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sequence specific recognition and scission of human genome by PNA/DNA hybrid G4s have also 
been demonstrated (Ishizuka et al. 2012). On the one hand, this sequence specific scission of DNA 
highlights the potential of PNA in gene manipulation; on the other hand, it may also lead to 
irreversible toxicity in normal tissues. With respect to our clamp approach, the binding between 
clamp and the G4-flanking region is a reversible process, and thus will not cause permanent 
damage as with PNA/DNA hybrid G4s that are foreign to a cell. As the majority of unmodified 
DNA suffers from stability issues in cells, clamps modified to the more stable PNA or morpholino 
backbone will be pursued in the future to explore their potential.  
Apart from the stability issues of unmodified DNA, all nucleic acids approach with few 
exceptions (DNA/RNA aptamers) face another challenge: in cell delivery. Two major classes of 
strategies have been employed to deliver nucleic acids into cells, including viral vector based 
transduction and liposome mediated transfection, with promising results seen from both strategies 
(Mali 2013). With liposomal-based strategies, FuGene and lipofectamine have been widely used 
for in vitro gene delivery, but neither these, nor viral vehicles are suitable for delivery of gene 
therapies systemically. In this work, we collaborated with a chemical engineering group that 
synthesized nine functionalizable block copolymers to deliver clamps into hard to transfect 
lymphoma cells. By cellular uptake studies, we demonstrated qualitatively that clamp A 5T could 
not be taken up by cells alone, and that it required transfection. Once being transfected in cells, 
clamp A 5T was able to cross the nuclear membrane and get access to chromosomes in breast 
cancer and Burkitt’s lymphoma cells as evidenced by the colocalization noted by microscopy and 
ChIP-PCR assays. With the nine copolymers, only the ethyl series were able to effectively transfect 
clamp A 5T into lymphoma cells. These findings are consistent with a recent set of studies on an 
unmodified DNA, PNT2258, which is an invading complementary oligonucleotide that targets the 
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distal region of the Bcl-2 promoter. This unmodified DNA also crosses the nucleus membrane and 
binds to its target region in the Bcl-2 promoter, facilitating apoptosis in lymphoma cells. This 
invading DNA PNT2258 is currently undergoing phase II clinical trials for diffuse B cell 
lymphomas, which makes it the first-in-class DNA interference (DNAi) therapy for cancer 
(Ebrahim et al. 2016; Tolcher et al. 2014). Both unmodified DNAs, Clamp A 5T and PNT2258, 
were able to readily cross the nuclear membrane and bind to their targets in the genome, which 
really highlights the potential of DNAi in future drug development. Further studies with the block 
copolymers demonstrated that the innate cytotoxicity of the ethyl series was dampened when they 
were complexed with DNA, suggesting the potential of these block copolymers for systemic 
delivery of gene therapies.  
As discussed above, many MYC-targeting strategies have been employed either directly or 
indirectly (Mertz et al. 2011; Posternak and Cole 2016; Sabnis et al. 2017). Compare to any other 
strategies, targeting the MYC promoter G4 specifically using this clamp approach takes advantage 
of the relationship between MYC promoter G4 formation and transcription, which is significantly 
higher in cancer cells versus normal cells. As shown in our ChIP-PCR assay, when MYC 
transcription was activated by E2 in MCF-7 breast cancer cells, more binding of clamp A 5T to its 
target was observed. This data is consistent with the theory that higher transcription activity 
generates more negative superhelicity in the NHE III1 region of the MYC promoter thus fostering 
more physiological G4 formation capable of being bound by clamp A 5T. In normal cells, MYC 
transcription activity is tightly under control, and less G4 formation will occur versus their 
transformed counterparts. This way, the presence of the in-cell G4 targets of the clamps is higher 
in cancer cells versus normal cells, which contributes to the selective gene regulation capability of 
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this clamp approach and many other future approaches that target the physiologically relevant 
MYC G4 specifically.  
Previous research has shown that MYC upregulation in MCF-7 cells is largely due to copy 
number amplification, whether or not the transcription activity of an individual MYC copy was 
elevated is still unclear (Shadeo and Lam 2006). Based on our qPCR studies, MYC expression in 
MCF-7 cells was not significantly downregulated by clamp A 5T. This could possibly be a cell 
line specific effect due to the gene amplification mechanism of MYC in MCF-7 cells. Also, time 
course cellular uptake assays demonstrated that clamp A 5T is only evident between 6 and 24 hr. 
This potentially contributes to the lack of significant changes in MYC gene expression, especially 
considering the high turnover rate of MYC mRNA and increased gene copy numbers in MCF-7 
cells.  
The moderately MYC G4 selective compound NSC 338258 downregulates MYC 
expression within 6 hours in RAJI lymphoma cells (Brown et al. 2011). In the current work, we 
observed a notable, but not significant, decrease of MYC expression in RAJI cells when treated 
with clamp A 5T either alone or transfected by Fugene and E50 copolymer. As there were only 
duplicate sample in this study, further work is required to determine significance. Further 
investigations are required to define the dose- and time-dependent effects on clamp A 5T on MYC 
expression in both breast cancer and lymphoma cells.  
Lastly, we explored the potential of using clamp A 5T as a diagnostic tool for specific 
MYC G4 detection in breast cancer and Burkitt’s lymphoma cells. Increasing evidence supports 
the bona fide G4 formation in cells. Several G4 detection methods have been developed to probe 
the intracellular G4 formation in human cells. Notably, a research group from the UK 
demonstrated the existence of endogenous DNA and RNA G4 formation in human cancer cells 
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using an engineered antibody, termed BG4 (Biffi et al. 2013; Biffi et al. 2014). Other G4 detecting 
strategies also have been adopted by researchers to detect and characterize DNA structures in vivo. 
These detecting strategies can be generally classified into either internal or external-fluorescent 
probes based on their mode of interaction with G4 structures, or into small molecule or nucleic 
acids probes according to the nature of materials. These G4-detecting small molecules bind to a 
G4 structure non-covalently, which activates their fluorescence through fluorescence resonance 
energy transfer  (Vummidi et al. 2013). However, these G4-interacting fluorescent probes are not 
without drawbacks. The majority of the small molecule probes are derived from previously 
discovered G4-interactive compounds, thus lacking specificity for individual G4s. For fluorescent 
antibodies or nucleic acid-based fluorescent probes, they mainly interact with pre-existing G4 
structures, which has little effect on the DNA conformational equilibrium; and this mode of 
interaction is not enough to recognize distinctive features of an individual G4. Therefore, all 
current G4 detecting methodologies are still restricted to general G4 detection with no specificity 
for an individual structure.  
With our clamp approach, we took advantage of the available unpaired nucleic acid bases 
flanking the MYC G4, which granted us the high specificity for a certain sequence thus a certain 
G4. As shown by the G4 induction assay, fluorescently labeled clamp A 5T, but no other 
fluorescent labeled DNA, was able to detect an increase in G4 formation induced by the selective 
MYC G4 stabilizing compound NSC 338258 in breast cancer and lymphoma cells. These 
observations further demonstrate that this clamp approach possesses high potential of being 
developed as an intracellular G4 recognition tool that evaluates the transcription activity of a 
certain gene. In this case, clamp A 5T can be potentially developed as a diagnostic tool to detect 
the MYC G41-4 formation in patient-derived cancer cells, correlating with hyperactivity of MYC 
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transcription. This information could be directive in terms of employing MYC G4-targeted 
therapies in the clinics.  
Overall, this nucleic acid clamp-based approach described herein is a novel way to target 
individual promoter G4s that regulate transcription of key genes involved in cancer, 
neurodegenerative, infectious or other diseases. There are still issues to be addressed before this 
MYC clamp could be clinically advanced, and future work is likely to focus on modifying the 
backbone of the clamp, such as replacing the DNA backbone with PNA, to make them more 
resistant to cellular enzymes that degrade unmodified DNA. Also, the linker type of the clamps 
could be optimized in future by replacing the nonfunctional restricting segment with a G4-
interacting moiety of the same length, thus presenting a dual-mode of action in terms of stabilizing 
the G4 structure. More importantly, the delivery of clamps into human cells should be tackled by 
optimizing the nano-based polymer complexation. To increase the effective concentration of the 
clamps in the nucleus, the clamps could also be optimized with the addition of a nuclear 
localization sequence, which enhances the nuclear entry as well as the cellular uptake.  
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CHAPTER IV. TARGETING NRAS 5’-UTR G4 WITH NA-CLAMPS 
 
 
4.1. Introduction  
 The majority of G4 research has been focused on promoter or telomeric DNA over for the 
past 20 years. However, G4s have been reported to form in RNA in cell as well. RNA molecules 
are transcribed as single stranded nucleic acids from DNA, and this nature of RNA allows for the 
formation of more complexed higher order structures, such as hairpins and G4s formed both intra-
and inter-molecularly (Halder & Hartig, 2011). An RNA G4 was first discovered in the 3’ rRNA 
of Escherichia coli (Jin, Gaffney, Wang, Jones, & Breslauer, 1992). An mRNA G4 was discovered 
in the 3’-UTR of insulin-like growth factor II (Christiansen, Kofod, & Nielsen, 1994), and many 
have reported RNA G4s in both regulatory and coding regions of mRNA of many genes, such as 
NRAS, VEGF, and Bcl-2 (Agarwala, Pandey, & Maiti, 2015; Jayaraj et al., 2012; Kumari, Bugaut, 
Huppert, & Balasubramanian, 2007; Millevoi, Moine, & Vagner, 2012). Thermodynamically, 
RNA G4s are generally more stable than DNA G4s due to the additional interactions of ribose C2’ 
hydroxyl groups with the surrounding DNA structures (Agarwala et al. 2015b; Arora and Maiti 
2009; Joachimi et al. 2009).  Just as DNA G4s, RNA structures have been visualized in human 
cells using the specific BG4 antibody, demonstrating their bona fide existence (Biffi et al., 2014). 
One recent report utilizing mouse embryonic cells revealed that RNA G4s are globally unfolded, 
which introduced more confounding factors on the in-cell formation of RNA G4s. This finding 
was not repeated in human cells, further research is required into the prevalence of this 
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phenomenon, especially considering the epigenetic differences, which largely impact gene 
expression profiles, between human and mouse (Guo & Bartel, 2016).   
Traditionally, mRNAs are translated through the cap-dependent mechanism, which 
involves three major steps to translate an mRNA into a protein. The first step is initiation, which 
is the rate limiting step that assembles ribosomes on the mRNA molecule. During initiation, a pre-
initiation ribosomal complex is assembled onto the 5’-cap of the mRNA, which then scans down 
the mRNA until it reaches an initiation codon (AUG), which triggers the recruitment of a 60S 
ribosomal subunit. The second step is elongation, which synthesizes the polypeptides into a chain 
and the last step is termination, which disassembles ribosomes from the mRNA molecules 
(Gebauer and Hentze 2004).  
Alternatively, the translation of mRNA could be initiated by non-cap dependent 
mechanisms involving internal ribosome entry sites (Baird et al. 2006). Both mechanisms of 
translation initiation are regulated by higher order RNA structures, including G4s (Bugaut and 
Balasubramanian 2012).  
 The RNA G4-forming sequences are highly enriched in the 5’-UTRs of the human genome 
(Huppert et al. 2008). Many genes containing 5’-UTR RNA G4s are associated with the hallmarks 
of cancer, as shown in table 1-1. NRAS, a human proto-oncogene contains one of the first 
identified 5’-UTR RNA G4s that functions as a translation inhibitor in vitro (Kumari et al. 2007). 
Various cellular activities are regulated by RNA G4s at both the DNA and RNA levels (Rhodes & 
Lipps, 2015). In the DNA level, RNA G4s can bind to RNA binding proteins that involves the 
regulation of DNA-related processes, such as recombination, or telomere elongation (Biffi et al. 
2012; Zheng et al. 2015). In the RNA level, particular with 5’-UTR RNA G4s, these secondary 
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structures inhibit the translation of their corresponding proteins in many oncogenes, such as 
NRAS, Bcl-2, VEGEF, and TRF2 (Cammas & Millevoi, 2017). 
 The NRAS (neuroblastoma RAS viral oncogene homolog) proto-oncogene is located on 
the short arm of chromosome 1, at positon 13.2. Together with kRAS, hRAS, mRAS and rRAS 
comprise the RAS oncogene family. They are intracellular signal cascade mediators, with intrinsic 
GTPase activity, functioning to initiate the mitogen-activated protein kinase-signaling (MAPK) 
pathway that is involved in cellular proliferation, differentiation and survival (Wennerberg et al. 
2005). When RAS proteins are bound to GTP, they are activated and facilitate signal transduction; 
after the conversion of GTP into GDP, the proteins return to their inactive form, and GDP has to 
be exchanged for GTP to re-initiate the process. A single point mutation of the RAS genes is 
sufficient to convert them into oncogenes, which is locked in the GTP bound active state that relays 
proliferation signaling constantly. Most commonly, mutations with RAS occur at codon 12, 13, or 
61 (Pylayeva-Gupta et al. 2011). For NRAS specifically, the most common mutation is at codon 
61, converting glutamine to a lysine, arginine, or leucine, thus disrupting GTP hydrolysis (Hodis 
et al. 2012).  
 NRAS mutations are most commonly seen in melanoma (15-20%) and acute myeloid 
leukemia (AML) (43%) (Hodis et al. 2012); (Mardis et al. 2009). In melanoma, tumors tend to 
have either NRAS or BRAF mutation, but not both (Banerji et al. 2008). Recently, inhibition of 
BRAF have been clinically achieved with vemurafenib or dabrafenib; shifting the therapeutic 
focus to the 15-20% of melanomas with NRAS mutations (Kudchadkar et al. 2012). To date, no 
effective strategies yet been developed to target these malignancies, which contribute to the high 
mortality rate of melanoma patients. Discovering and developing therapies towards melanomas 
with NRAS mutations is urgent and crucial.  
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 The RAS class proteins have long been the focus of drug discovery, with efforts focused 
on protein recruiting, membrane localization, and downstream signaling. RAS proteins bind to 
GTP with picomolar affinities while the abundance of GTP presence in cell approaches 
micromolar level. For this reason, nucleotide analogues that compete GTP binding from RAS 
proteins seem to be unpromising. Also, RAS proteins lack the active sites and binding pockets that 
could potentially be targeted by small molecules. For these reasons, RAS proteins have been 
considered as “undruggable” for the past several decades (Gysin et al. 2011). Since hydrophilic 
RAS proteins go through post-translational modification in order to achieve membrane 
localization, strategies targeting these have also been employed (Fiordalisi et al. 2003). 
Farnesyltransferase inhibitors (FTIs) have been demonstrated to be effective for blocking Ras 
farnesylation, subcellular localization and activity, thus inhibiting the growth of Ras-driven cancer 
cells (Brock et al. 2016). However, studies have shown that the most commonly mutated RAS 
isoforms, kRAS and NRAS, are still active even in the presence of FTIs, possibly due to lipid 
modification by geranylgeranyltransferase (Whyte et al. 1997). In addition, downstream effector 
signaling pathways of RAS, such as Raf-MEK-ERK and PI3K-AKT-mTOR signal transduction 
pathways have also been targeted. A synthetic benzyl styryl sulfone compound, called rigosertib, 
is currently in phase III clinical trials for chronic myeloid leukemia. This promising small molecule 
inhibitor can simultaneously inhibit both MAPK and PI3K signaling thus inhibiting tumor growth 
(Z. Liu et al. 2017; Prasad et al. 2016; F. Xu et al. 2014). Besides targeting RAS proteins directly, 
inhibiting the translation of RAS proteins has been explored using antisense or RNA interference 
strategies. Even though these strategies are promising in cells and some rodent models, the lack of 
safe and effective delivery vehicles to human patients is restricting their successful clinical 
applications (Smakman et al. 2005). 
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 In this work, we explored inhibiting the translation of NRAS mRNA via stabilizing its 5’-
UTR G4 (Figure 4-1). Previous research identified a G4-forming sequence in the 5’-UTR of the 
human NRAS mRNA, located 14 bps downstream of the 5’-cap and 222 bps upstream of the 
translation start site, which is evolutionarily conserved thorough many species including human, 
chimpanzee, macaque, rat, mouse and dog (Kumari et al. 2007). The study identified the NRAS 
RNA G4 as a stable parallel intramolecular G4, in the presence of 100 mM KCl. Mutational studies 
demonstrated that disruption of the NRAS RNA G4 led to a 3.6-fold increase in translation of 
NRAS protein in vitro. Further studies showed that the position of the G4 within the 5’-UTR of 
NRAS, and the number of guanines in the sequence, are key factors that affect the translational 
efficiency of NRAS in vitro (Kumari et al. 2008). These studies were the first to identify the NRAS 
RNA G4 as one that represses translation in vitro.  
 To date, only a small molecule approach has been employed primarily to target NRAS 
RNA G4 (Cammas and Millevoi 2017). General G4-interacting compounds, such as TMPYP4, 
that bind to both DNA and RNA G4s were shown to interact with this structure. In addition, two 
RNA-selective G4 stabilizers have been developed, including the polyacromatic molecule RGB1 
and carboxyPDS (carboxy pyridostatin). RGB1 was shown to stabilize the NRAS RNA G4, but 
not DNA G4s or any other RNA structures. Also, this compound significantly downregulated 
NRAS expression in MCF-7 breast cancer cells at the translational level, supporting the hypothesis 
that RGB1 stabilized the NRAS 5’-UTR G4 (Katsuda et al. 2016). This study indicated that 
stabilizing the 5’-UTR G4 of NRAS is a possible strategy to downregulate NRAS expression. 
However, the selectivity of RGB1 for an individual RNA G4 remains to be evaluated. Most likely, 
it can interfere with multiple RNA G4 structures, similarly to the majority of DNA G4 stabilizers, 
leading to possible off-target effects.  
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 Herein, we designed two NA-clamps (Figure 4-2) specifically for the NRAS 5’-UTR G4 
in order to stabilize this translationally repressing element. Similar to the MYC clamps, NRAS 
clamps are composed of the DNA complementing the flanking region and a spatial restricting 
element (polyethylene glycol) that locks G4. The recognition and stabilizing ability of the designed 
clamps toward NRAS G4, their cytotoxicity profile, and their in-cell activities were evaluated.  
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5′GAAACGTCCCGTGTGGGAGGGGCGGGTCTGGGTGCGGCCTGCCGCATGA
CTCGTGGTTCGGAGGCCCACGTGGCCGGGGCGGGGACTCAGGCGCCTGGGG
CGCCGACTGATTACGTAGCGGGCGGGGCCGGAAGTGCCGCTCCTTGGTGGG
GGCTGTTCATGGCGGTTCCGGGGTCTCCAACATTTTTCCCGGCTGTGGTCC
TAAATCTGTCCAAAGCAGAGGCAGTGGAGCTTGAGGTTCTTGCTGGTGTGA
A3′
NRAS mRNA G-Quadruplex
Figure 4-1.  Human NRAS 5’-Untranslated Region (5’-UTR) and the mRNA G-
Quadruplex. A parallel G4 structure (shown in red) is 14 nucleotides downstream of 
the 5’-cap and 222 nucleotides upstream of the translational start site. The entire 
sequence is the 5’-UTR of the NRAS gene; sequence highlighted is the NRAS WText 
oligonucleotide used in current research, and the G4-forming region is marked in red 
(Adapted from Kumari et al. 2007). 
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Figure 4-2. The central hypothesis of NA-clamps mediated stabilization of the 
NRAS 5’-UTR RNA G-quadruplex. The G4-forming region (red) of NRAS plus 14 
bps on both 5’- and 3’-ends (top) was used to design clamp 1 and clamp 2 with either 
14 or 10 bps flanking the 17.7 Å long polyethylene glycol linker, respectively. The 
expected G4 plus clamp complex (bottom) is predicted to downregulate NRAS 
translation.  
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4.2. Recognition and structural stabilization of the NA-clamps to NRAS G4 
 As an RNA G4, both the 5’ and 3’ flanking region of the G4 are usually unpaired and can 
be utilized as complementing bp for NA-clamps. Therefore, we designed two NA clamps, differing 
by the number of complementing bp on each side of the flanking region (14 bp for clamp 1 and 10 
bp for clamp 2) to recognize and stabilize the NRAS RNA G4. Based on previous experience with 
the MYC clamp, the linker length was kept at 17.7 Å by using the same polyethylene glycol linker 
as MYC clamp A (Figure 4-2). Even though both the physiologically relevant MYC promoter G4 
and the identified NRAS 5’-UTR G4 are parallel G4s, but the loop length difference of the two G4 
structures might cause differential spatial distance. All other oligonucleotides used in this chapter 
were listed in Table 2-2. 
 The G4 recognition of the NA-clamps was evaluated by EMSA (Figure 4-3A). Clamp 1 
and clamp 2 were incubated with NRAS WText and the G4 knockout MText sequences, in the 
presence of 100 mM KCl. Mixture DNAs with clamps were heated up to 95 °C and allowed to 
anneal slowly to room temperature. By EMSA, clamp 1 was seen to induced three upwardly shifted 
bands, while clamp 2 only induced one, with WText sequence, as compared to the control WText. 
With the G4 knockout MText sequence (complete G to T replacements on the second guanine run), 
only two faster migrating bands were observed with clamp 1, while one band was noted with clamp 
2, as compared to the MText sequence alone, indicating the two faster migrating bands with clamp 
1 and the single upwardly shifted band with clamp 2 are the complementing DNA complex 
introduced by the binding of clamps. Compared to the MText sequence, clamp 1 introduced a supra-
shifted band with the WText sequence, which may be a G4: clamp 1 complex. Further, ECD studies 
(Figure 4-3B) confirmed that the WText sequence alone (solid line) showed no observable G4 
structure formation. Upon the addition of clamp 1 (dashed line) and clamp 2 (dotted line), more 
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pronounced G4 signature cotton effects at 265 nm were observed, indicating G4 formation was 
induced, more notably by clamp 1. Also, a broadening of the spectrum around 280 nm was 
observed with both clamp 1 and clamp 2, indicating the formation of dsDNA between the flanking 
region of WText and clamp 1. As compared to clamp 2, clamp 1 produced a more intense G4 
signature, as well as the broadening of the spectrum around 280 nm. As compared to EMSA, only 
clamp 1 showed the supra-shifted band, but not clamp 2. However, in ECD, both clamps were able 
to induce more G4 formation. Possibly, clamp 2 can bind to one side of the flanking region but not 
both sides at the same time, thus no G4 is locked in between. Our previous study has shown that 
truncated NRAS sequence containing only the G4-forming region can form a more stable G4 
structure in the same condition, as compared to NRAS WText (data not shown). By binding to 
either side of the flanking region, clamp 2 could potentially change the structural equilibrium of 
the NRAS WText sequence, which allowed more G4 formation. Further studies with fragmented 
clamps and WText need to be conducted to confirm this hypothesis.  
 Previous research by the group discovered the NRAS RNA G4 showed this G4 structure 
is a very stable with 100 mM KCl (Kumari et al. 2007), which is different from the ECD findings 
observed above. The different oligonucleotide studied need to be considered. They used an RNA 
sequence containing only the G4-forming region plus three base pairs on the 5’-end (5 ′ -
UGUGGGAGGGGCGGGUCUGGG-3′), while we have to adopt a longer NRAS WText DNA 
sequence containing not only the G4-forming region, but also 14 flanking base pairs on both 5’- 
and 3’-end of the G4 to enable clamp binding. Studies have shown that G4 structures formed by 
RNA are thermodynamically more stable than G4s formed by their DNA counterparts, which 
might contribute the differences observed above (Agarwala et al. 2015b; Arora and Maiti 2009; 
Joachimi et al. 2009). Also, the additional complementing base pairs added on the flanking region 
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of the G4 can also disrupt the G4 formation of the region. To address this problem, we added 
acetonitrile (ACN), an osmolyte, used to induce the physiologically relevant structure in a test tube 
(Miller et al. 2010). The effect of ACN and clamp 1 or clamp 2 on the G4 formation of WText were 
evaluated by EMSA and ECD (Figure 4-4).   
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Figure 4-3. Binding of linked clamps 1 and 2 to the NRAS G4. (A) The binding of 
clamps 1 and 2 to NRAS WText and a G4 knockout MText was examined by EMSA. 
Three upwardly shifted bands were observed to occur between WText and clamp 1, 
while only one upwardly shifted band was observed with clamp 2. With the G4 
knockout NRAS sequence, clamp 1 produced only two upwardly shifted bands that 
matches the two faster migrating bands while clamp 2 produced only one upwardly 
shifted band, as with the WT sequence. (B) The control DNA alone (NRAS WText) 
demonstrated no G4 formation by ECD. Upon the addition of clamp 1 (dashed line) 
and clamp 2 (dotted line), a signature parallel G4 signal around 270 nm was induced. 
Also, a broadening of the spectrum around 275-280 nm, denoting the formation of 
dsDNA on the flanking region, was recorded. Compared to clamp 2, clamp 1 fostered 
more G4 with the NRAS WText sequence, which is consistent with the observations 
from EMSA.  
B
A
NRAS	WText NRAS	MTextNRAS WText NRAS Text 
 109 
 Upon the addition of 40% ACN (according to a ACN gradient study with WText, data not 
shown), clamp 1 fostered notably more supra-shifted banding, as compared to without ACN, 
indicating G4 formation while clamp 2 mediated only the complementing dsDNA, as evidenced 
by the darker bandings, as compared to without ACN. ECD was used to probe the structural 
changes after the addition of ACN and clamps. Without osmolyte, either WText alone (blue) or 
with 100 mM KCl (red) showed no G4 formation which is consistent with spectra recorded 
previously (Figure 4-3). Upon the addition of 40% ACN (green), a pronounced signature G4 cotton 
effect was induced, as evidenced by the minimum and maximum at 240 nm and 265 nm 
respectively, indicating the formation of a parallel G4 structure. Upon the addition of clamp 2 
(teal), the intensity of the G4 cotton effect was unchanged. Notably, upon the addition of clamp 1 
(purple), a more intense 265 nm cotton effect was observed, as well as a broadening of the 
spectrum around 275-280 nm, indicating the induction of G4 and the formation of dsDNA on the 
flanking region. These results further demonstrated that clamp 1, but not clamp 2 is able to 
facilitate NRAS G4 formation.  
 The G4-induction ability of clamp 1 was evaluated by comparing the binding patterns of 
pre-annealing and post-annealing clamp 1 with WText (Figure 4-5). Without the addition of 
osmolyte (Figure 4-5B), the incubation of clamp 1 with NRAS WText only fosters supra-shifted 
bands in a dose-dependent manner when clamp 1 and NRAS WText were annealed together (pre-
annealing). With post-annealing samples, no visible supra-shifted band was observed indicating 
no G4 was detected by clamp 1, which is consistent with the ECD data showing no stable G4 
formation by NRAS WText without the presence of ACN. Upon the addition of osmolyte (Figure 
4-5A), clamp 1 fostered more supra-shifted banding, as compared to the pre-annealed sample 
without ACN. Notably, with post-annealing samples, clamp 1 introduced a light supra-shifted 
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banding in the presence but not absence of ACN, indicating clamp 1 recognizes the NRAS G4 
formation.  
 Next, the G4 stabilization ability of the NA-clamps on NRAS WText sequence was 
examined by DMS footprinting study. All samples used in this study were pre-annealed under the 
conditions used in Figure 4-6. NRAS WText alone demonstrated no observable protection of the 
four guanine runs capable of participating G4 formation. Compared to WT alone, ACN facilitated 
G4 formation as evidenced by the lighter bandings from the four-participating guanine runs (red). 
Upon the addition of clamp 1, a more noticeable guanine protection pattern from the four guanine 
runs (red) was observed compared to either the control sample or sample annealed with ACN, 
demonstrating NRAS G4 stabilization by clamp 1. As compare to control, no observable guanine 
protection was detected when NRAS WText was annealed with clamp 2, suggesting clamp 2 is not 
effective at stabilizing the NRAS G4.   
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Figure 4-4. Binding of clamps to NRAS G4 under physiologically relevant 
condition. (A) ECD confirmed that 40% ACN (teal) facilitated the formation of 
NRAS G4, as compared to either NRAS WT alone (blue) or with 100 mM KCl (red). 
Upon the addition of clamp 1, a more notable signature parallel G4 cotton effect plus 
a broadening of the spectra around 275-280 nm was observed. While with clamp 2, 
no change was observed. (B) Clamps were incubated with NRAS WText with ACN 
pre-annealingly. Similar binding patterns were observed with both clamp 1 and clamp 
2 as previously. With clamp 1, ACN promoted the formation of the supra-shifted band. 
With clamp 2, only the slower migrating band was observed.  
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Figure 4-5. NRAS G4 induction by annealing with clamp 1. (A) Without the 
presence of ACN, incubation of clamp 1 with WText induced G4 formation only when 
clamp 1 was added before pre- annealing but not post-annealing. NRAS G4 was 
induced by as low as 0.5 equivalence of clamp 1 through pre-annealing incubation, 
but no G4 induction was observed even with two equivalences of clamp 1 by post-
annealing incubation. (B) Upon the addition of 40% ACN that mimics the 
physiological condition, one equivalence of clamp 1 induced a lighter supra-shifted 
band with post-annealing incubation, indicating clamp 1 binds to the G4 formed by 
WText sequence. With pre-annealing incubation, supra-shifted bands were observed at 
both ACN present and absent groups, which further demonstrated that clamp 1 
facilitates NRAS G4 formation at both conditions.  
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Figure 4-6. Clamp 1-mediated stabilization of NRAS G4. DMS-footprinting was 
utilized to confirm the NRAS G4 stabilization by clamp 1. NRAS G4-forming region 
was marked in red. Compared to without ACN, slight protection of all four guanine runs 
was observed indicating some G4 formation. Upon the addition of clamp 1, lighter 
bands from all four guanine runs were observed, either compared to the control or ACN 
group, demonstrating G4 stabilization by clamp 1. With clamp 2, no protection pattern 
of guanine was detected, indicating no G4 stabilization by clamp 2.  
NRASWText + + + +
KCl (100	mM) - + + +
40% ACN - + + +
Clamp	1 - - + -
Clamp 2 - - - +
G
TG
TG
G
G
A
G
G
G
G
C
G
G
G
TC
TG
G
G
TG
C
G
G
C
C
TG
C
ext
 114 
4.3. Intracellular activity of NRAS clamp 1  
 The experiments conducted above demonstrate that clamp 1 is able to recognize and 
stabilize NRAS G4. In this section, the cytotoxicity of clamp 1 will be evaluated on cancerous 
melanoma WM 3682 and non-cancerous HEK-293 cell lines. Also, the effect of clamp 1 and clamp 
2 on NRAS expression will be assessed on melanoma cells.  
 NRAS-mutated cancers are often addicted to their constitutive RAS activity, and down-
regulating protein expression is sufficient to decrease cell survival in melanoma cells only driven 
by NRAS mutation (Eskandarpour et al. 2005). A previous study successfully induced apoptosis 
of melanoma cells harboring only an NRAS mutation with targeted RNA interference, confirming 
that down-regulating NRAS mRNA expression is able to elicit apoptosis in addicted cells 
(Eskandarpour et al. 2005). In this study, a human metastatic melanoma cell line WM 3682 
(different from the study above), which contains only NRAS mutation (Q61L) but no BRAF, c-
KIT, PTEN, or any other common melanoma related gene mutations, was used for cellular viability 
and protein expression assays.  
 To test the effect of clamp 1 on cell survival, we used the non-cancerous cell line HEK-
293 and the malignant melanoma cell line WM 3682 (Figure 4-7). Increasing doses of clamp 1 
were transfected into HEK-293 and WM 3682 cells in micelles formed with FuGene HD one day 
post cell seeding, standard MTS assay was performed to measure cellular viability 48 and 72 hr 
post-transfection. Dose-dependent decrease of cellular viability in both cell lines at both time 
points were observed. Forty-eight hr post-transfection, melanoma cells showed higher sensitivity 
to clamp 1 treatment, as compared to non-cancerous HEK-293 cells, their ED50S were 670 and 
1040 ng, respectively. The differential response of the two cell lines to clamp 1 treatment was gone 
by 72 hr transfection.  
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 Based on the cytotoxicity data, a range of doses (500, 1000, 2500, 5000 ng) of clamp 1 and 
clamp 2 were transfected into WM 3682 melanoma cells to assess if the dose-dependent decrease 
of cellular viability of the melanoma cells by clamp 1 coincided with NRAS down-regulation. 
Western blot analysis was performed to determine NRAS protein levels on samples collected 48 
hr post-transfection (Figure 4-8A). Based on the densitometry analysis (Figure 4-8B), no dose-
dependent decrease of NRAS protein level was observed by clamp 1 and a does dependent increase 
was observed with clamp 2; further investigations of translational regulation at more time points 
remains necessary. Also, the intracellular stability of the clamps need to be evaluated.   
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Figure 4-7. Cytotoxicity of clamp 1 on cancerous melanoma WM 3682 and non-
cancerous HEK-293 cell lines. Dose-dependent decreases of cellular viability were 
observed with both cell lines 48 and 72 hr post-transfection of clamp 1. At 48 hr, WM 
3682 melanoma cells showed a notable lower ED50 compared to non-cancerous HEK-
293 cells. However, the difference of the IC50 was diminished 72 hr post-transfection.  
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Figure 4-8. Effect of clamps on NRAS translation.  (A) Clamp 1 was transfected into WM 
3682 melanoma cell by FuGene HD. Cells were lysed and a standard western blot was 
conducted to determine NRAS protein levels 48 hr post-transfection. Beta-actin was used as 
an internal control for protein expression. (B) Densitometry analysis of the immunoblots from 
(A) was performed using LiCor Odessey software to quantify NRAS protein levels. No dose-
dependent NRAS expression changes were observed with clamp 1 transfection. With clamp 
2, a dose-dependent increase of NRAS expression was observed.  
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4.4. Discussion  
 RNA G4s play important roles in translational regulation. Pioneering research using a 
eukaryotic cell free translation system demonstrated a naturally occurring G4 formed in the 5’-
UTR of NRAS mRNA is important in modulating the translational efficiency of the NRAS 
oncogene (Kumari et al. 2007).  After this mile stone work, other G4s formed in the 5’-UTR or 3’-
UTR of mRNAs were also shown to inhibit the translation of their corresponding genes, such as 
ZIC-117, BCL-2, MP3- MMP18, ERS1, TRF2, and PIM1 (Arora et al. 2008; Arora and Suess 
2011; Balkwill et al. 2009; Gomez et al. 2010; Morris and Basu 2009; Shahid et al. 2010). Notably, 
the research on ZIC-117 5’-UTR mRNA G4 was the first study that showed an RNA G4 structure 
that can repress gene translation in living human HeLa cells (Arora et al. 2008). Many more 
potential G4s formed in the regulatory regions of mRNA, based on bioinformatics analysis, remain 
to be studied (Huppert et al. 2008). For the current work, we focused on the first discovered NRAS 
5’-UTR G4 to evaluate the efficacy of the NA-clamp approach to stabilize naturally occurring 
RNA G4s, thus modulating gene translation.    
 To date, small molecules have been the main approach taken to target RNA G4 structures. 
Particularly for the NRAS RNA G4, two small molecules - RR110 and RGB1, have been 
developed to stabilize this G4 thus inhibiting the translation of NRAS. Notably, RGB1 not only 
showed inhibition efficacy of NRAS translation in vitro, and downregulated endogenous NRAS 
protein level in breast cancer cells (Bugaut et al. 2010; Katsuda et al. 2016). RGB1 was shown to 
be RNA versus DNA G4 selective, but selectivity for the NRAS RNA G4 specifically remains to 
be demonstrated. RR110 was shown to stabilize NRAS G4, but not selective over DNA G4 or 
dsDNA based on their screening strategy. Compared to small molecule strategy, we employed an 
NA-clamp-based approach with high specificity for targeting the NRAS RNA G4 structure.  
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In this work, we designed two NA-clamps (clamp 1 and 2) to recognize and stabilize NRAS 
RNA G4. However, only clamp 1 demonstrated its NRAS G4 recognition and stabilization 
capability. These two clamps are both composed of two pieces of oligonucleotides complementing 
the 5’- and 3’- flanking regions of NRAS RNA G4 and a polyethylene glycol linker connecting 
these together. Clamp 1 contains 28, as compared to 20, bps of complementary nucleotides, which 
would be expected to grant clamp 1 higher binding affinity to the NRAS G4. Our previous work 
targeting the MYC DNA G4 with clamp A, using the same polyethylene linker, showed that 18 
bps on the 5’-side plus 5 bps on the 3’-side of the clamp, 23 bps altogether, was sufficient to grant 
high binding affinity and specificity to its target G4 sequence (Hao et al. 2016). Compared to clamp 
2, clamp 1 possesses only four more base pairs on each side of the complementing 
oligonucleotides; However, these eight extra base pairs made a marked difference in terms of 
NRAS G4 recognition and stabilization, indicating the sufficient base pairs complementing the 
flanking region of the NRAS G4 is required to achieve stabilization.  
DNA oligonucleotides rather than RNA nucleotide sequences was used in this study in 
order to be more cost efficient. Previous research established that RNA G4s are more stable than 
DNA G4s thermodynamically (Agarwala et al. 2015b; Arora and Maiti 2009; Joachimi et al. 2009). 
The initial work, which described NRAS RNA G4, showed this parallel G4 structure is very stable 
thermodynamically with a TM of > 95 °C  (Kumari et al. 2007).  In this work, we showed that the 
DNA version of the same NRAS WT sequence, containing only the G4-forming region, had a 
much lower TM (79 °C) compared to its RNA counterparts. Moreover, the longer flaking region 
further disrupted the formation of this G4.  
 Therapeutically, RAS proteins, including NRAS, have been well validated as molecular 
targets for a variety of cancer types. Particularly for NRAS, around 15% of melanomas are driven 
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by NRAS mutations, and are considered untreatable. Targeted therapeutic development for 
melanomas harboring NRAS mutation is urgent and necessary. Previous RAS targeting 
approaches have focused on inhibiting the membrane localization of the proteins or targeting 
downstream signaling pathways (Brock et al. 2016; Fiordalisi et al. 2003; Z. Liu et al. 2017; Prasad 
et al. 2016; Smakman et al. 2005; Vojtek et al. 1993; F. Xu et al. 2014).  However, none of the 
above approaches has made it to the clinic. Other than small molecules, siRNA has also been used 
to target NRAS expression with promising efficacy on downregulating NRAS expression. 
However, the delivery of siRNA systemically is an obstacle for patients. In addition, NRAS 
mutations commonly occur in codon 61 with three major different mutation types, including Q61K, 
Q61R, Q61L (Hou et al. 2012), thus requiring siRNAs to be multiple designed against individual 
mutations to achieve high selectivity. In contrast, modulating NRAS translation by targeting the 
5’-UTR G4 of its mRNA is not restricted by the mutation types of the gene. Therapeutics 
developed by targeting NRAS G4 therefore will have a wider application window compared to 
siRNAs designed for individual mutations.  
Despite demonstrating stabilization of the NRAS 5’-UTR G4, endogenous protein 
downregulation was not observed in melanoma cells 48 hr post-transfection of clamp 1. This result 
could be caused by an instability of clamp 1 in cytoplasm; stability studies need to be completed. 
Previous study showed that an RNA G4 stabilizing small molecule, RGB1, was able to 
downregulate endogenous NRAS protein expression in cells, indicating a role for the structure 
itself (Katsuda et al. 2016). On the other hand, a recent study showed that RNA G4 structures are 
globally unfolded in eukaryotic cells (Guo and Bartel 2016). Researchers from the same study 
above proposed that the NRAS G4 sequence can function as a protein binding site, and it is the 
proteins bound to the sequence that sequester translational machinery, thus inhibiting translation 
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rather than the G4 structure formed by the sequence (Guo and Bartel 2016). Notably, if these was 
no initial G4 formation, and the sequence was pre-occupied by proteins, the access of clamp 1 to 
the G4-forming sequence would be blocked. Further research should be carried out to identify the 
potential binding proteins of the NRAS G4 to unravel the mystery of G4 targeting with NA-clamp 
approach. 
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CHAPTER V. CONCLUSION 
 
 
 G-quadruplexes (G4s) are non-canonical secondary nucleic acid structures formed by DNA 
or RNA sequences, usually in the biologically important regions such as promoters of DNA, 5’-
UTRs of mRNA and telomeres (Verma et al. 2008). This biological importance has resulted in the 
emergence of targeting G4 structures as a therapeutic strategy for the regulation of oncogene 
expression on both DNA and RNA levels (Balasubramanian et al. 2011, Cimino-Reale et al. 2016). 
G4 mediated transcriptional and translational silencing mainly functions through sequestering the 
binding of transcription factors, polymerases and translational machineries to the promoters of 
DNA or the 5’-UTRs of mRNA. This has allowed for the development of multiple strategies to 
stabilize G4 structures in the promoter or 5’-UTR of oncogenes in order to downregulate oncogene 
expression.  
Extensive efforts have been exerted to develop G4 stabilizing small molecules (Maji and 
Bhattacharya 2014). Notably, two G4-interacting compounds, quarfloxin and CX5461, have 
entered phase II clinical trials for treating carcinoid/neuroendocrine and triple negative breast 
cancer, respectively. While quarfloxin failed phase II clinical trial due to high albumin binding, it 
represents the first in class G4-interacting compound that provided insights for G4 targeting in 
cancer treatment. CX5461 is still under active clinical investigation to determine its clinical 
efficacy. For MYC specifically, NSC338258, a representative small molecule, displayed 
preferential binding to MYC promoter G4 with nanomolar affinity and downregulated MYC 
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expression in lymphoma cells. However, this compound also showed binding and stabilization to 
other promoter G4s, such as the ones in VEGF and HIF-1α genes — stressing the importance of 
target specificity (Brown et al. 2011).  
Nucleic acid-based strategies have also been employed to target certain oncogene 
promoters, such as MYC and Bcl-2. In particular, MYC G4-forming sequence pu27 has been 
utilized in leukemia cells, which resulted in profound damage to both telomeric and non-telomeric 
regions of DNA, inducing cancer cell apoptosis (Islam et al. 2014; Sedoris et al. 2012). Guanine 
rich PNAs have also been used to target the G4-forming region of MYC by forming PNA/DNA 
hybrid quadruplexes thus downregulating MYC expression (Gupta et al. 2013; Roy et al. 2007). 
Other types of DNAi work have showed promising effect in treating cancer. Notably, one 
unmodified oligonucleotide PNT 2258 was utilized to target the distal region of the BCL-2 
promoter to downregulate BCL-2 expression and inducing apoptosis of cancer cells. PNT 2235 is 
currently under phase II clinical trials for diffuse large B cell lymphoma (Ebrahim et al. 2016; 
Tolcher et al. 2014). Although PNT 2228 is a non-G4-mediated approach, it still highlights the 
potential of using nucleic acid based approaches as cancer therapeutics.  
To target individual G4s with high specificity, we adopted a novel nucleic acid-based 
approach to stabilize G4s. Clamps comprise two segments of oligonucleotides complementing to 
the 5’ and 3’- flanking regions of the G4s with a linker connecting the two segments together.  The 
complementing oligonucleotides on the flanking region of the G4 grant the clamps high binding 
specificity, while the linker is optimized to the proximal distance of the G4 — enabling the clamps 
to recognize and stabilize the G4 structure. In this work, we designed clamps that stabilize MYC 
promoter G4 and NRAS 5’-UTR G4 to demonstrate this clamp approach on both DNA and RNA 
level.  
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MYC promoter G4 is the most well characterized G4 structure to date. Previous research 
has identified multiple G4 structures formed in the guanine and cytosine rich NHE III1 region of 
the MYC promoter, including G41-4, G42-5, and G41-5 (Dettler et al. 2011; Siddiqui-Jain et al. 2002; 
Sun and Hurley 2009). To date, the physiologically relevant MYC G4 has been identified as a 
parallel structure G41-4, with the loop length of 1:2:1 from the 5’ to 3’ direction, under supercoiled 
DNA conditions, which you would find in a cell under physiological conditions (Sun and Hurley 
2009). MYC promoter G4 is a silencing element of MYC transcription, and stabilizing this 
physiologically-relevant MYC G4 is a practical strategy to downregulate MYC expression (Brooks 
and Hurley 2010). For example, small molecule NSC 338258 downregulates MYC expression in 
lymphoma cells by stabilizing the physiologically relevant MYC promoter G4 (Brown et al. 2011). 
In this work, we utilized a different stabilizing strategy, NA-clamps, that possess higher specificity 
towards the physiologically relevant MYC G41-4.  
Clamp A presented specific recognition to its designed G4 target G41-4 but not other G4 
isoforms in the equilibrium within the NHE III1 region. Also, clamp A stabilized G41-4 in vitro, as 
demonstrated by DMS-footprinting. More importantly, clamp A was able to stabilize this 
physiologically relevant G41-4 in supercoiled plasmids and downregulates MYC promoter activity 
in living cells, as evidenced by luciferase reporter assay. A cellular viability assay also showed 
that clamp A possesses differential cytotoxicity profile towards cancerous vs non-cancerous cell 
lines.  
To reduce the cost and increase the modification flexibility of clamp A, we optimized 
clamp A by replacing the original polyethylene glycol linker with five thymines that share the 
same length with the linker on clamp A, and yielded a new clamp termed clamp A 5T. With a 
dramatic cost reduction and more flexible modification potential, we demonstrated that clamp A 
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5T was able to specifically recognize and stabilize the physiologically relevant MYC G41-4 just as 
clamp A. Using fluorescently labeled clamp A 5T, we identified that clamp A 5T was able to be 
transfected into living cells, and more importantly, localized in the nucleus. By using biotinylated 
clamp A 5T, we were able to immunoprecipitate the physiological binding target of clamp A 5T 
in human breast cancer cells and confirmed its binding to the endogenous MYC promoter DNA, 
as supported by ChiP-PCR experiment.  
All nucleic acids based therapeutics, including the NA-clamp approach discussed herein, 
face one common challenging problem — the intracellular delivery. To deliver NA-clamps in cells, 
especially hard-to-transfect lymphoma cells, we collaborated with a chemical engineering group 
that synthesized nine block copolymers to facilitate delivery. Among these nine block copolymers, 
we identified that the ethyl series copolymers were able to effectively transfect both RAJI and 
CA46 Burkitt’s lymphoma cells with fluorescent labeled clamp A 5T. Based on fluorescent 
microscopy studies, we discovered that FAM-clamp A 5T was only stable up to 24 hour 
intracellularlly. Lastly, we evaluated the effect of clamp A 5T on the transcription of MYC in 
MCF-7 and RAJI cells. Even though no significant downregulation of MYC was observed 24 hr 
post-transfection in both cell lines, there was a decrease of MYC in cells treated with clamp A 5T 
in both cells. The in-cell stability of clamp A 5T needs to be optimized before its effect on MYC 
transcription could be confirmed.   
Lastly, we explored the potential application of clamp A 5T as a clinical diagnostic 
companion for the indication of G4 small molecule employment. Through G4 induction assay, we 
showed that fluorescently labeled clamp A 5T was able to detect induced MYC G4 formation in 
fixed and permeabilized breast cancer and lymphoma cells by increasing concentrations of MYC 
G4 selective small molecule NSC 338258. This exploration further demonstrated that clamp A 5T 
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is highly specific for MYC G4 recognition. Clamp A 5T could be potentially be developed as a 
diagnostic companion in the clinics to detect the hyperactivity of MYC transcription in cancer cells 
and inform the usage of MYC selective G4 stabilizing small molecules.  
At the translational level, RNA G4s are repressors of gene translation into their protein 
products (Bugaut and Balasubramanian 2012). Particularly, NRAS 5’-UTR G4 was the first 
reported mRNA G4 that functioned as a translation silencing element (Kumari et al. 2007). Small 
molecules have been developed to target NRAS RNA G4 to downregulate NRAS expression. Most 
notably, RGB1, a RNA G4 selective G4 stabilizing compound, has demonstrated its efficacy in 
downregulating endogenous NRAS protein level in breast cancer cells (Katsuda et al. 2016). 
However, the specificity of RGB1 over NRAS G4 and its mechanism of action still requires further 
elucidation. In this work, we applied NA-clamp approach to the NRAS 5’-UTR G4 by designing 
two clamps (clamp 1 and clamp 2) for NRAS G4 specifically. Based on the binding assays, we 
determined that clamp 1 but not clamp 2 was able to recognize NRAS G4 formation, with clamp 
1 exhibiting NRAS G4 stabilization as demonstrated by DMS-footprinting. Through cellular 
viability assay, we observed that clamp 1 was cytotoxic to both cancerous melanoma and non-
cancerous HEK-293 cells. However, clamp 1 showed much lower IC50 on cancerous melanoma 
cell versus non-cancerous HEK-293 cells, indicating selective cytotoxicity before clamps were 
digested in cells. Unfortunately, no NRAS protein downregulation was observed in melanoma 
cells after treating with either clamp 1 or clamp 2. However, a recent finding revealed that RNA 
G4s are universally unraveled in eukaryotic cells, and the G4-forming sequences are bound by 
multiple proteins to maintain the single stranded form of RNA (Guo and Bartel 2016). If this holds 
true in melanoma cells, then it is understandable that clamp 1 was not able to get access to its 
physiological target in cells thus further pharmacological effects would not be observed.  
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Overall, we demonstrated that NA-clamp approach could be applied to both promoter G4 
and 5’-UTR G4 for specific recognition and stabilization, providing the foundation for the future 
development of NA-clamps into effective therapeutics, or as diagnostic companions for MYC, 
NRAS, or other G4-related cancer types. 
 
 
  
 128 
 
 
 
 
 
 
 
REFERENCES 
  
 129 
Agarwala, P., Pandey, S., and Maiti, S. (2015a), 'The tale of RNA G-quadruplex', Org Biomol 
Chem, 13 (20), 5570-85. 
Agarwala, P., et al. (2015b), 'Human telomeric RNA G-quadruplex response to point mutation in 
the G-quartets', J Phys Chem B, 119 (13), 4617-27. 
Aird, F., et al. (2017), 'Replication Study: BET bromodomain inhibition as a therapeutic strategy 
to target c-Myc', Elife, 6. 
Albert, T., et al. (2001), 'The chromatin structure of the dual c-myc promoter P1/P2 is regulated 
by separate elements', J Biol Chem, 276 (23), 20482-90. 
Alitalo, K., et al. (1983), 'Homogeneously staining chromosomal regions contain amplified 
copies of an abundantly expressed cellular oncogene (c-myc) in malignant 
neuroendocrine cells from a human colon carcinoma', Proc Natl Acad Sci U S A, 80 (6), 
1707-11. 
Amati, B., et al. (2001), 'Function of the c-Myc oncoprotein in chromatin remodeling and 
transcription', Biochim Biophys Acta, 1471 (3), M135-45. 
Amati, B., et al. (1993), 'Oncogenic activity of the c-Myc protein requires dimerization with 
Max', Cell, 72 (2), 233-45. 
Arora, A. and Maiti, S. (2009), 'Differential biophysical behavior of human telomeric RNA and 
DNA quadruplex', J Phys Chem B, 113 (30), 10515-20. 
Arora, A. and Suess, B. (2011), 'An RNA G-quadruplex in the 3' UTR of the proto-oncogene 
PIM1 represses translation', RNA Biol, 8 (5), 802-5. 
Arora, A., et al. (2008), 'Inhibition of translation in living eukaryotic cells by an RNA G-
quadruplex motif', RNA, 14 (7), 1290-6. 
Baird, S. D., et al. (2006), 'Searching for IRES', RNA, 12 (10), 1755-85. 
Balasubramanian, S., Hurley, L. H., and Neidle, S. (2011), 'Targeting G-quadruplexes in gene 
promoters: a novel anticancer strategy?', Nat Rev Drug Discov, 10 (4), 261-75. 
Balkwill, G. D., et al. (2009), 'Repression of translation of human estrogen receptor alpha by G-
quadruplex formation', Biochemistry, 48 (48), 11487-95. 
Banerji, U., et al. (2008), 'BRAF and NRAS mutations in melanoma: potential relationships to 
clinical response to HSP90 inhibitors', Mol Cancer Ther, 7 (4), 737-9. 
Bang, Ivar, Lyttkens, H, and Sandgren, J (1910), 'Über die Bestimmung des Blutzuckers', 
Hoppe-Seyler´ s Zeitschrift für physiologische Chemie, 65 (5-6), 497-503. 
Bates, P. J., et al. (2009), 'Discovery and development of the G-rich oligonucleotide AS1411 as a 
novel treatment for cancer', Exp Mol Pathol, 86 (3), 151-64. 
Berberich, S. J. and Postel, E. H. (1995), 'PuF/NM23-H2/NDPK-B transactivates a human c-myc 
promoter-CAT gene via a functional nuclease hypersensitive element', Oncogene, 10 
(12), 2343-7. 
Bid, H. K., et al. (2016), 'The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis 
in Models of Childhood Sarcoma', Mol Cancer Ther, 15 (5), 1018-28. 
Biffi, G., Tannahill, D., and Balasubramanian, S. (2012), 'An intramolecular G-quadruplex 
 130 
structure is required for binding of telomeric repeat-containing RNA to the telomeric 
protein TRF2', J Am Chem Soc, 134 (29), 11974-6. 
Biffi, G., et al. (2013), 'Quantitative visualization of DNA G-quadruplex structures in human 
cells', Nat Chem, 5 (3), 182-6. 
Biffi, G., et al. (2014), 'Visualization and selective chemical targeting of RNA G-quadruplex 
structures in the cytoplasm of human cells', Nat Chem, 6 (1), 75-80. 
Blackwood, E. M. and Eisenman, R. N. (1991), 'Max: a helix-loop-helix zipper protein that 
forms a sequence-specific DNA-binding complex with Myc', Science, 251 (4998), 1211-
7. 
Bochman, M. L., Paeschke, K., and Zakian, V. A. (2012), 'DNA secondary structures: stability 
and function of G-quadruplex structures', Nat Rev Genet, 13 (11), 770-80. 
Bouchard, C., et al. (2004), 'Myc-induced proliferation and transformation require Akt-mediated 
phosphorylation of FoxO proteins', EMBO J, 23 (14), 2830-40. 
Boxer, L. M. and Dang, C. V. (2001), 'Translocations involving c-myc and c-myc function', 
Oncogene, 20 (40), 5595-610. 
Boxer, R. B., et al. (2004), 'Lack of sustained regression of c-MYC-induced mammary 
adenocarcinomas following brief or prolonged MYC inactivation', Cancer Cell, 6 (6), 
577-86. 
Brock, E. J., et al. (2016), 'How to Target Activated Ras Proteins: Direct Inhibition vs. Induced 
Mislocalization', Mini Rev Med Chem, 16 (5), 358-69. 
Brooks, T. A. and Hurley, L. H. (2009), 'The role of supercoiling in transcriptional control of 
MYC and its importance in molecular therapeutics', Nat Rev Cancer, 9 (12), 849-61. 
--- (2010), 'Targeting MYC Expression through G-Quadruplexes', Genes Cancer, 1 (6), 641-49. 
Brooks, T. A., Kendrick, S., and Hurley, L. (2010), 'Making sense of G-quadruplex and i-motif 
functions in oncogene promoters', FEBS J, 277 (17), 3459-69. 
Brown, R. V., et al. (2011), 'Demonstration that drug-targeted down-regulation of MYC in non-
Hodgkins lymphoma is directly mediated through the promoter G-quadruplex', J Biol 
Chem, 286 (47), 41018-27. 
Bryan, T. M. and Baumann, P. (2011), 'G-quadruplexes: from guanine gels to 
chemotherapeutics', Mol Biotechnol, 49 (2), 198-208. 
Bugaut, A. and Balasubramanian, S. (2012), '5'-UTR RNA G-quadruplexes: translation 
regulation and targeting', Nucleic Acids Res, 40 (11), 4727-41. 
Bugaut, A., et al. (2010), 'Small molecule-mediated inhibition of translation by targeting a native 
RNA G-quadruplex', Org Biomol Chem, 8 (12), 2771-6. 
Burger, A. M., et al. (2005), 'The G-quadruplex-interactive molecule BRACO-19 inhibits tumor 
growth, consistent with telomere targeting and interference with telomerase function', 
Cancer Res, 65 (4), 1489-96. 
Cammas, A. and Millevoi, S. (2017), 'RNA G-quadruplexes: emerging mechanisms in disease', 
Nucleic Acids Res, 45 (4), 1584-95. 
 131 
Chen, B. J., et al. (2014), 'Small molecules targeting c-Myc oncogene: promising anti-cancer 
therapeutics', Int J Biol Sci, 10 (10), 1084-96. 
Chipumuro, E., et al. (2014), 'CDK7 inhibition suppresses super-enhancer-linked oncogenic 
transcription in MYCN-driven cancer', Cell, 159 (5), 1126-39. 
Chisholm, O., Stapleton, P., and Symonds, G. (1992), 'Constitutive expression of exogenous myc 
in myelomonocytic cells: acquisition of a more transformed phenotype and inhibition of 
differentiation induction', Oncogene, 7 (9), 1827-36. 
Christensen, C. L., et al. (2014), 'Targeting transcriptional addictions in small cell lung cancer 
with a covalent CDK7 inhibitor', Cancer Cell, 26 (6), 909-22. 
Chung, W. J., et al. (2014), 'Solution structure of a G-quadruplex bound to the bisquinolinium 
compound Phen-DC(3)', Angew Chem Int Ed Engl, 53 (4), 999-1002. 
Cimino-Reale, G., Zaffaroni, N., and Folini, M. (2016), 'Emerging Role of G-quadruplex DNA 
as Target in Anticancer Therapy', Curr Pharm Des. 
Cole, M. D. and Cowling, V. H. (2008), 'Transcription-independent functions of MYC: 
regulation of translation and DNA replication', Nat Rev Mol Cell Biol, 9 (10), 810-5. 
Cowling, V. H. and Cole, M. D. (2007), 'The Myc transactivation domain promotes global 
phosphorylation of the RNA polymerase II carboxy-terminal domain independently of 
direct DNA binding', Mol Cell Biol, 27 (6), 2059-73. 
Cowling, V. H., et al. (2006), 'A conserved Myc protein domain, MBIV, regulates DNA binding, 
apoptosis, transformation, and G2 arrest', Mol Cell Biol, 26 (11), 4226-39. 
d'Adda di Fagagna, F., Teo, S. H., and Jackson, S. P. (2004), 'Functional links between telomeres 
and proteins of the DNA-damage response', Genes Dev, 18 (15), 1781-99. 
d'Adda di Fagagna, F., et al. (2003), 'A DNA damage checkpoint response in telomere-initiated 
senescence', Nature, 426 (6963), 194-8. 
Dahm, R. (2008), 'Discovering DNA: Friedrich Miescher and the early years of nucleic acid 
research', Hum Genet, 122 (6), 565-81. 
Dalla Favera, Riccardo, Wong-Staal, Flossie, and Gallo, Robert C (1982), 'Onc gene 
amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of 
the same patient'. 
Dalla-Favera, R., et al. (1982), 'Human c-myc onc gene is located on the region of chromosome 
8 that is translocated in Burkitt lymphoma cells', Proc Natl Acad Sci U S A, 79 (24), 
7824-7. 
Dang, C. V. (2010), 'Enigmatic MYC Conducts an Unfolding Systems Biology Symphony', 
Genes Cancer, 1 (6), 526-31. 
--- (2012), 'MYC on the path to cancer', Cell, 149 (1), 22-35. 
Dani, C., et al. (1984), 'Extreme instability of myc mRNA in normal and transformed human 
cells', Proc Natl Acad Sci U S A, 81 (22), 7046-50. 
Delmore, J. E., et al. (2011), 'BET bromodomain inhibition as a therapeutic strategy to target c-
Myc', Cell, 146 (6), 904-17. 
 132 
Dettler, J. M., et al. (2011), 'DSC deconvolution of the structural complexity of c-MYC P1 
promoter G-quadruplexes', Biophys J, 100 (6), 1517-25. 
Dexheimer, T. S., et al. (2009), 'NM23-H2 may play an indirect role in transcriptional activation 
of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1)', 
Mol Cancer Ther, 8 (5), 1363-77. 
Dominguez-Sola, D., et al. (2007), 'Non-transcriptional control of DNA replication by c-Myc', 
Nature, 448 (7152), 445-51. 
Drygin, D., et al. (2009), 'Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis', 
Cancer Res, 69 (19), 7653-61. 
Drygin, Denis, et al. (2008), 'Quarfloxin (CX-3543) disrupts the Nucleolin/rDNA quadruplex 
complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor 
activity in models of cancer', (AACR). 
Duan, W., et al. (2001), 'Design and synthesis of fluoroquinophenoxazines that interact with 
human telomeric G-quadruplexes and their biological effects', Mol Cancer Ther, 1 (2), 
103-20. 
Dubik, D. and Shiu, R. P. (1988), 'Transcriptional regulation of c-myc oncogene expression by 
estrogen in hormone-responsive human breast cancer cells', J Biol Chem, 263 (25), 
12705-8. 
Eberhardy, S. R. and Farnham, P. J. (2002), 'Myc recruits P-TEFb to mediate the final step in the 
transcriptional activation of the cad promoter', J Biol Chem, 277 (42), 40156-62. 
Ebrahim, A. S., et al. (2016), 'PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell 
cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-
Hodgkin's lymphoma', Oncotarget, 7 (27), 42374-84. 
Egler, R. A., et al. (2005), 'Regulation of reactive oxygen species, DNA damage, and c-Myc 
function by peroxiredoxin 1', Oncogene, 24 (54), 8038-50. 
Egly, J. M. and Coin, F. (2011), 'A history of TFIIH: two decades of molecular biology on a 
pivotal transcription/repair factor', DNA Repair (Amst), 10 (7), 714-21. 
Escot, C., et al. (1986), 'Genetic alteration of the c-myc protooncogene (MYC) in human primary 
breast carcinomas', Proc Natl Acad Sci U S A, 83 (13), 4834-8. 
Eskandarpour, M., et al. (2005), 'Suppression of oncogenic NRAS by RNA interference induces 
apoptosis of human melanoma cells', Int J Cancer, 115 (1), 65-73. 
Filippakopoulos, P., et al. (2010), 'Selective inhibition of BET bromodomains', Nature, 468 
(7327), 1067-73. 
Fiordalisi, J. J., et al. (2003), 'High affinity for farnesyltransferase and alternative prenylation 
contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors', J Biol 
Chem, 278 (43), 41718-27. 
Gabert, J., et al. (1989), 'Detection of residual bcr/abl translocation by polymerase chain reaction 
in chronic myeloid leukaemia patients after bone-marrow transplantation', Lancet, 2 
(8672), 1125-8. 
Gebauer, F. and Hentze, M. W. (2004), 'Molecular mechanisms of translational control', Nat Rev 
 133 
Mol Cell Biol, 5 (10), 827-35. 
Gellert, M., Lipsett, M. N., and Davies, D. R. (1962), 'Helix formation by guanylic acid', Proc 
Natl Acad Sci U S A, 48, 2013-8. 
Gomez, D., et al. (2004), 'Telomerase downregulation induced by the G-quadruplex ligand 
12459 in A549 cells is mediated by hTERT RNA alternative splicing', Nucleic Acids Res, 
32 (1), 371-9. 
Gomez, D., et al. (2010), 'A G-quadruplex structure within the 5'-UTR of TRF2 mRNA represses 
translation in human cells', Nucleic Acids Res, 38 (20), 7187-98. 
Gomez, D., et al. (2003), 'Resistance to the short term antiproliferative activity of the G-
quadruplex ligand 12459 is associated with telomerase overexpression and telomere 
capping alteration', J Biol Chem, 278 (50), 50554-62. 
Gomez-Roman, N., et al. (2006), 'Activation by c-Myc of transcription by RNA polymerases I, II 
and III', Biochem Soc Symp,  (73), 141-54. 
Gonzalez, V. and Hurley, L. H. (2010), 'The c-MYC NHE III(1): function and regulation', Annu 
Rev Pharmacol Toxicol, 50, 111-29. 
Gonzalez, V., et al. (2009), 'Identification and characterization of nucleolin as a c-myc G-
quadruplex-binding protein', J Biol Chem, 284 (35), 23622-35. 
Grand, C. L., et al. (2002), 'The cationic porphyrin TMPyP4 down-regulates c-MYC and human 
telomerase reverse transcriptase expression and inhibits tumor growth in vivo', Mol 
Cancer Ther, 1 (8), 565-73. 
Guo, J. U. and Bartel, D. P. (2016), 'RNA G-quadruplexes are globally unfolded in eukaryotic 
cells and depleted in bacteria', Science, 353 (6306). 
Gupta, A., et al. (2013), 'Strand invasion of DNA quadruplexes by PNA: comparison of 
homologous and complementary hybridization', Chembiochem, 14 (12), 1476-84. 
Guschlbauer, W., Chantot, J. F., and Thiele, D. (1990), 'Four-stranded nucleic acid structures 25 
years later: from guanosine gels to telomer DNA', J Biomol Struct Dyn, 8 (3), 491-511. 
Gusse, M., et al. (1989), 'Translocation of a store of maternal cytoplasmic c-myc protein into 
nuclei during early development', Mol Cell Biol, 9 (12), 5395-403. 
Gutierrez, C., et al. (1988), 'Is c-myc protein directly involved in DNA replication?', Science, 240 
(4856), 1202-3. 
Gysin, S., et al. (2011), 'Therapeutic strategies for targeting ras proteins', Genes Cancer, 2 (3), 
359-72. 
Halder, K. and Hartig, J. S. (2011), 'RNA quadruplexes', Met Ions Life Sci, 9, 125-39. 
Hanahan, D. and Weinberg, R. A. (2011), 'Hallmarks of cancer: the next generation', Cell, 144 
(5), 646-74. 
Hansel-Hertsch, R., et al. (2016), 'G-quadruplex structures mark human regulatory chromatin', 
Nat Genet, 48 (10), 1267-72. 
Hao, T., Gaerig, V. C., and Brooks, T. A. (2016), 'Nucleic acid clamp-mediated recognition and 
stabilization of the physiologically relevant MYC promoter G-quadruplex', Nucleic Acids 
 134 
Res, 44 (22), 11013-23. 
Hart, J. R., et al. (2014), 'Inhibitor of MYC identified in a Krohnke pyridine library', Proc Natl 
Acad Sci U S A, 111 (34), 12556-61. 
He, T. C., et al. (1998), 'Identification of c-MYC as a target of the APC pathway', Science, 281 
(5382), 1509-12. 
Herbig, U., et al. (2004), 'Telomere shortening triggers senescence of human cells through a 
pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a)', Mol Cell, 14 (4), 
501-13. 
Herkert, B. and Eilers, M. (2010), 'Transcriptional repression: the dark side of myc', Genes 
Cancer, 1 (6), 580-6. 
Hodis, E., et al. (2012), 'A landscape of driver mutations in melanoma', Cell, 150 (2), 251-63. 
Hou, J. Q., et al. (2012), 'New insights from molecular dynamic simulation studies of the 
multiple binding modes of a ligand with G-quadruplex DNA', J Comput Aided Mol Des, 
26 (12), 1355-68. 
Hsu, T. Y., et al. (2015), 'The spliceosome is a therapeutic vulnerability in MYC-driven cancer', 
Nature, 525 (7569), 384-8. 
Huppert, J. L. and Balasubramanian, S. (2007), 'G-quadruplexes in promoters throughout the 
human genome', Nucleic Acids Res, 35 (2), 406-13. 
Huppert, J. L., et al. (2008), 'G-quadruplexes: the beginning and end of UTRs', Nucleic Acids 
Res, 36 (19), 6260-8. 
Ishizuka, T., et al. (2012), 'G-rich sequence-specific recognition and scission of human genome 
by PNA/DNA hybrid G-quadruplex formation', Angew Chem Int Ed Engl, 51 (29), 7198-
202. 
Islam, M. A., et al. (2014), 'c-Myc quadruplex-forming sequence Pu-27 induces extensive 
damage in both telomeric and nontelomeric regions of DNA', J Biol Chem, 289 (12), 
8521-31. 
Itzen, F., et al. (2014), 'Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation', 
Nucleic Acids Res, 42 (12), 7577-90. 
Ivancich, M., et al. (2017), 'Treating Cancer by Targeting Telomeres and Telomerase', 
Antioxidants (Basel), 6 (1). 
Jain, M., et al. (2002), 'Sustained loss of a neoplastic phenotype by brief inactivation of MYC', 
Science, 297 (5578), 102-4. 
Jayaraj, G. G., et al. (2012), 'Potential G-quadruplexes in the human long non-coding 
transcriptome', RNA Biol, 9 (1), 81-6. 
Jin, R., et al. (1992), 'Thermodynamics and structure of a DNA tetraplex: a spectroscopic and 
calorimetric study of the tetramolecular complexes of d(TG3T) and d(TG3T2G3T)', Proc 
Natl Acad Sci U S A, 89 (18), 8832-6. 
Joachimi, A., Benz, A., and Hartig, J. S. (2009), 'A comparison of DNA and RNA quadruplex 
structures and stabilities', Bioorg Med Chem, 17 (19), 6811-5. 
 135 
Jones, T. R. and Cole, M. D. (1987), 'Rapid cytoplasmic turnover of c-myc mRNA: requirement 
of the 3' untranslated sequences', Mol Cell Biol, 7 (12), 4513-21. 
Jung, L. A., et al. (2017), 'OmoMYC blunts promoter invasion by oncogenic MYC to inhibit 
gene expression characteristic of MYC-dependent tumors', Oncogene, 36 (14), 1911-24. 
Kanazawa, S., et al. (2003), 'c-Myc recruits P-TEFb for transcription, cellular proliferation and 
apoptosis', Oncogene, 22 (36), 5707-11. 
Katsuda, Y., et al. (2016), 'A Small Molecule That Represses Translation of G-Quadruplex-
Containing mRNA', J Am Chem Soc, 138 (29), 9037-40. 
Kerkhoff, E., Bister, K., and Klempnauer, K. H. (1991), 'Sequence-specific DNA binding by 
Myc proteins', Proc Natl Acad Sci U S A, 88 (10), 4323-7. 
Kim, N. W., et al. (1994), 'Specific association of human telomerase activity with immortal cells 
and cancer', Science, 266 (5193), 2011-5. 
Kouzine, F., et al. (2008), 'The functional response of upstream DNA to dynamic supercoiling in 
vivo', Nat Struct Mol Biol, 15 (2), 146-54. 
Kudchadkar, R., Paraiso, K. H., and Smalley, K. S. (2012), 'Targeting mutant BRAF in 
melanoma: current status and future development of combination therapy strategies', 
Cancer J, 18 (2), 124-31. 
Kumar, N., et al. (2008), 'Silencing c-MYC expression by targeting quadruplex in P1 promoter 
using locked nucleic acid trap', Biochemistry, 47 (50), 13179-88. 
Kumari, S., Bugaut, A., and Balasubramanian, S. (2008), 'Position and stability are determining 
factors for translation repression by an RNA G-quadruplex-forming sequence within the 
5' UTR of the NRAS proto-oncogene', Biochemistry, 47 (48), 12664-9. 
Kumari, S., et al. (2007), 'An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene 
modulates translation', Nat Chem Biol, 3 (4), 218-21. 
Kuzyk, A. and Mai, S. (2014), 'c-MYC-induced genomic instability', Cold Spring Harb Perspect 
Med, 4 (4), a014373. 
Lacy, J., Summers, W. P., and Summers, W. C. (1989), 'Post-transcriptional mechanisms of 
deregulation of MYC following conversion of a human B cell line by Epstein-Barr virus', 
EMBO J, 8 (7), 1973-80. 
Lavelle, C. (2008), 'DNA torsional stress propagates through chromatin fiber and participates in 
transcriptional regulation', Nat Struct Mol Biol, 15 (2), 123-5. 
Lee, D. U., et al. (2016), 'Nonselective inhibition of the epigenetic transcriptional regulator BET 
induces marked lymphoid and hematopoietic toxicity in mice', Toxicol Appl Pharmacol, 
300, 47-54. 
Lee, H. C., et al. (2017), 'RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic 
Strategy to Target MYC in Multiple Myeloma', Br J Haematol, 177 (1), 80-94. 
Lemarteleur, T., et al. (2004), 'Stabilization of the c-myc gene promoter quadruplex by specific 
ligands' inhibitors of telomerase', Biochem Biophys Res Commun, 323 (3), 802-8. 
Levens, D. (2008), 'How the c-myc promoter works and why it sometimes does not', J Natl 
 136 
Cancer Inst Monogr,  (39), 41-3. 
Lin, C. and Yang, D. (2017), 'Human Telomeric G-Quadruplex Structures and G-Quadruplex-
Interactive Compounds', Methods Mol Biol, 1587, 171-96. 
Liu, J., et al. (2006), 'The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a 
pulse of c-myc expression', EMBO J, 25 (10), 2119-30. 
Liu, L., et al. (2012), 'Deregulated MYC expression induces dependence upon AMPK-related 
kinase 5', Nature, 483 (7391), 608-12. 
Liu, Z., Sun, Q., and Wang, X. (2017), 'PLK1, A Potential Target for Cancer Therapy', Transl 
Oncol, 10 (1), 22-32. 
Louis, S. F., et al. (2005), 'c-Myc induces chromosomal rearrangements through telomere and 
chromosome remodeling in the interphase nucleus', Proc Natl Acad Sci U S A, 102 (27), 
9613-8. 
Luscher, B. and Eisenman, R. N. (1990), 'New light on Myc and Myb. Part I. Myc', Genes Dev, 4 
(12A), 2025-35. 
Mali, S. (2013), 'Delivery systems for gene therapy', Indian J Hum Genet, 19 (1), 3-8. 
Marcel, V., et al. (2011), 'G-quadruplex structures in TP53 intron 3: role in alternative splicing 
and in production of p53 mRNA isoforms', Carcinogenesis, 32 (3), 271-8. 
Marcu, K. B., Bossone, S. A., and Patel, A. J. (1992), 'myc function and regulation', Annu Rev 
Biochem, 61, 809-60. 
Mardis, E. R., et al. (2009), 'Recurring mutations found by sequencing an acute myeloid 
leukemia genome', N Engl J Med, 361 (11), 1058-66. 
Mathad, R. I., et al. (2011), 'c-MYC promoter G-quadruplex formed at the 5'-end of NHE III1 
element: insights into biological relevance and parallel-stranded G-quadruplex stability', 
Nucleic Acids Res, 39 (20), 9023-33. 
Mertz, J. A., et al. (2011), 'Targeting MYC dependence in cancer by inhibiting BET 
bromodomains', Proc Natl Acad Sci U S A, 108 (40), 16669-74. 
Meyer, N. and Penn, L. Z. (2008), 'Reflecting on 25 years with MYC', Nat Rev Cancer, 8 (12), 
976-90. 
Miller, M. C., et al. (2010), 'Hydration is a major determinant of the G-quadruplex stability and 
conformation of the human telomere 3' sequence of d(AG3(TTAG3)3)', J Am Chem Soc, 
132 (48), 17105-7. 
Millevoi, S., Moine, H., and Vagner, S. (2012), 'G-quadruplexes in RNA biology', Wiley 
Interdiscip Rev RNA, 3 (4), 495-507. 
Miyazaki, T., et al. (2012), 'Telomestatin impairs glioma stem cell survival and growth through 
the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb', 
Clin Cancer Res, 18 (5), 1268-80. 
Montenegro, R. C., et al. (2016), 'BET inhibition as a new strategy for the treatment of gastric 
cancer', Oncotarget, 7 (28), 43997-4012. 
Morris, M. J. and Basu, S. (2009), 'An unusually stable G-quadruplex within the 5'-UTR of the 
 137 
MT3 matrix metalloproteinase mRNA represses translation in eukaryotic cells', 
Biochemistry, 48 (23), 5313-9. 
Mosmann, T. (1983), 'Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays', J Immunol Methods, 65 (1-2), 55-63. 
Moyzis, R. K., et al. (1988), 'A highly conserved repetitive DNA sequence, (TTAGGG)n, 
present at the telomeres of human chromosomes', Proc Natl Acad Sci U S A, 85 (18), 
6622-6. 
Muller, S. and Rodriguez, R. (2014), 'G-quadruplex interacting small molecules and drugs: from 
bench toward bedside', Expert Rev Clin Pharmacol, 7 (5), 663-79. 
Muller, S., et al. (2010), 'Small-molecule-mediated G-quadruplex isolation from human cells', 
Nat Chem, 2 (12), 1095-8. 
Muller, S., et al. (2012), 'Pyridostatin analogues promote telomere dysfunction and long-term 
growth inhibition in human cancer cells', Org Biomol Chem, 10 (32), 6537-46. 
Nau, Marion M, et al. (1985), 'L-myc, a new myc-related gene amplified and expressed in human 
small cell lung cancer', Nature, 318 (6041), 69-73. 
Neidle, S. (2010), 'Human telomeric G-quadruplex: the current status of telomeric G-
quadruplexes as therapeutic targets in human cancer', FEBS J, 277 (5), 1118-25. 
Neidle, Stephen and Parkinson, Gary N (2003), 'The structure of telomeric DNA', Current 
opinion in structural biology, 13 (3), 275-83. 
Niu, Z., et al. (2015), 'Knockdown of c-Myc inhibits cell proliferation by negatively regulating 
the Cdk/Rb/E2F pathway in nasopharyngeal carcinoma cells', Acta Biochim Biophys Sin 
(Shanghai), 47 (3), 183-91. 
Ohnmacht, S. A. and Neidle, S. (2014), 'Small-molecule quadruplex-targeted drug discovery', 
Bioorg Med Chem Lett, 24 (12), 2602-12. 
Oster, S. K., et al. (2002), 'The myc oncogene: MarvelouslY Complex', Adv Cancer Res, 84, 81-
154. 
Park, J., et al. (2001), 'The ATM-related domain of TRRAP is required for histone 
acetyltransferase recruitment and Myc-dependent oncogenesis', Genes Dev, 15 (13), 
1619-24. 
Patel, J. H., et al. (2004), 'Analysis of genomic targets reveals complex functions of MYC', Nat 
Rev Cancer, 4 (7), 562-8. 
Payne, G. S., Bishop, J. M., and Varmus, H. E. (1982), 'Multiple arrangements of viral DNA and 
an activated host oncogene in bursal lymphomas', Nature, 295 (5846), 209-14. 
Pennarun, G., et al. (2008), 'Role of ATM in the telomere response to the G-quadruplex ligand 
360A', Nucleic Acids Res, 36 (5), 1741-54. 
Phatak, P., et al. (2007), 'Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits 
clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell 
targeting mechanism', Br J Cancer, 96 (8), 1223-33. 
Piazza, A., et al. (2010), 'Genetic instability triggered by G-quadruplex interacting Phen-DC 
 138 
compounds in Saccharomyces cerevisiae', Nucleic Acids Res, 38 (13), 4337-48. 
Pirami, L., et al. (1991), 'Mouse macrophage clones immortalized by retroviruses are 
functionally heterogeneous', Proc Natl Acad Sci U S A, 88 (17), 7543-7. 
Posternak, V. and Cole, M. D. (2016), 'Strategically targeting MYC in cancer', F1000Res, 5. 
Prasad, A., et al. (2016), 'ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates 
oxidative stress signals in head and neck cancer cell lines', Oncotarget, 7 (48), 79388-
400. 
Prochownik, E. V. (2008), 'c-Myc: linking transformation and genomic instability', Curr Mol 
Med, 8 (6), 446-58. 
Prochownik, E. V. and Vogt, P. K. (2010), 'Therapeutic Targeting of Myc', Genes Cancer, 1 (6), 
650-59. 
Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011), 'RAS oncogenes: weaving a 
tumorigenic web', Nat Rev Cancer, 11 (11), 761-74. 
Ramsay, G. M., et al. (1990), 'Neoplastic transformation and tumorigenesis by the human 
protooncogene MYC', Proc Natl Acad Sci U S A, 87 (6), 2102-6. 
Rapp, U. R., et al. (2009), 'MYC is a metastasis gene for non-small-cell lung cancer', PLoS One, 
4 (6), e6029. 
Rhodes, D. and Lipps, H. J. (2015), 'G-quadruplexes and their regulatory roles in biology', 
Nucleic Acids Res, 43 (18), 8627-37. 
Roy, S., et al. (2007), 'High-affinity homologous peptide nucleic acid probes for targeting a 
quadruplex-forming sequence from a MYC promoter element', Biochemistry, 46 (37), 
10433-43. 
Sabnis, H. S., Somasagara, R. R., and Bunting, K. D. (2017), 'Targeting MYC Dependence by 
Metabolic Inhibitors in Cancer', Genes (Basel), 8 (4). 
Salvati, E., et al. (2007), 'Telomere damage induced by the G-quadruplex ligand RHPS4 has an 
antitumor effect', J Clin Invest, 117 (11), 3236-47. 
Savino, M., et al. (2011), 'The action mechanism of the Myc inhibitor termed Omomyc may give 
clues on how to target Myc for cancer therapy', PLoS One, 6 (7), e22284. 
Sears, R., et al. (2000), 'Multiple Ras-dependent phosphorylation pathways regulate Myc protein 
stability', Genes Dev, 14 (19), 2501-14. 
Sedoris, K. C., et al. (2012), 'Genomic c-Myc quadruplex DNA selectively kills leukemia', Mol 
Cancer Ther, 11 (1), 66-76. 
Sekaran, V., Soares, J., and Jarstfer, M. B. (2014), 'Telomere maintenance as a target for drug 
discovery', J Med Chem, 57 (3), 521-38. 
Sen, D. and Gilbert, W. (1988), 'Formation of parallel four-stranded complexes by guanine-rich 
motifs in DNA and its implications for meiosis', Nature, 334 (6180), 364-6. 
Shachaf, C. M., et al. (2008), 'Genomic and proteomic analysis reveals a threshold level of MYC 
required for tumor maintenance', Cancer Res, 68 (13), 5132-42. 
 139 
Shadeo, A. and Lam, W. L. (2006), 'Comprehensive copy number profiles of breast cancer cell 
model genomes', Breast Cancer Res, 8 (1), R9. 
Shahid, R., Bugaut, A., and Balasubramanian, S. (2010), 'The BCL-2 5' untranslated region 
contains an RNA G-quadruplex-forming motif that modulates protein expression', 
Biochemistry, 49 (38), 8300-6. 
Shin-ya, K., et al. (2001), 'Telomestatin, a novel telomerase inhibitor from Streptomyces 
anulatus', J Am Chem Soc, 123 (6), 1262-3. 
Siddiqui-Jain, A., et al. (2002), 'Direct evidence for a G-quadruplex in a promoter region and its 
targeting with a small molecule to repress c-MYC transcription', Proc Natl Acad Sci U S 
A, 99 (18), 11593-8. 
Simonsson, T., Pecinka, P., and Kubista, M. (1998), 'DNA tetraplex formation in the control 
region of c-myc', Nucleic Acids Res, 26 (5), 1167-72. 
Slavc, I., et al. (1990), 'myc gene amplification and expression in primary human neuroblastoma', 
Cancer Res, 50 (5), 1459-63. 
Smakman, N., et al. (2005), 'Dual effect of Kras(D12) knockdown on tumorigenesis: increased 
immune-mediated tumor clearance and abrogation of tumor malignancy', Oncogene, 24 
(56), 8338-42. 
Soucek, L., et al. (1998), 'Design and properties of a Myc derivative that efficiently 
homodimerizes', Oncogene, 17 (19), 2463-72. 
Soucek, L., et al. (2002), 'Omomyc, a potential Myc dominant negative, enhances Myc-induced 
apoptosis', Cancer Res, 62 (12), 3507-10. 
Soucek, L., et al. (2008), 'Modelling Myc inhibition as a cancer therapy', Nature, 455 (7213), 
679-83. 
Spencer, C. A. and Groudine, M. (1991), 'Control of c-myc regulation in normal and neoplastic 
cells', Adv Cancer Res, 56, 1-48. 
Stasik, C. J., et al. (2010), 'Increased MYC gene copy number correlates with increased mRNA 
levels in diffuse large B-cell lymphoma', Haematologica, 95 (4), 597-603. 
Stewart, S. A. and Weinberg, R. A. (2006), 'Telomeres: cancer to human aging', Annu Rev Cell 
Dev Biol, 22, 531-57. 
Studzinski, G. P., et al. (1986), 'Participation of c-myc protein in DNA synthesis of human cells', 
Science, 234 (4775), 467-70. 
Sun, D. and Hurley, L. H. (2009), 'The importance of negative superhelicity in inducing the 
formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for 
drug targeting and control of gene expression', J Med Chem, 52 (9), 2863-74. 
Taetz, S., et al. (2006), 'Biopharmaceutical characterization of the telomerase inhibitor 
BRACO19', Pharm Res, 23 (5), 1031-7. 
Tolcher, A. W., et al. (2014), 'A phase 1 study of the BCL-2-targeted deoxyribonucleic acid 
inhibitor (DNAi) PNT2258 in patients with advanced solid tumors', Cancer Chemother 
Pharmacol, 73 (2), 363-71. 
 140 
Vafa, O., et al. (2002), 'c-Myc can induce DNA damage, increase reactive oxygen species, and 
mitigate p53 function: a mechanism for oncogene-induced genetic instability', Mol Cell, 9 
(5), 1031-44. 
Varmus, H. E. (1984), 'The molecular genetics of cellular oncogenes', Annu Rev Genet, 18, 553-
612. 
Verma, A., et al. (2008), 'Genome-wide computational and expression analyses reveal G-
quadruplex DNA motifs as conserved cis-regulatory elements in human and related 
species', J Med Chem, 51 (18), 5641-9. 
Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993), 'Mammalian Ras interacts directly 
with the serine/threonine kinase Raf', Cell, 74 (1), 205-14. 
Vummidi, B. R., Alzeer, J., and Luedtke, N. W. (2013), 'Fluorescent probes for G-quadruplex 
structures', Chembiochem, 14 (5), 540-58. 
Wade, M. and Wahl, G. M. (2006), 'c-Myc, genome instability, and tumorigenesis: the devil is in 
the details', Curr Top Microbiol Immunol, 302, 169-203. 
Wang, C., et al. (2011), 'Estrogen induces c-myc gene expression via an upstream enhancer 
activated by the estrogen receptor and the AP-1 transcription factor', Mol Endocrinol, 25 
(9), 1527-38. 
Wang, S. K., Wu, Y., and Ou, T. M. (2015a), 'RNA G-Quadruplex: The New Potential Targets 
for Therapy', Curr Top Med Chem, 15 (19), 1947-56. 
Wang, Y., et al. (2015b), 'CDK7-dependent transcriptional addiction in triple-negative breast 
cancer', Cell, 163 (1), 174-86. 
Wang, Y. H., et al. (2005), 'Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast 
tumor cells growth in vitro and in vivo', Breast Cancer Res, 7 (2), R220-8. 
Watson, J. D. and Crick, F. H. (1953), 'Molecular structure of nucleic acids; a structure for 
deoxyribose nucleic acid', Nature, 171 (4356), 737-8. 
Watts, J. K. and Corey, D. R. (2012), 'Silencing disease genes in the laboratory and the clinic', J 
Pathol, 226 (2), 365-79. 
Wennerberg, K., Rossman, K. L., and Der, C. J. (2005), 'The Ras superfamily at a glance', J Cell 
Sci, 118 (Pt 5), 843-6. 
Whyte, D. B., et al. (1997), 'K- and N-Ras are geranylgeranylated in cells treated with farnesyl 
protein transferase inhibitors', J Biol Chem, 272 (22), 14459-64. 
Wierstra, I. and Alves, J. (2008), 'The c-myc promoter: still MysterY and challenge', Adv Cancer 
Res, 99, 113-333. 
Williamson, J. R. (1994), 'G-quartet structures in telomeric DNA', Annu Rev Biophys Biomol 
Struct, 23, 703-30. 
Williamson, J. R., Raghuraman, M. K., and Cech, T. R. (1989), 'Monovalent cation-induced 
structure of telomeric DNA: the G-quartet model', Cell, 59 (5), 871-80. 
Wolfer, A. and Ramaswamy, S. (2011), 'MYC and metastasis', Cancer Res, 71 (6), 2034-7. 
Xu, F., et al. (2014), 'Rigosertib as a selective anti-tumor agent can ameliorate multiple 
 141 
dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome', 
Sci Rep, 4, 7310. 
Xu, H., et al. (2017), 'CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in 
BRCA1/2 deficient tumours', Nat Commun, 8, 14432. 
Yang, D., et al. (2010), 'Therapeutic potential of a synthetic lethal interaction between the MYC 
proto-oncogene and inhibition of aurora-B kinase', Proc Natl Acad Sci U S A, 107 (31), 
13836-41. 
Zamiri, B., et al. (2014), 'TMPyP4 porphyrin distorts RNA G-quadruplex structures of the 
disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of 
RNA-binding proteins', J Biol Chem, 289 (8), 4653-9. 
Zhang, X., Ge, Y. L., and Tian, R. H. (2009), 'The knockdown of c-myc expression by RNAi 
inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo', Cell 
Mol Biol Lett, 14 (2), 305-18. 
Zhang, Z., et al. (2016), 'BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian 
Cancer by Downregulating FoxM1', Theranostics, 6 (2), 219-30. 
Zheng, S., et al. (2015), 'Non-coding RNA Generated following Lariat Debranching Mediates 
Targeting of AID to DNA', Cell, 161 (4), 762-73. 
 
 
 
 
 
 
 
 
 
 
 142 
 
 
 
VITA 
 
 
Taisen Hao was born in Shaanxi, China on October 17, 1995. He graduated from Beijing 
University of Chinese Medicine with a degree in Pharmaceutical Engineering in 2013. The 
following fall, he enrolled in the Ph.D. program of Pharmaceutical Sciences (Pharmacology) at 
The University of Mississippi. Taisen earned his doctoral candidacy in March 2016, and received 
his Ph.D. in Pharmaceutical Sciences (Pharmacology) in July 2017. 
